Piperazine derivatives that destabilize androgen receptors

ABSTRACT

This invention relates to new piperazine derivatives of general formula I, 
                 
 
in which V, W, n, R, R′, i, j, Y and Z have the meaning that is indicated in the description.
 
     The compounds according to the invention are distinguished by a diazacycloalkane substituent. They have at their disposal a special action with respect to the action that destabilizes the androgen receptor and can be used, for example, for treating prostrate cancer.

This application claims the benefit of the filing date of U.S. Provisional Application Ser. No. 60/406,650 filed Aug. 29, 2002 and U.S. Provisional Application Ser. No. 60/383,785, filed May 30, 2002.

This invention relates to substituted piperazine derivatives that destabilize the androgen receptor (AR), and process for the production of these piperazine derivatives, their intermediate products as well as pharmaceutical preparations that contain the piperazine derivatives according to the invention and their use for the production of pharmaceutical agents.

In industrialized countries, prostate cancer, behind lung cancer, is the second main cause of death by cancer in men. In men over 55 years of age, 4% of deaths are attributed to a prostate tumor disease, and it is suggested that the proportion in men over 80 increases up to 80% of deaths. The mortality rate is still always relatively low, but it increases annually to about 14%. The number of men in whom a prostate tumor was diagnosed increased in recent years by 30%, which can be attributed, however, less to an increasing number of new diseases but rather to that the population is generally older, that the diagnostic processes have improved and that systematic screening programs were introduced (E. J. Small, D. M. Reese, Curr. Opi. Oncol. 2000, 12, 265-272).

The prostate tumor grows in an androgen-dependent manner in the early stages. As long as the tumor is limited locally to the prostate, it can be treated removed by surgical intervention or by radiation therapy, whereby these methods are associated with corresponding risks. In the cases in which the tumor is no longer locally limited, and has already formed metastases, the tumor is treated in a palliative manner by reduction of the testosterone level in the blood. This is carried out either surgically by castration or medicinally by treatment with antiandrogens (bicalutamide, cyproterone acetate, flutamide), LHRH agonists (buserelin, zoladex), LHRH antagonists (cetrorelix) or 5α-reductase inhibitors (finasteride). Since the adrenal androgen synthesis remains unaffected in surgical castration, more recently a combined surgical and medicinal treatment is frequently performed. This treatment, however, has only temporary success, since renewed growth of the tumor generally occurs after two years at the latest, and said renewed growth in most cases is then hormone-independent (L. J. Denis, K. Griffith, Semin. in Surg. Onc. 2000, 18, 52-74). Up until now despite intensive research in the last 50 years, there has been no effective treatment against these advanced stages. The 5-year survival rate in these patients is under 15%.

There are various indications that show that the androgen receptor plays an important role in the development and the growth of the prostate tumor not only in the early hormone-dependent stages but also in late hormone-independent stages of the tumor progression.

The androgen receptor belongs to the family of steroid hormone receptors that act as transcription factors. The androgen receptor binds androgens, by which it is stabilized and protected from a quick proteolytic degradation. After hormone binding, it is transported into the nucleus where it activates certain genes by binding to so-called androgen-responsive DNA elements that are in promoter regions (D. J. Lamb et al., Vitamn. Horm. 2001, 62, 199-230).

Studies on prostate tumors show that an amplification of the androgen receptor locus was detected in 30% of the advanced tumors. In other cases, a number of mutations were found in the androgen receptor gene that are located in various domains of the androgen receptor molecule and result in altered receptor properties. Mutated receptors can have either a higher affinity for androgens, can be constitutively active, can change their ligand specificity, such that they are activated by other steroid hormones or even antiandrogens, can be activated via interactions with molecules from other growth-promoting signal-transmission methods, which change interaction with co-factors, or can activate other target genes (J. P. Elo, T. Visakorpi, Ann. Med. 2001, 33, 130-41).

The identification of antiandrogens that inhibit not only the natural androgen receptor but also its mutated forms and in addition change the receptor molecule so that it is destabilized, would presumably be very helpful in treating prostate tumors in various stages. Such compounds could prevent a recurrence of tumor growth or at least considerably delay such recurrence. In the case of the estrogen receptor, ligands could be identified that destabilize the receptor and result in a reduction of the receptor content in vitro and in vivo (S. Dauvois et al. Proc. Natl. Acad. Sci. USA 1992, 89, 4037-41; R. A. McClelland et al. Eur. J. Cancer 1996, 32A, 413-6).

Nonsteroidal antiandrogens are described in U.S. Pat. No. 5,411,981 (phenylimidazolidine derivatives), in WO97/00071 (specifically substituted phenyldimethylhydantoins as well as imino or thione derivatives thereof), in WO00/37430 (phenylalanines, phenylhydantoins as well as phenylureas), in WO01/58855 (aminopropanilides) and in EP1122242 (substituted cyanophenylpiperazines).

The object of this invention consists in making available compounds with antiandrogenic action that destabilize the androgen receptor, inhibit the prostate tumor growth and simultaneously have a high, optionally oral bioavailability.

Studies with nonsteroidal antiandrogens have shown that they have advantages compared to the steroidal compounds and therefore are to be preferred. Thus with nonsteroidal compounds, a more selective action can be achieved with fewer adverse side effects. In contrast to the steroidal antiandrogens, e.g., the progestagenic activity is lacking in the known nonsteroids bicalutamide and flutamide, and in addition, their use results in an increase in the testosterone level in the serum, which clinically could result in preserving potency.

This object is achieved according to the invention by the new compounds of general formula I:

This invention relates to compounds of general formula I, whereby

-   -   V stands for a substituted, aromatic radical of general formula         II,         in which     -   A stands for an acetyl group, an acetylamino group, a cyano         group, a nitro group, a trifluoromethyl group, or a halogen         (fluorine, chlorine),     -   B stands for a hydrogen atom, a halogen (fluorine, chlorine) or         a trifluoromethyl group, or     -   A and B together stand for a cyclic group of formula III or IV         that is bonded to the aromatic ring, whereby E stands for a         methylene group or an oxygen atom,     -   W stands for a heterocyclic compound of formula V,         in which     -   T can represent carbon or nitrogen,     -   if T stands for carbon, a double bond is to be present between Q         and T, and Q means a group ═C(CH₃)— and U means oxygen, and n is         to assume one of the integral values 1, 2, 3, 4, 5, 6, 7, or 8,         or     -   if T stands for nitrogen, a single bond is to be present between         Q and T, and Q means a group —C(CH₃)₂— and U means sulfur, and n         is to assume one of the integral values 2, 3, 4, 5, 6, 7, or 8,     -   i and j, independently of one another, stand for the values 1         and 2, whereby i+j can assume the value 2 or 3,     -   R and R′, independently of one another, can be a hydrogen atom         or a methyl group,     -   Y stands for a bond between the heterocyclic nitrogen and Z, for         a carbonyl group —C(O)—, for a sulfonyl group —S(O)₂—, for an         iminocarbonyl group —C(O)N(Z′)—, for an iminosulfonyl group         —S(O)₂N(Z′)—, for an imino(thioxomethyl) group —C(S)N(Z′)—, for         an oxycarbonylimino(thioxomethyl) group —C(S)N(Z′)C(O)O—, for an         oxycarbonyl group —C(O)O—, for a sulfanylcarbonyl group —C(O)S—,         and     -   Z and Z′, independently of one another, stand for an unbranched         C₁-C₈-alkyl group or branched C₃-C₈-alkyl group, a         C₃-C₆-cycloalkyl group that is optionally substituted with a         phenyl radical, a (C₃-C₆-cycloalkyl)-C₁-C₄-alkylene group, a         branched or unbranched C₂-C₅-alkenyl group, a branched or         unbranched C₂-C₅-alkenyl group, a C₃-C₅-alkinyl group, a         C₁-C₄-alkoxy group, cyano group, phenylsulfanyl group or         hydroxy-C₁-C₄-alkylene group, a (2-methoxyethoxy)methyl group, a         [2-(2-methoxyethoxy)ethoxy]methyl group, a         2-(2-methoxyethoxy)ethyl group, a 2-[2-(2-methoxyethoxy         )ethoxy]ethyl group, a C₁-C₄-alkoxy-C₁-C₄-alkylene group, a         C₁-C₄-alkyxycarbonyl-C₁-C₄-alkylene group, an adamantyl group, a         trichloroacetyl group; an aryl, heteroaryl, heterocyclyl,         aryl-C₁-C₄-alkylene, heteroaryl-C₁-C₄-alkylene,         aryloxy-C₁-C₄-alkylene, heteroaryloxy-C₁-C₄-alkylene,         aryl-C₁-C₄-alkylenoxy-C₁-C₄-alkylene group that is unsubstituted         or that is substituted with up to three branched or unbranched         C₁-C₄-alkyl, C₂-C₆-alkenyl, C₃-C₆-cycloalkyl,         C₃-C₆-cycloalkyloxy, phenyl, cyano, halogen, methoxy, ethoxy,         phenoxy, benzyloxy, methylsulfanyl, ethylsulfanyl,         benzylsulfanyl, phenylsulfanyl, dimethylamino, acetylamino,         trifluoromethyl, trifluoromethoxy, trifluoromethylsulfanyl,         acetyl, (1-iminoethyl) or nitro groups, or a radical of formula         C_(p)F_(q)H_(r) with p=1, 2, 3, 4, q>1 and q+r=2p+1, and     -   Z′ in addition to the above-mentioned definitions stands for a         hydrogen atom.

The compounds according to the invention are distinguished in that in each case they contain a diazacycloalkane nucleus whose nitrogen atoms are presented in substituted form in each case.

The unbranched C₁-C₈-alkyl groups for radicals Z and Z′ can be, for example, a methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl or n-octyl group; the branched C₃-C₈-alkyl groups are an iso-propyl, iso-butyl, sec-butyl, tert-butyl, iso-pentyl, neo-pentyl, 2-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 2-methylhexyl, 2,2-dimethylpentyl, 2,2,3-trimethylbutyl or 2,3,3-trimethylbutyl group.

The C₃-C₆-cycloalkyl groups that are optionally substituted with a phenyl radical for radicals Z and Z′ can readily be a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or phenylcyclopropyl group, phenylcyclobutyl, phenylcyclopentyl, or phenylcyclohexyl group.

The (C₃-C₆-cycloalkyl)-C₁-C₄-alkylene groups for radicals Z and Z′ can be, for example, a cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclopropylethyl, cyclobutylethyl, cyclopentylethyl, cyclohexylethyl, cyclopropylpropyl, cyclobutylpropyl, cyclopentylpropyl, cyclohexylpropyl, cyclopropylbutyl, cyclobutylbutyl, cyclopentylbutyl or cyclohexylbutyl group.

The branched or unbranched C₂-C₅-alkenyl groups for the radicals Z and Z′ can be, for example, a vinyl, allyl, homoallyl, (E)-but-2-enyl, (Z)-but-2-enyl, (E)-but-1-enyl, (Z)-but-1-enyl, pent-4-enyl, (E)-pent-3-enyl, (Z)-pent-3-enyl, (E)-pent-2-enyl, (Z)-pent-2-enyl, (E)-pent-1-enyl, (Z)-pent-1-enyl, 2-methylvinyl, 3-methylbut-3-enyl, 2-methylbut-3-enyl, (E)-2-methylbut-2-enyl, (Z)-2-methylbut-2-enyl, or 3-methylbut-2-enyl group.

The C₃-C₅-alkinyl groups for radicals Z and Z′ can be, for example, a prop-1-inyl, prop-2-inyl, but-1-inyl, but-2-inyl, but-3-inyl, pent-1-inyl, penty-2-inyl, pent-3-inyl, pent-4-inyl, 1-methylprop-2-inyl, 1-methylbut-3-inyl, or 1-ethylprop-2-inyl group.

The C₁-C₄-alkoxy groups for radicals Z and Z′ can be, for example, a methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, sec-butoxy, iso-butoxy or tert-butoxy group.

The C₁-C₄-alkylene groups within radicals Z and Z′ can be, for example, a methylene group (—CH₂—), ethylidene group [—CH(CH₃)—], ethylene group (—CH₂CH₂—), 1,3-propylene group (—CH₂CH₂CH₂—), 1,2-propylene group [—CH₂CH(CH₃)—], 1,4-butylene group (—CH₂CH₂CH₂CH₂—), 1,3-butylene group [—CH₂CH₂CH(CH₃)—], 1,2-butylene group [—CH₂CH(CH₂CH₃)—], 2-methyl-1,2-propylene group [—CH₂C(CH₃)₂—], or 2-methyl-1,3-propylene group [—CH₂CH(CH₃)CH₂—].

The hydroxy-C₁-C₄-alkylene groups for radicals Z and Z′ can be a hydroxymethyl group (HOCH₂—), 2-hydroxyethyl group (HOCH₂CH₂—), 1-hydroxyethyl group [CH₃CH(OH)—], 3-hydroxypropyl group (HOCH₂CH₂CH₂—), 2-hydroxypropyl group [CH₃CH(OH)CH₂CH₂—], 1-hydroxypropyl group [CH₃CH₂CH(OH)—], 4-hydroxybutyl group (HOCH₂CH₂CH₂CH₂—), 3-hydroxybutyl group [CH₃CH(OH)CH₂CH₂—], 2-hydroxybutyl group [CH₃CH₂CH(OH)CH₂—], 1-hydroxybutyl group [CH₃CH₂CH₂CH(OH)—], 1-hydroxy-1-methylethyl group [(CH₃)₂C(OH)—], or 1-hydroxy-1-methylpropyl group [CH₃CH₂C(CH₃)(OH)—].

The C₁-C₄-alkoxycarbonyl-C₁-C₄-alkylene groups for radicals Z and Z′ are, for example, a combination of the C₁-C₄-alkoxycarbonyl group and the C₁-C₄-alkylene group. A C₁-C₄-alkoxycarbonyl group is defined as methoxycarbonyl-[MeOC(O)—], ethoxycarbonyl [EtOC(O)—), n-propoxycarbonyl-[CH₃CH₂CH₂OC(O)—], iso-propoxycarbonyl-[(CH₃)₂CHOC(O)—], n-butoxycarbonyl-[CH₃CH₂CH₂CH₂OC(O)—], iso-butoxycarbonyl-[(CH₃)₂CHCH₂OC(O)—], sec-butoxycarbonyl-[CH₃CH₂(CH₃)CHOC(O)—], tert-butoxycarbonyl [(CH₃)₃COC(O)—]. A C₁-C₄-alkylene group is defined as the C₁-C₄-alkylene groups that are further mentioned above. For example, the following radicals can be produced from the combination of these groups to form the C₁-C₄-alkoxycarbonyl-C₁-C₄-alkylene groups: (methoxycarbonyl)methyl-[CH₃OC(O)CH₂—], (ethoxycarbonyl)methyl-[CH₃CH₂OC(O)CH₂—], (n-propoxycarbonyl)methyl-[CH₃CH₂CH₂OC(O)CH₂—], (iso-propoxycarbonyl)methyl-[(CH₃)₂CHOC(O)CH₂—], (n-butoxycarbonyl)methyl-[CH₃CH₂CH₂CH₂OC(O)CH₂—], (iso-butoxycarbonyl)methyl-[(CH₃)₂CHCH₂OC(O)CH₂—], (sec-butoxycarbonyl)methyl-[CH₃CH₂(CH₃)CHOC(O)CH₂—], (tert-butoxycarbonyl)methyl-[(CH₃)₃COC(O)CH₂—], 2-(methoxycarbonyl)ethyl-[CH₃OC(O)CFH₂CH₂—], 2-(ethoxycarbonyl)ethyl-[CH₃CH₂OC(O)CH₂CH₂—], 2-(n-propoxycarbonyl)ethyl-[CH₃CH₂CH₂OC(O)CH₂CH₂—, 2-(iso-propoxycarbonyl)ethyl-[(CH₃)₂CHOC(O)CH₂CH₂—], 2-(n-butoxycarbonyl)ethyl-[CH₃CH₂CH₂CH₂OC(O)CH₂CH₂—], 2-(iso-butoxycarbonyl)ethyl-[(CH₃)₂CHCH₂OC(O)CH₂CH₂—], 2-(sec-butoxycarbonyl)ethyl-[CH₃CH₂(CH₃)CHOC(O)CH₂CH₂—], 2-(tert-butoxycarbonyl)ethyl-[(CH₃)₃COC(O)CH₂CH₂—].

The aryl groups for radicals Z and Z′ can be a phenyl, naphthalen-1-yl, naphthalen-2-yl, [1,1′-biphenyl]-2-yl, [1,1′-biphenyl]-3-yl or a [1,1′-biphenyl]-4-yl group.

The heteroaryl groups for radicals Z and Z′ can be a pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, benzofuranyl, benzothienyl, 1,3-benzodioxolyl, 2,1,3-benzothiadiazolyl, indolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, pyrrolyl, pyrazolyl or an imidazolyl group that is linked via one of the sites that can be substituted.

The heterocyclyl groups for radicals Z and Z′ can be piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, imidazolidinyl or a pyrrolidinyl group that is linked via one of the sites that can be substituted.

The substituents of the aryl, heteroaryl and heterocyclyl radicals, also in each case within the aryl-C₁-C₄-alkylene, heteroaryl-C₁-C₄-alkylene, aryloxy-C₁-C₄-alkylene, heteroaryloxy-C₁-C₄-alkylene, aryl-C₁-C₄-alkylenoxy-C₁-C₄-alkylene units for radical Z, can be, i.a.,

-   -   Unbranched or branched C₁-C₄-alkyl groups (methyl, ethyl,         n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, as well as         tert-butyl-) and/or C₂-C₆-alkenyl groups (vinyl, allyl,         homoallyl, (E)-but-2-enyl, (Z)-but-2-enyl, pent-4-enyl,         (E)-pent-3-enyl, (Z)-pent-3-enyl, (E)-pent-2-enyl,         (Z)-pent-2-enyl, 2-methylvinyl, 3-methylbut-3-enyl,         2-methylbut-3-enyl, (E)-2-methylbut-2-enyl,         (Z)-2-methylbut-2-enyl, 2-ethylprop-2-enyl, hex-5-enyl,         (E)-hex-4-enyl, (Z)-hex-4-enyl, (E)-hex-3-enyl, (Z)-hex-3-enyl,         (E)-hex-2-enyl, (Z)-hex-2-enyl, 1-methylpent-4-enyl,         (E)-1-methylpent-3-enyl, (Z)-1-methylpent-3-enyl,         1-ethylbut-3-enyl, (E)-1-methylpent-2-enyl,         (Z)-1-methylpent-2-enyl) and/or C₃-C₆-cycloalkyl groups         (cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl) and/or         halogen (fluorine, chlorine, bromine, iodine).

The aryl-C₁-C₄-alkylene groups for radicals Z and Z′ can be a combination of the above-defined aryl and C₁-C₄-alkyl groups, for example: a phenylmethyl, 1-phenylethyl, 2-phenylethyl, 1-methyl-1-phenylethyl, 3-phenylpropyl-4-phenylbutyl, (naphthalen-1-yl)methyl, 1-(naphthalen-1-yl)ethyl, 2-(naphthalen-1-yl)-ethyl, (naphthalen-2-yl)methyl, 1-(naphthalen-2-yl)ethyl, 2-(naphthalen-2-yl)ethyl, ([1,1′-biphenyl]-2-yl)methyl, ([1,1′-biphenyl]-3-yl)methyl or a ([1,1′-biphenyl]-4-yl)methyl group.

The heteroaryl-C₁-C₄-alkylene groups for radicals Z and Z′ can be a combination of the above-defined heteroaryl and C₁-C₄-alkylene groups, for example a (pyridin-2-yl)methyl, (pyridin-3-yl)methyl, (pyridin-4-yl)methyl, (furan-2-yl)methyl, (furan-3-yl)methyl, (thien-2-yl)methyl, (thien-3-yl)methyl, 2-(thien-2-yl)ethyl or a 2-(thien-3-yl)ethyl group.

The aryloxy-C₁-C₄-alkylene groups for radicals Z and Z′ can be a combined linkage of the above-defined aryl and C₁-C₄-alkylene groups via an ether group (—O—), for example: a phenoxymethyl, 1-phenoxyethyl, 2-phenoxyethyl, 1-methyl-1-phenoxyethyl, 3-phenoxypropyl, 4-phenoxybutyl, [(naphthalen-1-yl)oxy]methyl, 1-[(naphthalen-1-yl)oxy]ethyl, 2-[(naphthalen-1-yl)oxy]-ethyl, [(naphthalen-2-yl)oxy]methyl, 1-[(naphthalen-2-yl)oxy]ethyl, 2-[(naphthalen-2-yl)-oxy]ethyl, [([1,1′-biphenyl]-2-yl)oxy]methyl, [([1,1′-biphenyl]-3-yl)oxylmethyl or a [([1,1′-biphenyl]-4-yl)oxy]methyl group.

The heteroaryloxy-C₁-C₄-alkylene groups for radicals Z and Z′ can be a combined linkage of the previously defined heteroaryl and C₁-C₄-alkylene groups via an ether group (—O—), for example: a [(pyridin-2-yl)oxy]methyl, [(pyridin-3-yl)oxylmethyl or a [(pyridin-4-yl)oxy]methyl group.

The aryl-C₁-C₄-alkylenoxy-C₁-C₄-alkylene groups for radicals Z and Z′ can be a sequentially combined linkage of the above-defined aryl and C₁-C₄-alkylene groups via an ether group (—O—) to the alkylene group, for example: a (phenylmethoxy)methyl group or a 2-(phenylmethoxy)ethyl group.

The radical of formula C_(p)F_(q)H_(r) with p=1,2,3,4, q>1 and q+r=2p+1 for the radical Z can be a trifluoromethyl, pentafluoroethyl, perfluoropropyl, perfluorobutyl or a 2,2,2-trifluoroethyl group.

Preferred according to this invention are those compounds of general formula I, in which:

-   -   A stands for a cyano group,     -   B stands for a trifluoromethyl group, or     -   AB together stand for a cyclic group of formula IIIa that is         bonded to the aromatic ring,     -   n stands for one of the integral values 1 (only for the case         that T represents carbon), 2, 3, 4, 5, 6, 7 or 8,     -   i and j stand for the value 1,     -   R and R′ stand f6r a hydrogen atom,     -   Y stands for a carbonyl group —C(O)—, for a sulfonyl group         —S(O)₂—, for an iminocarbonyl group —C(O)N(Z′)—, for an         iminosulfonyl group —S(O)₂ N(Z′), for an imino(thioxomethyl)         group —C(S)N(Z′), for an oxycarbonylimino(thioxomethyl) group         —C(S)N(Z′)C(O)O—, for an oxycarbonyl group —C(O)O—, for a         sulfanylcarbonyl group —C(O)S—, and     -   Z and Z′, independently of one another, stand for an unbranched         C₁-C₄-alkyl group or branched C₃-C₄-alkyl group, a         C₃-C₆-cycloalkyl group that is optionally substituted for one         with a phenyl radical, a (C₃-C₆-cycloalkyl)-C₁-C₄-alkylene         group, a branched or unbranched C₂-C₃-alkenyl group, a         C₁-C₄-alkoxy, cyano, phenylsulfanyl, or hydroxy-C₁-C₄-alkylene         group, a (2-methoxyethoxy)methyl group, a         [2-(2-methoxyethoxy)-ethoxy]methyl group, a         2-(2-methoxyethoxy)ethyl group, a         2-[2-(2-methoxyethoxy)ethoxylethyl group, a         C₁-C₄-alkoxy-C₁-C₄-alkylene group, a         C₁-C₄-alkoxycarbonyl-C₁-C₄-alkylene group; an aryl, heteroaryl,         heterocyclyl, aryl-C₁-C₄-alkylene, heteroaryl-C₁-C₄-alkylene,         aryloxy-C₁-C₄-alkylene, heteroaryloxy-C₁-C₄-alkylene,         aryl-C₁-C₄-alkylenoxy-C₁-C₄-alkylene group that is unsubstituted         or that is substituted with up to three branched or unbranched         C₁-C₄-alkyl, C₂-C₄-alkenyl, C₃-C₆-cylcoalkyl,         C₃-C₆-cycloalkyloxy, phenyl, cyano, halogen, methoxy, ethoxy,         phenoxy, benzyloxy, methylsulfanyl, ethylsulfanyl, benzyl,         sulfanyl, phenylsulfanyl, dimethylamino, acetylamino,         trifluoromethyl, trifluoromethoxy, trifluoromethylsulfanyl, or         acetyl groups, or a radical of formula C_(p)F_(q)H_(r) with         p=1,2,3,4, q>and q+r=2p+1, and     -   Z′ in addition to the above-mentioned definitions stands for a         hydrogen atom.

For the formation of pharmaceutically compatible salts of the compounds of general formula I according to the invention, according to the methods that are known to one skilled in the art, i.a., hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid, and nitric acid are considered as inorganic acids; i.a., acetic acid, propionic acid, hexanoic acid, octanoic acid, decanoic acid, olcic acid, stcaric acid, maleic acid, fumaric acid, succinic acid, benzoic acid, ascorbic acid, oxalic acid, salicylic acid, tartaric acid, citric acid, lactic acid, glycolic acid, malic acid, mandelic acid, cinnamic acid, glutaminic acid, and aspartic acid are considered as carboxylic acids, and, i.a., methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid as well as naphthalensulfonic acid are considered as sulfonic acids.

The compounds of Examples 1 to 745 that are mentioned below according to the invention are especially preferred.

Pharmacological Studies

The compounds according to the invention were tested in various models. The compounds of general formula I according to the invention are distinguished in that in this case, these are compounds with antiandrogenic action that destabilize the androgen receptor, inhibit the prostate tumor growth and simultaneously have a high, optionally oral bio-availability.

The in-vitro tests regarding the influences on the activities of the androgen receptor were performed as follows:

In the diagrams presented here, the following abbreviations were used:

-   -   Bicalutamide:         N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide     -   R1881: Methyltrienolone,         17β-hydroxy-17α-methylestra-4,9,11-trien-3-one     -   CPA: Cyproterone acetate,         17-(acetyloxy)-6-chloro-1β,2β-dihydro-3′H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione     -   Compound B:         4-[2,5-Dihydro-3-methyl-4-[4-[4-(methylsulfonyl)piperazin-1-yl]butyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile         (Example 117)         Model 1: Destabilization of the AR in LNCaP Cells by Test         Substances

In a 25 cm² cell culture flask, 2*10⁶ LNCaP cells in 6 ml of RPMI 1640 without phenol red are grown with 4 mmol of glutamine and 5% activated-carbon-treated serum (CCS) and are cultivated overnight at 37° C., 5% CO₂, in a moist atmosphere. On the next day, the cells are treated with the test substance at a concentration of 10 or 1 μm, whereby the final concentration of the solvent is 0.5% DMSO. As a control, cells are treated only with 0.5% DMSO. After an incubation time of 24 hours, the medium is changed with a renewed addition of substance and another 24 hours of incubation. After 48 hours, the cells are washed with PBS, dissolved with PBS/20 mmol of EDTA, washed again with PBS-CA²⁺/Mg²⁺ and then frozen for at least two hours as cell pellets at −80° C. Then, the cell pellet is resuspended in 200 μl of lysis buffer (50 mmol of tris/HCl, pH 7.5; 150 mmol of NaCl, 1.5 mmol of MgCl₂, 0.2% SDS, 10% glycerol, 1 mmol of DTT, 0.01×complete-EDTA protease inhibitors (Roche, Mannheim)) and treated with 10 U benzonase (Merck, Darnstadt) for 10 minutes at 4° C. After 5 mmol of EDTA is added, insoluble material is pelletized, and 25 μg of the cell extract is separated in a 4-12% SDS-polyacrylamide gel (Invitrogen). Then, the proteins are transferred to nitrocellulose (HyBondECL, Amersham) and incubated with monoclonal antibodies against the androgen receptor (AR441; Santa Cruz Biotechnologies; 1:400 dilution) and actin (ICN, 1:5000-1:20,000 dilution). After incubation with the secondary antibodies (anti-mouse IgG-HRP, Amersham or -AP, Invitrogen), the Western blot is developed by chemiluminescnce (ECL, Amersham; Western Breeze, Invitrogen), and the light signals are quantified with a Chemilmager™ (Kodak). The amount of androgen receptor is calculated in a ratio to actin as a percentage of the DMSO control.

Table 1 shows the action of selected test substances at concentrations of 10 or 1 μM on the content of androgen receptor protein in the human prostate cell line LNCaP. The data correspond to the proportion by percentage of the AR content of cells that were treated only with the solvent DMSO (=control). The treatment of the cells with the cited test substances results in a treatment concentration of 10 μM in a reduction of the AR content to one-fifth of the control (22% of Example 248: 4-[2,5-dihydro-3-[6-[4-(2-methoxybenzoyl)piperazin-1-yl]hexyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile). The comparison substance bicalutamide does not influence the AR content, while the synthetic androgen R1881 stabilizes the AR protein. The latter is known from the literature (J. A. Kemppainen et al. J. Biol. Chem. 1992, 267, 968-974).

Example 248: 4-[2,5-Dihydro-3-[6-[4-(2-methoxybenzoyl)piperazin-1-yl]hexyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile and Example 629: 4-[3-[5-[4-(ethyl-sulfonyl)piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile reduce the AR content also at a concentration of 1 μM to a value up to half of the control. By the reduction of the AR content, which presumably is carried out by a destabilization of the AR protein, the inhibitory action of the antihormones on the cell proliferation is to be further intensified.

TABLE 1 AR Content (%) in LNCaP Cells After Treatment with Selected Test Substances AR Content Ex- [%] am- At 10 At 1 ple Test Substance μM μM 248 4-[2,5-Dihydro-3-[6-[4-(2-methoxybenzoyl)- 22 51 piperazin-1-yl]hexyl]-4-methyl-2,5-dioxo-1H-pyrrol- 1-yl]-2-(trifluoromethyl)benzonitrile 158 4-[3-[5-[4-(3,4-Dimethoxybenzoyl)piperazin-1- 22 yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 117 4-[2,5-Dihydro-3-methyl-4-[4-[4-(methylsulfonyl)- 36 57 piperazin-1-yl]butyl]-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile  90 4-[3-[4-[4-(2-Chlorobenzoyl)piperazin-1-yl]butyl]- 34 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 300 4-[3-[6-[4-[(4-Cyanophenyl)sulfonyl]piperazin- 35 1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 365 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5- 36 82 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]- N-(2,6-dichloropyridin-4-yl)piperazine-1- carboxamide 264 4-[3-[6-[4-[(4-Chlorophenoxy)acetyl]piperazin-1- 37 yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 340 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5- 41 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]- N-[3-(methylsulfanyl)phenyl]piperazine-1- carboxamide 207 4-[3-[5-[4-[(2,1,3-Benzothiadiazol-4- 42 yl)sulfonyl]piperazin-1-yl]pentyl]-2,5-dihydro-4- methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 326 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5- 45 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(3-fluorophenyl)-piperazine- 1-carboxamide 330 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5- 46 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(4-fluorophenyl)- piperazine-1-carboxamide 295 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4- 48 (phenylsulfonyl)piperazin-1-yl]hexyl]-1H-pyrrol-1- yl]-2-(trifluoromethyl)benzonitrite 296 4-[2,5-Dihydro-3-methyl-4-[6-[4-(methyl- 48 sulfonyl)piperazin-1-yl]hexyl]-2,5-dioxo-1H-pyrrol- 1-yl]-2-(trifluoromethyl)benzonitrile  96 4-[3-[4-[4-[4-(Dimethylamino)benzoyl]piperazin-1- 50 yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 315 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5- 52 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]- N-phenylpiperazine-1-carboxamide 121 4-[3-[4-[4-[(4-Cyanophenyl)sulfonyl]piperazin-1- 53 yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol- 1-yl]-2-(trifluoromethyl)benzonitrile  93 4-[3-[4-[4-(Cyclobutylcarbonyl)piperazin-1- 53 yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 297 4-[2,5-Dihydro-3-methyl-4-[6-[4-[(4- 59 methylphenyl)sulfonyl]piperazin-1-yl]hexyl]-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 351 [4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5- 61 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]- N-(2,6-dichlorophenyl)piperazine-1-carboxamide 350 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5- 61 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]- N-(2,6-difluorophenyl)piperazine-1-carboxamide 324 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5- 62 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]- N-[2-(trifluoromethyl)phenyl]piperazine-1- carboxamide 270 4-[2,5-Dihydro-3-methyl-4-[6-[4-(3-methyl-1- 65 oxobutyl)piperazin-1-yl]hexyl]-2,5-dioxo-1H-pyrrol- 1-yl]-2-(trifluoromethyl)benzonitrile  99 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[4-[4-[(thien- 66 2-yl)carbonyl]piperazin-1-yl]butyl]-1H-pyrrol-1-yl]- 2-(trifluoromethyl)benzonitrile 342 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5- 67 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[4-(methylsulfanyl)phenyl]piperazine- 1-carboxamide 268 4-[3-[6-[4-(4-Cyanobenzoyl)piperazin-1-yl]hexyl]- 73 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 319 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5- dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]- 74 N-(1-methylethyl)-piperazine-1-carboxamide 629 4-[3-[5-[4-(Ethylsulfonyl)piperazin-1-yl]pentyl]-4,4- 54 dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 696 S-Methyl 4-[6-[3-[4-cyano-3-(trifluoro- 60 methyl)phenyl]-5,5-dimethyl-4-oxo-2- thioxoimidazolidin-1-yl]hexyl]piperazine- 1-carbothioate 524 4-[4,4-Dimethyl-5-oxo-3-[2-[4-[(thien-2- 61 yl)carbonyl]-piperazin-1-yl]propyl]-2- thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 546 4-[4,4-Dimethyl-3-[4-[4-(2-methyl-1- 68 oxopropyl)piperazin-1-yl]butyl]-5-oxo-2- thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 653 4-[4,4-Dimethyl-3-[6-[4-(2-methyl-1- 71 oxopropyl)piperazin-1-yl]hexyl]-5-oxo-2- thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 632 4-[3-[5-[4-[(4-Cyanophenyl)sulfonyl]piperazin-1- 75 yl]pentyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile Bica- N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4- 100  luta- fluorophenyl)sulfonyl]-2-hydroxy-2- mide methylpropanamide R- 17β-Hydroxy-17α-methylestra-4,9,11-trien-3-one 250  1881 (10 nM) Model 2: Inhibition of the Proliferation of LNCaP Cells

For the proliferation assay, 6000 LNCaP cells/well are grown in a microtiter plate (96-well) in 50 μl of RPMI 1640 medium with 5% CCS and cultivated as in Model 1. After 24 hours, the cells receive 50 μl of twice-concentrated test substance that is diluted in culture medium. The solvent concentration is 0.5% DMSO. After 4 days, the cells receive another 100 μl of once-concentrated test substance that is diluted in culture medium. After 7-8 days, the proliferation rate of the cells is determined by means of crystal violet assay (Gillies et al. Anal. Biochem. 1986, 159, 109-113). For determining antagonism, the substance treatment is performed in the presence of 0.1 nM of R1881 (1:1000 dilution of ethanolic solution). Control cells receive only 0.5% DMSO. For the agonism, the cells are treated only with test substance (without R1881).

Table 2 shows the inhibitory action of test substances on the proliferation of human androgen-dependent prostate cell line LNCaP. The inhibition of the cell proliferation is an important requirement for the therapeutic use of substances in the treatment of prostate cancer. Seven AR-destabilizing test substances that are selected according to the invention inhibit the cell proliferation in the presence of 0.1 nM of synthetic androgen R1881 with a similar to considerably lower IC₅₀, such as the approved nonsteroidal antiandrogen bicalutamide. In a substance concentration of 1 μM, the proliferation is reduced by at least 80% compared to the cell growth in the presence of 0.1 nM of R1881. Example 696: S-Methyl 4-[6-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]piperazine-1-carbothioate and Example 653: 4-[4,4-dimethyl-3-[6-[4-(2-methyl-1-oxopropyl)piperazin-1-yl]hexyl]-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile completely block the growth at this concentration, while bicalutamide, under these conditions, achieves only an inhibition of 85%. Up to a tested concentration of 10 μM, a proliferation-stimulating action was not observed in any one of the seven test substances.

TABLE 2 Inhibition of the Proliferation of LNCaP Cells by Test Substances. % In- Ex- IC50 hibition am- [10⁻⁷ at ple Test Substance M] 1 μM 248 4-[2,5-Dihydro-3-[6-[4-(2-methoxybenzoyl)- 2.5 97.6 piperazin-1-yl]hexyl]-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 315 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 3.8 80.8 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-phenylpiperazine-1-carboxamide 516 4-[3-[3-[4-(2-Methoxybenzoyl)piperazin-1- 0.26 107 yl]propyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 546 4-[4,4-Dimethyl-3-[4-[4-(2-methyl-1- 0.8 97.5 oxopropyl)-piperazin-1-yl]butyl]-5-oxo-2- thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 602 4-[3-[5-[4-(2,2-Dimethyl-1-oxopropyl)-piperazin- 0.18 92 1-yl]pentyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 629 4-[3-[5-[4-(Ethylsulfonyl)piperazin-1- 1.4 94.6 yl]pentyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 638 4-[5-[3-[4-Cyano-3-(trifluoromethyl)phenyl]- 0.33 95 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]pentyl]-N-ethylpiperazine-1-carbothioamide 645 4-[4,4-Dimethyl-3-[6-[4-methylpiperazin-1- 0.26 92 yl)hexyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2 (trifluoromethyl)benzonitrile 648 4-[6-[3-[4-Cyano-3-(trifluoromethyl)phenyl]- 0.11 99 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]hexyl]piperazine-1-carbonitrile 653 4-[4,4-Dimethyl-3-[6-[4-(2-methyl-1- 0.9 108 oxopropyl)piperazin-1-yl]hexyl]-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 656 4-8 3-[6-[4-(2-Hydroxy-2-methyl-1-oxopropyl)- 0.26 99 piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile

TABLE 3 (Continuation) Inhibition of the Proliferation of LNCaP Cells by Test Substances. % In- Ex- IC50 hibition am- [10⁻⁷ at ple Test Substance M] 1 μM 670 4-[4,4-Dimethyl-5-oxo-2-thioxo-3-[6-[4- 0.24 96 (trifluoracetyl)piperazin-1-yl]hexyl]- imidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 672 4-[4,4-Dimethyl-5-oxo-3-[6-[4-[(thien-2- 0.26 100 yl)acetyl]piperazin-1-yl]hexyl]-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 0.55 97 679 rel-4-[3-[6-[(2R,5S)-2,5-Dimethyl-4-[(thien-2- yl)carbonyl]piperazin-1-yl]hexyl]-4,4-dimethyl- 5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 696 S-Methyl 4-[6-[3-[4-cyano-3-(trifluoromethyl)- 0.2 110 phenyl]-5,5-dimethyl-4-oxo-2- thioxoimidazolidin-1-yl]hexyl]-piperazine-1- carbothioate 706 4-[3-[7-[4-(Methoxyacetyl)piperazin-1- 0.19 101 yl]heptyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 723 4-[4,4-Dimethyl-3-[8-[4-(methylsulfonyl)- 0.26 90 piperazin-1-yl]octyl]-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile Bica- N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4- 3.8 84.6 lut- fluorophenyl)sulfonyl]-2-hydroxy-2- amide methylpropanamide Model 3: Inhibition of the Proliferation of Other Cell Lines That do not Originate From the Prostate

To examine the growth-inhibiting action of test substances in cells that are not of prostatic origin, MaTu cells, MaTu/Adr cells, HaCaT cells and A431 cells were treated with test substances, whereby

MaTu: means human breast cancer cell line MaTu/Adr: means adriamycin-resistant MaTu cell line HaCaT: means human fibroblast cell line A-431: means human epidermis cell line.

Depending on the cell line, 1000-4000 cells/well were grown in RPMI 1640 medium (A431; MaTu and MaTu/Adr) or DMEM/HAM'SF12 medium (HaCaT) without phenol red with 2 mmol of L-glutamine and 10% CCS, and after a 24-hour incubation, they were treated with various concentrations of test substances diluted in culture medium. After a 3-day treatment period, the number of cells was determined by crystal violet assay, as in Model 2. The solvent control contained 0.1% ethanol.

Table 3 shows the effect of selective test substances on the proliferation of human cells that do not originate from the prostate. The substances were tested at a concentration of 10 μM, and the data correspond to the proportion, in percent, of the cell growth of the solvent control. It turns out that the test substances exerted no inhibitory action on the four different cell lines or, in individual cases, only a slight inhibitory action. Under the given test conditions, the comparison substance bicalutamide showed a slight inhibition in all cell lines except for MaTu. These results indicate that the antiproliferative action of the test substances is androgen receptor-dependent and that even at high substance concentrations in the micromolecular range, no secondary cytotoxic actions occur.

TABLE 4 Action of Selective Test Substances on the Proliferation of Non-Prostate Cells at a Concentration of 10 μM. Proliferation in the Cell Line Test Substance (Example No.) MaTu MaTu/Adr A431 HaCaT 4-[2,5-Dihydro-3-methyl-4-[4-[4- 103 ± 10% 94 ± 4% 100 ± 5% 104 ± 6% (methylsulfonyl)piperazin-1- yl]butyl]-2,5-dioxo-1H-pyrrol-1- yl]-2-(trifluoromethyl)- benzonitrile (117) 4-[3-[4-[4-(2-Chlorobenzoyl)- 96 +/− 3% 80 +/− 2% 98 +/− 7% 102 +/− 12% piperazin-1-yl]butyl]-2,5-dihydro- 4-methyl-2,5-dioxo-1H-pyrrol-1- yl]-2-(trifluoromethyl)- benzonitrile (90) 4-[2,5-Dihydro-3-[6-[4-(2- 98 +/− 4% 88 +/− 4% 102 +/− 5% 104 +/− 7% methoxybenzoyl)piperazin-1- yl]hexyl]-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile (248) 4-[6-[1-[4-Cyano-3-(trifluoro- 95 +/− 7% 90 +/− 10% 95 +/− 5% 102 +/− 6% methyl)phenyl]-2,5-dihydro-4- methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-phenylpiperazine-1- carboxamide (315) Bicalutamide 97 ± 3% 84 ± 6% 89 ± 7% 92 ± 3% Model 4: Antiandrogenic Action of Selective Test Substances on the Growth of Accessory Sexual Glands of Mice

The function and the size of accessory sexual glands (prostate and seminal vesicles) depend on androgens. In castrated animals, a growth of these (organs is induced by androgen administration. The simultaneous treatment with antiandrogens inhibits this growth, depending on the dose.

To examine the test substances, the mice were castrated. The treatment with testosterone propionate (0.03 mg/mouse) and the test substances (formulated 2×daily 30 mg/kg s.c. in benzyl benzoate-castor oil (10:90)) was on the same day. The treatment was carried out over 7 days and at the end of the test, the weights of the seminal vesicles and prostates were determined. The inhibition, in percent, of the seminal vesicle growth was calculated relative to the control groups (with and without testosterone). As a reference substance, cyproterone acetate (30 mg/kg s.c.) was used.

The results are shown in Table 4.

The treatment with the test substances of Example 629: 4-[3-[5-[4-(ethylsulfonyl)-piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)-benzonitrile and Example 546: 4-[4,4-dimethyl-3-[4-[4-(2-methyl-1-oxopropyl)piperazin-1-yl]butyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)-benzonitrile resulted in an almost 100% inhibition of the growth of the seminal vesicles, while the treatment with the reference substance cyproterone acetate resulted in an inhibition of only 85%. The inhibiting values for bicalutamide, determined in preceding tests, was also only at 86%.

TABLE 4 Action of Selective Test Substances on Testosterone-Stimulated Growth of the Seminal Vesicles at a Dose of 2 × 30 mg/kg. % Inhibition of the MSB Example Test Substance Growth 629 4-[3-[5-[4-(Ethylsulfonyl)piperazin-1-yl] 98 pentyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 546 4-[4,4-Dimethyl-3-[4-[4-(2-methyl-1- 98 oxopropyl)-piperazin-1-yl]butyl]-5-oxo-2- thioxoimidazolidin-1- yl]-2-(trifluoromethyl)benzonitrile 696 S-Methyl 4-[6-[3-[4-cyano-3- 87 (trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2- thioxoimidazolidin-1-yl]hexyl]-piperazine-1- carbothioate CPA 17-(Acetyloxy)-6-chloro-1β,2β-dihydro-3′H- 85 cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione Bica- N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4- 86 lutamide fluorophenyl)-sulfonyl]-2-hydroxy-2- methylpropanamide Model 5: Antiandrogenic Action of a Selective Test Substance on the Growth of Human Prostate Cancer Xenografts In Vivo

In this invention, the action of Example 117 according to the invention: 4-[2,5-dihydro-3-methyl-4-[4-[4-(methylsulfonyl)piperazin-1-yl]butyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile on the tumor growth in vivo was studied by means of mouse-xenograft modules, in which the compound according to the invention was continuously administered subcutaneously.

The CWR22 tumor model [M. A. Wainstein, F. He, D. Robinson, H. J. Kung, S. Schwartz, J. M. Giaconia, N. L. Edgehouse, T. P. Pretlow, D. R. Bodner, E. D. Kursh, Cancer Res. 1994, 1; 54(23), 6049-52] is a hormone-dependent human prostate carcinoma model. The tumor model was established and further propagated by “scrial passaging” of prostate cancer tissue, which was removed during an OP in immunodeficient hairless mice. The androgen-dependent LNCaP prostate cancer model was also established from a patient tumor. This tumor model grows both in cell culture and as a xenotransplant on immunodeficient mice (Culig, Hoffman Brit. J. Cancer, 1999, 242-251). For therapy tests, 6-week-old male hairless mice (NMRI mice, M&B, Bornholdtgard, Denmark) were supplemented with testosterone pellets (12.5 mg, 90-day release; IRA, Sarasota, Fla.). Either LNCaP cells (1.5×10⁶ cells) or small CWR22 tumor fragments (2×2 mm) were implanted subcutaneously in the left flank of the animals. After the tumors reached a size of 20-25 mm², the treatment with the invention substance was begun. [M. A. Wainstein, F. He, D. Robinson, H. J. Kung, S. Schwartz, J. M. Giaconia, N. L. Edgehouse, T. P. Pretlow, D. R. Bodner, E. D. Kursch, Cancer Res. 1994, 1; 54(23), 6049-52].

The results are shown in FIGS. 1 and 2.

FIGS. 1 and 2 show that, while the tumor grows quickly in the untreated control animals, the treatment with the invention substance results in a considerable growth inhibition of the prostate tumors. Both in the CWR22 tumor and in the LNCaP tumor, this growth inhibition is comparable to the effects of castration.

In both models, the inhibition of the tumor growth is superior in comparison to treatment with the antiandrogen bicalutamide. FIG. 1 shows growth inhibition of LNCaP prostate cancers by substance B of the invention and bicalutamide with administration 2 × daily s.c. with 30 mg/kg. FIG. 2 shows growth inhibition of CWR22 prostate cancers by substance B of the invention and bicalutamide with administration 2 × daily s.c. with 30 mg/kg.

In this invention, the action of a compound according to the invention on the tumor growth in vivo by means of a mouse-xenograft model was studied, in which the compound according to the invention was administered subcutaneously 2×daily over the entire treatment period. In comparison to the untreated control animals, an inhibition of tumor growth resulted. Retardation of the tumor growth was shown to be significant in castrated mice. The treatment was well-tolerated.

This invention shows that the compound according to the invention causes an inhibition of the prostate tumor growth that is superior to that of bicalutamide.

Dosage

In general, satisfactory results can be expected when the daily doses encompass a range of 5 μg to 50 mg of the compound according to the invention per kg of body weight. In larger mammals, for example humans, a recommended daily dose lies in the range of 10 μg to 30 mg per kg of body weight. Suitable dosages for the compounds according to the invention are from 0.005 to 50 mg per day per kg of body weight, depending on the age and constitution of the patient, whereby the necessary daily dose can be administered one or more times.

The formulation of the pharmaceutical preparations based on the new compounds is carried out in a way that is known in the art by the active ingredient being processed with the vehicles, fillers, substances that influence decomposition, binding agents, moisturizers, lubricants, absorbing agents, diluents, flavoring correctives, dyes, etc., that are commonly used in galenicals, and being converted into the desired form of administration. In this case, reference is made to Remington's Pharmaceutical Science, 15^(th) Edition. Mack Publishing Company, East Pennsylvania (1980).

For oral administration, especially tablets, coated tablets, capsules, pills, powders, granulates, lozenges, suspensions, emulsions or solutions are suitable. For parenteral administration, injection and infusion preparations are possible. For intra-articular injection, correspondingly prepared crystal suspensions can be used. For intramuscular injection, aqueous and oily injection solutions or suspensions and corresponding depot preparations are used. For rectal administration, the new compounds can be used in the form of suppositories, capsules, solutions (e.g., in the form of enemas) and ointments both for systemic and for local therapy. For topical application, formulations in gels, ointments, fatty ointments, creams, pastes, powders, milks and tinctures are possible. The dosage of the compounds of general formula I should be 0.01%-20% in these preparations to achieve an adequate pharmacological action. The topical application can also be carried out by means of a transdermal system, for example a patch.

The invention also comprises the compounds of general formula I according to the invention as therapeutic active ingredients. In addition, the compounds of general formula I according to the invention are part of the invention as therapeutic active ingredients together with pharmaceutically compatible and acceptable adjuvants and vehicles. The invention also comprises a pharmaceutical composition that contains one of the pharmaceutically active compounds according to the invention or mixture thereof and a pharmaceutically compatible salt or pharmaceutically compatible adjuvants and vehicles.

Subjects of this invention are therefore also pharmaceutical compositions that contain at least one compound of general formula I, optionally together with pharmaceutically compatible adjuvants and/or vehicles.

These pharmaceutical compositions and pharmaceutical agents can be provided for oral, rectal, subcutaneous, transdermal, percutaneous, intravenous or intramuscular administration. In addition to commonly used vehicles and/or diluents, they contain at least one compound of general formula I.

The pharmaceutical agents of the invention are produced in a known way with commonly used solid or liquid vehicles or diluents and the commonly used pharmaceutical-technical adjuvants according to the desired type of administration with a suitable dosage. The preferred preparations consist of a form for dispensing that is suitable for oral administration. Such forms for dispensing are, for example, tablets, film tablets, coated tablets, capsules, pills, powders, solutions or suspensions or else depot forms.

The pharmaceutical compositions, which contain at least one of the compounds according to the invention, are preferably administered orally.

Parenteral preparations, such as injection solutions, are also considered.

In addition, for example, suppositories are also named as preparations.

Corresponding tablets can be obtained, for example, by mixing active ingredient with known adjuvants, for example inert diluents such as dextrose, sugar, sorbitol, mannitol, polyvinyl pyrrolidone, explosives such as corn starch or alginic acid, binding agents such as starches or gelatins, lubricants such as magnesium stearate or talc and/or agents for achieving a depot effect, such as carboxylpolymethylene, carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets can also consist of several layers.

Coated tablets can accordingly be produced by coating cores, which are produced analogously to the tablets, with agents that are commonly used in tablet coatings, for example polyvinyl pyrrolidone or shellac, gum arabic, talc, titanium oxide or sugar. In this case, the shell of the coated tablet can also consist of several layers, whereby the adjuvants that are mentioned above in the tablets can be used.

In addition, solutions or suspensions with the compounds of general formula I according to the invention can contain taste-improving agents such as saccharin, cyclamate or sugar, as well as, e.g., flavoring substances, such as vanilla or orange extract. In addition, they can contain suspending adjuvants such as sodium carboxymethyl cellulose or preservatives such as p-hydroxybenzoates.

The capsules that contain compounds of general formula I can be produced, for example, by the compound(s) of general formula I being mixed with an inert vehicle such as lactose or sorbitol and encapsulated in gelatin capsules.

Suitable suppositories can be produced, for example, by mixing with vehicles that are provided for this purpose, such as neutral fats or polyethylene glycol or derivatives thereof.

The compounds according to the invention can be administered combined with one or more of the following active ingredients for therapy of prostate cancers:

-   1) Gonadotropic-hormone (GnRH) agonists -   2) 5α-Reductase inhibitor such as finasteride -   3) Cytostatic agents -   4) VEGF-kinase inhibitors -   5) Antigestagens -   6) Antiestrogens -   7) Antisense oligonucleotides -   8) EGF antibodies -   9) Estrogens

It is also possible, when treating prostate cancer with the compounds according to the invention, to combine their use with a clinical radiology method that is known in the art. (Laverdiere, J. et al., 1997, Intl. J. of Rad. One. Biol. Phys., 37, 247-252; Bolla, M. et al., 1997, New Engl. J. Med., 377, 95-300.)

Moreover, the compounds of general formula I according to the invention can be used for therapy and prophylaxis of other disease conditions that are not mentioned above.

The compounds of general formula I according to the invention can be produced as described below.

This invention also relates to the intermediate products of general formula VII V—W—(CH₂)_(n)—I  VII as well as of general formula VIII

in which

-   -   V stands for a substituted, aromatic radical of general formula         II,         in which     -   A stands for an acetyl group, an acetylamino group, a cyano         group, a nitro group, a trifluoromethyl group, or a halogen         (fluorine, chlorine),     -   B stands for a hydrogen atom, a halogen (fluorine, chlorine) or         a trifluoromethyl group, or     -   A and B together stand for a cyclic group of formula III or IV         that is bonded to the aromatic ring, whereby E stands for a         methylene group or an oxygen atom,     -   W stands for a heterocyclic compound of formula V,         in which     -   T stands for carbon, and a double bond is present between Q and         T, and Q means a group ═C(CH₃)— and U means oxygen,     -   n can assume one of the integral values 1, 2, 3, 4, 5, 6, 7, or         8,     -   i and j, independently of one another, stand for the values 1         and 2, whereby i+j can assume the value 2 or 3,     -   R and R′, independently of one another, can be a hydrogen atom         or a methyl group,         as well as the intermediate products of general formula VII and         of general formula VIII,         in which     -   A and B together stand for a cyclic group of formula III or IV         that is bonded to the aromatic ring, whereby E stands for a         methylene group or an oxygen atom,     -   W stands for a heterocyclic compound of formula V,         in which     -   T stands for nitrogen, and a single bond is present between Q         and T, and Q means a group —C(CH₃)₂— and U means sulfur,     -   n can assume one of the integral values 4, 5, 6, 7, or 8,     -   i and j, independently of one another, stand for the values 1         and 2, whereby i+j can assume the value 2 or 3,     -   R and R′, independently of one another, can be a hydrogen atom         or a methyl group.

This invention is explained in more detail based on the examples below without being limited thereto.

Synthesis Diagrams

According to the following diagram, maleimide derivatives of chain lengths n=4 to 8 can be produced:

According to the following diagram, maleimide derivatives of chain lengths n=1 to 8 can be produced:

According to the following diagram, thiohydantoin derivatives of chain lengths n=4 to 8 can be produced:

According to the following diagram, thiohydantoin derivatives of chain lengths n=2 to 8 can be produced:

Without further claboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

In the foregoing and in the following examples, all temperatures are set forth uncorrected in degrees Celsius and, all parts and percentages are by weight, unless otherwise indicated.

Production Process EXAMPLE 1 1,1-Dimethylethyl 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]piperazine-1-carboxylate

1a) Dimethyl (Z)-2-(5-Chloropentyl)-3-methyl-2-butenedicarboxylate

For the production of a Grignard reagent, 4.1 g of magnesium chips in 22 ml of tetrahydrofuran was introduced under nitrogen atmosphere, mixed with 31.3 g of 1-bromo-5-chloropentane in 200 ml of tetrahydrofuran, and it was stirred for 1 hour at room temperature. This mixture was then added in drops under nitrogen atmosphere and while being stirred at −35 to −40° C. to a suspension of 34.7 g of copper(I)-bromide-dimethyl sulfide complex in 700 ml of tetrahydrofuran, and it was stirred for another 2 hours at −40° C. Then, it was cooled to −65 to −70° C., and a solution of 20 g of dimethyl acetylenedicarboxylate and 48 ml of hexamethylphosphoric acid triamide in 290 ml of tetrahydrofuran were added in drops at this temperature while being stirred; after 5 minutes, a solution of 95 ml of hexamethylphosphoric acid triamide in 95 ml of tetrahydrofuran was added at −65 to −70° C., it was stirred for another 5 minutes at this temperature, 100 g of iodomethane in 280 ml of tetrahydrofuran was added in drops, and this mixture was heated overnight to room temperature. For working-up, it was cooled to −60° C. while being stirred, 410 ml of saturated ammonium chloride solution (with concentrated ammonia solution set at a pH of 8) was added in drops, heated to room temperature and stirred for 45 minutes at room temperature. This mixture was extracted four times with ethyl acetate, the combined organic phases were washed with saturated ammonium chloride solution (with concentrated ammonia solution set at a pH of 8) until the organic phase was light blue and then washed with water until the organic phase was colorless. After washing with saturated sodium chloride solution, drying on sodium sulfate and concentration by evaporation, it was chromatographed on silica gel with ethyl acetate/hexane, and thus in addition to 7.2 g of dimethyl (E)-2-(5-chloropentyl)-3-methyl-2-butenedicarboxylate, in each case 10.0 g of the title compound was obtained as a yellowish oil.

¹H-NMR (300 MHz, CDCl₃): δ [ppm]=3.76 s (3H, OCH₃); 3.75 s (3H, OCH₃); 3.53 t (J=6.5 Hz, 2H, CH₂Cl); 2.35 tbr (J=7 Hz, 2H, CH₂olefin); 1.95 s (3H, CH₃); 1.78 m (2H, CH₂); 1.47 m (4H, CH₂).

1b) 3-(5-Chloropentyl)-4-methyl-2,5-furandione

86 ml of water as well as 164 ml of a solution of lithium hydroxide in water (1 mol/l) were added to a solution of 7.16 g of (Z)-dimethyl 2-(5-chloropentyl)-3-methyl-2-butenedicarboxylate that was stirred under nitrogen atmosphere, and it was stirred for 2 days at room temperature. For working-up, it was concentrated by evaporation, the residue was dissolved in 290 ml of water, set at pH 2 with hydrochloric acid (2 mol/l) while being cooled in an ice bath and extracted three times with diethyl ether. The combined organic phases were washed with saturated sodium chloride solution, dried on sodium sulfate, concentrated by evaporation, and the title compound was thus obtained as a yellowish oil.

¹H-NMR (300 MHz, CDCl₃): δ [ppm]=3.54 t (J=6.5 Hz, 2H, CH₂Cl); 2.48 tbr (J=7.5 Hz, 2H, CH₂olefin); 2.08 sbr (3H, CH₃); 1.81 m (2H, CH₂); 1.63 m (2H, CH₂); 1.51 m (2H, CH₂).

1c) 4-[3-(5-Chloropentyl)-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

A mixture of 9.46 g of 3-(5-chloropentyl)-4-methyl-2,5-furandione and 8.13 g of 4-amino-2-(trifluoromethyl)benzonitrile in 22 ml of ethanol was mixed under a nitrogen atmosphere with 2.5 g of an activated molecular sieve (0.3 nm), and it was stirred for 2 days at 90° C. For working-up, the molecular sieve was filtered off after cooling, washed with ethanol, and the combined ethanol solutions were concentrated by evaporation. The residue was taken up in ethyl acetate and washed with water as well as saturated sodium chloride solution. After drying on sodium sulfate and concentration by evaporation, it was chromatographed on silica gel with ethyl acetate/hexane/toluene, and 11.69 g of the title compound was thus obtained as a white solid.

¹H-NMR (300 MHz, CDCl₃): δ [ppm]=8.06 sbr (1H, aryl); 7.91 s (2H, aryl); 3.56 t (J=7 Hz, 2H, CH₂Cl); 2.53 t (J=7.5 Hz, 2H, CH₂olefin); 2.11 s (3H, CH₃); 1.83 m (2H, CH₂); 1.69-1.50 m (4H, CH₂).

1d) 4-[2,5-Dihydro-3-(5-iodopentyl)-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

A mixture of 11.68 g of 4-[3-(5-chloropentyl)-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile and 18.2 g of sodium iodide in 180 ml of ethylmethylketone was stirred under a nitrogen atmosphere for 19 hours at 80° C. After cooling, it was diluted with ethyl acetate and washed with water as well as saturated sodium chloride solution. After drying on sodium sulfate and concentration by evaporation, 11.26 g of the title compound was obtained as a white solid.

¹H-NMR (300 MHz, CDCl₃): δ [ppm]=8.06 sbr (1H, aryl); 7.91 s (2H, aryl); 3.20 t (J=7 Hz, 2H, CH₂I); 2.52 t (J=7.5 Hz, 2H, CH₂olefin); 2.11 s (3H, CH₃); 1.86 m (2H, CH₂); 1.63 m (2H, CH₂); 1.50 m (2H, CH₂).

1e) 1,1-Dimethylethyl 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]piperazine-1-carboxylate

1.56 g of 1,1-dimethylethyl piperazine-1-carboxylate was added under a nitrogen atmosphere to a solution of 2.0 g of 4-[2,5-dihydro-3-(5-iodopentyl)-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile in 53 ml of tetrahydrofuran, and this mixture was stirred for 7 days at room temperature. For working-up, it was diluted with ethyl acetate and washed with semi-saturated sodium bicarbonate solution. After drying on sodium sulfate and concentration by evaporation, it was chromatographed with methanol/dichloromethane on silica gel, and thus 2.2 g of the title compound was obtained as a yellowish oil.

¹H-NMR (300 MHz, CDCl₃): δ [ppm]=8.06 sbr (1H, aryl); 7.90 m (2H, aryl); 3.43 m (4H, piperazine); 2.50 tbr (J=7.5 Hz, 2H, CH₂olefin); 2.40-2.31 m (4H, piperazine); 2.40-2.31 m (2H, CH₂piperazine); 2.09 s (3H, CH₃); 1.66-1.36 m (6H, CH₂); 1.45 s (9H, CH₃).

EXAMPLE 2 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-(piperazin-1-yl)pentyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

60 ml of trifluoroacetic acid was added in drops to a solution of 4.5 g of 1,1-dimethylethyl 4-[5-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]piperazine-1-carboxylate in 120 ml of dichloromethane under a nitrogen atmosphere and while being cooled in an ice bath, and it was stirred for 1 hour at room temperature. For working-up, the reaction solution was diluted with 250 ml of toluene, and the mixture was concentrated by evaporation. The residue was taken up in ethyl acetate and washed with saturated sodium bicarbonate solution. After drying on sodium sulfate and concentration by evaporation, it was chromatographed with methane/dichloromethane on silica gel, and 3.5 g of the title compound was thus obtained as a white solid.

¹H-NMR (300 MHz, CD₃OD): δ [ppm]=8.13 dbr (J=2 Hz, 1H, aryl); 8.08 dbr (J=8.5 Hz, 1H, aryl); 8.01 dd (J=8.5 Hz+2 Hz, 1H, aryl); 3.18 m (4H, piperazine); 2.69 m (4H, piperazine); 2.53 tbr (J=7.5 Hz, 2H, CH₂olefin); 2.47 tbr (J=7.5 Hz, 2H, CH₂piperazine); 2.07 s (3H, CH₃); 1.69-1.53 m (4H, CH₂); 1.44 m (2H, CH₂).

EXAMPLE 3 4-[2,5-Dihydro-3-methyl-4-[5-[4-[2-(methylsulfanyl)phenyl]piperazin-1-yl]pentyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

9 mg of 1-(2-thiomethylphenyl)piperazine in 0.5 ml of tetrahydrofuran was added to a solution of 10 mg of 4-[2,5-dihydro-3-(5-iodopentyl)-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile in 0.4 ml of tetrahydrofuran, and the mixture was stirred for 2 days at room temperature. For working-up, the reaction mixture was diluted with ethyl acetate and washed with semi-saturated sodium bicarbonate solution. After the organic phase was concentrated by evaporation, it was chromatographed with methanol/dichloromethane on silica gel, and 6 mg of the title compound was thus obtained as a yellowish oil.

ESI-MS: 557.

EXAMPLE 4 4-[3-[5-[4-(4-Cyanobenzoyl)piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

0.2 ml of a solution of triethylamine in tetrahydrofuran (1.5 mol/l) and 7 mg of 4-cyanobenzoyl chloride in 0.4 ml of tetrahydrofuran were added to a solution of 9 mg of 4-[2,5-dihydro-3-methyl-2,5-dioxo-4-[5-(piperazin-1-yl)-pentyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile in 0.4 ml of tetrahydrofuran, and the mixture was stirred for 8 hours at room temperature. For working-up, the reaction mixture was diluted with ethyl acetate and washed with semi-saturated sodium bicarbonate solution. After the organic phase was concentrated by evaporation, it was chromatographed with methanol/dichloromethane on silica gel, and 7 mg of the title compound was thus obtained as a yellowish oil.

ESI-MS: 564.

EXAMPLE 5 4-[3-[5-[4-[(3-Fluorophenyl)sulfonyl]piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

0.2 ml of a solution of triethylamine in tetrahydrofuran (1.5 mol/l) and 8 mg of 3-fluorophenylsulfonyl chloride in 0.4 ml of tetrahydrofuran were added to a solution of 9 mg of 4-[2,5-dihydro-3-methyl-2,5-dioxo-4-[5-(piperazin-1-yl)pentyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile in 0.4 ml of tetrahydrofuran, and the mixture was stirred for 8 hours at room temperature. For working-up, the reaction mixture was diluted with ethyl acetate and washed with semi-saturated sodium bicarbonate solution. After the organic phase was concentrated by evaporation, it was chromatographed with methanol/dichloromethane on silica gel, and 6 mg of the title compound was thus obtained as a white solid.

ESI-MS: 593.

EXAMPLE 6 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-[4-(dimethylamino)phenyl]piperazine-1-carboxamide

0.2 ml of a solution of triethylamine in tetrahydrofuran (1.5 mol/l) and 7 mg of 4-(dimethylamino)phenylisocyanate in 0.4 ml of tetrahydrofuran were added to a solution of 9 mg of 4-[2,5-dihydro-3-methyl-2,5-dioxo-4-[5-(piperazin-1-yl)pentyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile in 0.4 ml of tetrahydrofuran, and the mixture was stirred for 8 hours at room temperature. For working-up, the reaction mixture was diluted with ethyl acetate and washed with semi-saturated sodium bicarbonate solution. After the organic phase was concentrated by evaporation, it was chromatographed with methanol/dichloromethane on silica gel, and 3 mg of the title compound was thus obtained as a yellowish oil.

ESI-MS: 597.

EXAMPLE 7 4-[2,5-Dihydro-3-methyl-4-[3-[4-(1-methylethylsulfonyl)piperazin-1-yl]propyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

7a) Dimethyl (Z)-2-Methyl-3-(prop-2-enyl)-2-butenedicarboxylate

A solution of allylmagnesium chloride in tetrahydrofuran (8.5 ml, c=2.0 M) was added in drops under nitrogen atmosphere and while being stirred at −35 to −40° C. to a suspension of 3.47 g of copper(I)-bromide-dimethylsulfide complex in 70 ml of tetrahydrofuran, and it was stirred for 2 hours at −40° C. Then, it was cooled to −70° C., and a solution of 2.0 g of dimethyl acetylenedicarboxylate and 4.8 ml of hexamethylphosphoric acid triamide in 29 ml of tetrahydrofuran was added in drops at this temperature while being stirred. After 5 minutes, a solution of 9.5 ml of hexamethylphosphoric acid triamide in 9.5 ml of tetrahydrofuran was added at −70° C. It was stirred for 5 minutes at this temperature, then 4.2 ml of iodomethane in 28 ml of tetrahydrofuran was added in drops, and this mixture was heated overnight to room temperature. For working-up, it was cooled to −60° C. while being stirred, 200 ml of saturated ammonium chloride solution (with concentrated ammonia solution set at pH 8) was added in drops, it was heated to room temperature and stirred for 45 minutes at room temperature. This mixture was extracted four times with ethyl acetate, the combined organic phases were washed with saturated ammonium chloride solution (with concentrated ammonia solution set at pH 8) until the organic phase was light blue and was then washed with water until the organic phase was colorless. After washing with saturated sodium chloride solution, drying on sodium sulfate and concentration by evaporation, it was chromatographed on silica gel with ethyl acetate/hexane, and 980 mg of the title compound in addition to 950 mg of dimethyl (E)-2-methyl-3-(prop-2-enyl)-2-butenedicarboxylate in cache case were obtained as a yellowish oil.

¹H-NMR (300 MHz, CDCl₃): δ [ppm]=5.8 m (1H); 5.1 m (2H); 3.77 s (3H); 3.75 s (3H); 3.10 d (J=6.58 Hz, 2H); 1.96 s (3H). ESI-MS: 198

7b) 3-Methyl-4-(prop-2-enyl)-2,5-furandione

10 ml of water as well as 16 ml of a solution of lithium hydroxide in water (1 mol/l) were added to a solution, stirred under a nitrogen atmosphere, of 980 mg of the compound, produced under 7a, in 10 ml of tetrahydrofuran, and it was stirred for 2 days at room temperature. For working-up, it was concentrated by evaporation, the residue was dissolved in 30 ml of water, the pH was set at 2 with hydrochloric acid (2 mol/l) while being cooled in an ice bath, and it was extracted three times with diethyl ether. The combined organic phases were washed with saturated sodium chloride solution, dried on sodium sulfate, concentrated by evaporation, and 750 mg of the title compound was thus obtained as a yellowish oil.

ESI-MS: 152.

7c) 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-(prop-2-enyl)-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

A mixture of 750 mg of the compound, produced under 7b, and 920 mg of 4-amino-2-(trifluoromethyl)benzonitrile in 10 ml of ethanol was mixed under a nitrogen atmosphere with 0.5 g of an activated molecular sieve (0.3 nm) and stirred for 2 days at 90° C. For working-up, the molecular sieve was filtered off after cooling, washed with ethanol, and the combined ethanol solutions were concentrated by evaporation. The residue was taken up in ethyl acetate and washed with water as well as saturated sodium chloride solution. After drying on sodium sulfate and concentration by evaporation, it was chromatographed on silica gel with ethyl acetate/hexane, and 731 mg of the title compound was thus obtained as a colorless oil.

ESI-MS: 320.

7d) 4-[2,5-Dihydro-3-(3-hydroxypropyl)-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

A solution of 720 mg of the compound, produced under 7c, in 15 ml of THF was mixed under a nitrogen atmosphere at −78° C. with 5.9 ml of a 0.5 molar solution of 9-borabicyclo(3.3.1)nonane. The solution was slowly heated to room temperature and stirred overnight at room temperature. The solution that was stirred vigorously was mixed at 0° C. with 3.1 ml of 10% sodium hydroxide solution and with 2.7 ml of 33% hydrogen peroxide solution, and it was stirred for 12 hours at room temperature. For working-up, it was mixed with water (20 ml) and extracted three times with ethyl acetate. The combined organic phases were washed with saturated sodium chloride solution, dried on sodium sulfate, concentrated by evaporation, chromatographed on silica gel with ethyl acetate/hexane, and 623 mg of the title compound was thus obtained as a yellowish oil.

ESI-MS: 338.

7e) 4-[2,5-Dihydro-3-(3-iodopropyl)-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

A solution of 610 mg of the compound, produced under 7d, of 565 mg of triphenylphosphine and 183 mg of 1H-imidazole in 50 ml of THF was mixed under a nitrogen atmosphere with 545 mg of iodine. The solution was stirred overnight at room temperature and then mixed with 20 ml of water and 10 ml of 20% sodium thiosulfate solution and extracted three times with ethyl acetate. The combined organic phases were washed with saturated sodium chloride solution, dried on sodium sulfate, concentrated by evaporation, chromatographed on silica gel with ethyl acetate/hexane, and 572 mg of the title compound was thus obtained as a yellowish oil.

ESI-MS: 448.

7f) 1,1-Dimethylethyl 4-[3-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]propyl]piperazine-1-carboxylate

The production of the title compound was carried-out analogously to the reaction described under 1e. Starting from 550 mg of the compound that was produced under 7e, 372 mg of the title compound was obtained.

ESI-MS: 506.

7g) 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[3-(piperazin-1-yl)propyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

350 mg of the compound that was produced under 7f was stirred with 3 ml of trifluoroacetic acid in 10 ml of dichloromethane for 6 hours at room temperature. The reaction mixture was concentrated by evaporation in a vacuum and concentrated by evaporation several times with toluene in a vacuum, taken up in methanol, set at a pH of 8 to 9 with anion exchanger (Bio-Rad AG 1-X8, OH form), filtered, and concentrated by evaporation in a vacuum. 227 mg of the title compound was obtained as a crude product, which was further reacted in this form.

ESI-MS: 406.

7h) 4-[2,5-Dihydro-3-methyl-4-[3-[4-(1-methylethylsulfonyl)piperazin-1-yl]propyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

25 mg of the compound that was produced under 7g was stirred with 11 μl of 1-methylethylsulfonyl chloride and 25 μl of triethylamine in 2 ml of tetrahydrofuran for 16 hours at room temperature. The reaction mixture was concentrated by evaporation in a vacuum. Column chromatography on silica gel with a mixture that consists of hexane/ethyl acetate yielded 23 mg of the title compound as a colorless oil.

ESI-MS: 512.

EXAMPLE 8 4-[2,5-Dihydro-3-methyl-4-[[4-(1-methylethylsulfonyl)piperazin-1-yl]methyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

8a) Dimethyl (Z)-2-Ethenyl-3-methyl-2-butenedicarboxylate

The reaction of vinylmagnesium chloride with 5 g of dimethyl acetylenedicarboxylate analogously to the instructions described under 7a yielded 1.8 g of the title compound as a yellowish oil.

ESI-MS: 184.

8b) 4-[3-Ethenyl-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

The reaction of 1.8 g of the compound, produced under 8a, analogously to the instructions described under 7b and 7c yielded 1.1 g of the title compound as a colorless oil.

ESI-MS: 306.

8c) 4-[3-(1,2-Dihydroxyethyl)-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

A solution of 1.1 g of the compound, produced under 8b, in 50 ml of acetone was mixed at room temperature with a solution of 640 mg of N-methylmorpholine-N-oxide in 10 ml of water and 0.9 ml of a 10% solution of osmium tetraoxide. It was stirred for 30 hours at room temperature, then mixed with saturated sodium thiosulfate solution and extracted three times with ethyl acetate. The combined organic phases were washed with saturated sodium chloride solution, dried on sodium sulfate, concentrated by evaporation, chromatographed with dichloromethane/methanol on silica gel, and 770 mg of the title compound was thus obtained as a colorless oil.

ESI-MS: 340.

8d) 4-[3-Formyl-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

A solution of 750 mg of the compound, produced under 8c, in 50 ml of dichloromethane was mixed at room temperature in succession with 619 mg of sodium periodate and with 5 ml of a 10% aqueous solution of sodium bicarbonate. It was stirred for 5 hours at room temperature, then mixed with sodium sulfate and diluted with 50 ml of dichloromethane. The mixture was filtered and concentrated by evaporation. 705 mg of the title compound was obtained as a crude product, which was further reacted in this form.

ESI-MS: 308.

8e) 4-[2,5-Dihydro-3-methyl-4-[[4-(1-methylethylsulfonyl)piperazin-1-yl]methyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

25 mg of the compound, produced under 8d, in 1 ml of 1,2-dichloroethane was mixed with 19 mg of 1-(1-methylethylsulfonyl)piperazine and stirred for 15 minutes at room temperature. 25 mg of sodium tris-acetoxy borohydride was added in portions, and it was stirred for 2 hours at room temperature. The reaction mixture was mixed with 10 ml of sodium bicarbonate solution, stirred for 15 minutes at room temperature, and extracted three times with ethyl acetate. The combined organic phases were washed with saturated sodium chloride solution, dried on sodium sulfate, concentrated by evaporation and chromatographed with dichloromethane/methanol on silica gel. 17 mg of the title compound was obtained as a colorless oil.

ESI-MS: 484.

EXAMPLE 9 4-[2,5-Dihydro-3-methyl-4-[7-[4-(1-methylethylsulfonyl)piperazin-1-yl]heptyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

9a) Dimethyl (Z)-2-[7-[(4-Methoxyphenyl)methoxy]heptyl]-3-methyl-2-butenedicarboxylate

The reaction of 12.4 g of 1-[[(7-chloroheptyl)oxy]methyl]-4-methoxybenzene with 5.0 g of dimethyl acetylene dicarboxylate analogously to the instructions described under 1a yielded 4.18 g of the title compound as a yellowish oil.

ESI-MS: 378.

9b) 4-[2,5-Dihydro-3-[7-[(4-methoxyphenyl)methoxy]heptyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

The reaction of 4.10 g of the compound, produced under 9a, analogously to the instructions described under 7b and 7c yielded 3.35 g of the title compound as a colorless oil.

ESI-MS: 514.

9c) 4-[2,5-Dihydro-3-(7-hydroxyheptyl)-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

3.30 g of the compound, produced under 9b, in 100 ml of dichloromethane was mixed with 10 ml of water and 1.90 g of 4,5-dichloro-3,6-dioxocyclohexa-1,4-diene-1,2-dicarbonitrile, and it was stirred for 5 hours at room temperature. The reaction mixture was mixed with 20 ml of sodium bicarbonate solution and extracted three times with dichloromethane. The combined organic phases were washed with saturated sodium chloride solution, dried on sodium sulfate, concentrated by evaporation and chromatographed with dichloromethane/methanol on silica gel. 2.05 g of the title compound was obtained as a colorless oil.

ESI-MS: 394.

9d) 4-[3-(7-Iodoheptyl)-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

The reaction of 2.0 g of the compound, produced under 9c, analogously to the instructions that are described under 7e, yielded 1.99 g of the title compound as a colorless oil.

ESI-MS: 504.

9e) 1,1-Dimethylethyl 4-[7-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]heptyl]piperazine-1-carboxylate

The production of the title compound was carried out analogously to the reaction that was described under 1e. Starting from 1.95 g of the compound that was produced under 9c, 1.01 g of the title compound was obtained.

ESI-MS: 562.

9f) 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[7-(piperazin-1-yl)heptyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

The production of the title compound was carried out analogously to the reaction that was described under 7g. Starting from 1.0 g of the compound that was produced under 9e, 707 mg of the title compound was obtained.

ESI-MS: 462.

9g) 4-[2,5-Dihydro-3-methyl-4-[7-[4-(1-methylethylsulfonyl)piperazin-1-yl]heptyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

The production of the title compound was carried out analogously to the reaction that was described under 7h. Starting from 25 mg of the compound that was produced under 9f, 20 mg of the title compound was obtained.

ESI-MS: 568.

EXAMPLE 10 1,1-Dimethylethyl 4-[5-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-thioxoimidazolidin-1-yl]pentyl]piperazine-1-carboxylate

10a) 5-[3-(5-Hydroxypentyl)-5-imino-4,4-dimethyl-2-thioxoimidazolidin-1-yl]isobenzofuran-1(3H)-one

5 g of 5-aminoisobenzofuran-1-(3H)-one, whose production is described in R. N. Warrener, L. Liu, R. A. Russell, Tetrahedron 1998, 54, 7485-7496, with 2.8 ml of thiophosgene in 70 ml of water, was stirred for one hour at room temperature under nitrogen atmosphere. The reaction mixture was filtered. The residue was washed with water and then dried for 30 minutes at 60° C. in a vacuum. The thus-obtained crude isothiocyanate was combined with the cyanoamine that was produced by four hours of stirring of 520 μl of acetone cyanohydrin with 617 μl of 5-aminopentan-1-ol at room temperature, and it was heated to boiling with 4.7 ml of triethylamine in 100 ml of tetrahydrofuran for 30 minutes. After concentration by evaporation in a vacuum, the title compound was obtained as a crude product, which was immediately further reacted.

10b) 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-(5-hydroxypentyl)-5,5-dimethyl-2-thioxoimidazolidin-4-one

The crude product that was produced under 10a was stirred with 17 ml of 4 molar aqueous hydrochloric acid in 150 ml of methanol overnight at room temperature. The reaction mixture was then poured onto saturated, aqueous sodium bicarbonate solution and extracted with ethyl acetate. The organic phase was washed with saturated aqueous sodium chloride solution, dried on sodium sulfate, filtered and concentrated by evaporation in a vacuum. Column chromatography on silica gel with a mixture that consists of hexane/ethyl acetate yields 4.0 g of the title compound as a colorless foam.

¹H-NMR (300 MHz, CDCl₃): δ [ppm]=8.03 d (J=8 Hz, 1H, aryl); 7.53 ddbr (J=8 Hz+1 Hz, 1H, aryl); 7.52 d (J=1 Hz, 1H, aryl); 5.37 s (1H, CH₂O); 3.71 m (2H, CH₂OH); 3.69 m (2H, CH₂N); 1.89 m (2H, CH₂); 1.66 m (2H, CH[₂); 1.58 s (6H, CH₃); 1.49 m (2H, CH₂).

10c) 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[5-[[(4-methylphenyl)sulfonyl]oxy]pentyl]-2-thioxoimidazolidin-4-one

3.9 g of the compound that was produced under 10b was stirred with 12.3 g of p-toluenesulfonic acid chloride and 15 ml of triethylamine in 100 ml of dichloromethane for one hour at room temperature. The reaction mixture was poured into saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The organic phase was washed with saturated aqueous sodium chloride solution, dried on sodium sulfate, filtered and concentrated by evaporation in a vacuum. Column chromatography on silica gel with a mixture that consists of hexane/ethyl acetate yields 5.15 g of the title compound as a colorless foam.

Flash point 164.9° C. (methanol).

1H-NMR (300 MHz, CDCl₃): δ [ppm]=8.04 d (J=8 Hz, 1H, aryl); 7.81 d (J=9 Hz, 2H, tolyl); 7.54 dbr (J=8 Hz, 1H, aryl); 7.53 sbr (1H, aryl); 7.37 d (J=9 Hz, 2H, tolyl); 5.38 s (1H, CH₂O); 4.08 t (J=6 Hz, 2H, CH₂OTs); 3.68 m (2H, CH₂N); 1.86 m (2H, CH₂); 1.76 m (2H, CH₂); 1.58 s (6H, CH₃); 1.49 m (2H, CH₂).

10d) 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-(5-iodopentyl)-2-thioxo-imidazolidin-4-one

5.15 g of the compound that was produced under 10c was heated to boiling with 3 g of sodium iodide in 100 ml of acetone for one hour. The reaction mixture was filtered at room temperature and concentrated by evaporation in a vacuum. Column chromatography on silica gel with a mixture that consists of hexane/ethyl acetate yields 4.16 g of the title compound as a yellowish foam.

¹H-NMR (300 MHz, CDCl₃): δ [ppm]=8.03 d (J=8 Hz, 1H, aryl); 7.53 ddbr (J=8 Hz+2 Hz, 1H, aryl); 7.52 sbr (1H, aryl); 5.37 s (1H, CH₂O); 3.70 m (2H, CH₂N); 3.23 t (J=7 Hz, 2H, CH₂I); 1.89 m (4H, CH₂); 1.59 s (6H, CH₃); 1.53 m (2H, CH₂).

10c) 1,1-Dimethylethyl-4-[5-[3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]piperazine-1-carboxylate

1 g of the compound that was produced under 10d was stirred with 790 mg of 1,1-dimethylethyl piperazine-1-carboxylate and 591 μl of triethylamine for three days at room temperature. The reaction mixture was concentrated by evaporation in a vacuum. Column chromatography on silica gel with a mixture that consists of hexane/ethyl acetate yields 903 mg of the title compound as a yellowish foam.

¹H-NMR (300 MHz, CDCl₃): δ [ppm]=8.04 d (J=8 Hz, 1H, aryl); 7.54 dbr (J=8 Hz, 1H, aryl); 7.52 sbr (1H, aryl); 5.37 s (1H, CH₂O); 3.69 m (2H, CH₂N); 3.44 m (4H, piperazine); 2.38 m (4H, piperazine); 2.36 m (2H, CH₂piperazine); 1.86 m (2H, CH₂); 1.58 s (6H, CH₃); 1.57 m (2H, CH₂); 1.46 s (9H, ^(t)Bu); 1.42 m (2H, CH₂).

EXAMPLE 11 3-(1.3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[5-(piperazin-1-yl)pentyl]-5,5-dimethyl-2-thioxoimidazolidin-4-one

450 mg of the compound that was produced under 10e was stirred with 653 μl of trifluoroacetic acid in 8.5 ml of dichloromethane for 24 hours at room temperature. The reaction mixture was concentrated by evaporation in a vacuum and concentrated by evaporation in a vacuum several times with toluene, taken up in methanol, set at a pH of 8 to 9 with anion exchanger (Bio-Rad AG 1-X8, OH form), filtered, and concentrated by evaporation in a vacuum. 313 mg of the title compound was obtained as a crude product, which was further reacted in this form.

¹H-NMR (300 MHz, CD₃OD): δ [ppm]=7.96 d (J=8 Hz, 1H, aryl); 7.57 dbr (J=8 Hz, 1H, aryl); 7.65 sbr (1H, aryl); 5.43 s (1H, CH₂O); 3.75 m (2H, CH₂N); 2.87 m (4H, piperazine); 2.48 m (4H, piperazine); 2.39 m (2H, CH₂piperazine); 1.88 m (2H, CH₂); 1.61 m (2H, CH₂); 1.58 s (6H, CH₃); 1.42 m (2H, CH₂).

EXAMPLE 12 4-[5-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]-N-ethylpiperazine-1-carbothioamide

20 mg of the compound that was produced under 11 was heated to 80° C. with 7.7 ml of isothiocyanatoethane and 12.4 μl of triethylamine in 3 ml of tetrahydrofuran for 6 hours. The reaction mixture was concentrated by evaporation in a vacuum. Column chromatography on silica gel with a mixture that consists of hexane/ethyl acetate yields 1.1 mg of the title compound as a colorless oil.

¹H-NMR (300 MHz, CDCl₃): δ [ppm]=8.02 d (J=8 Hz, 1H, aryl); 7.53 dbr (J=8 Hz, 1H, aryl); 7.51 sbr (1H, aryl); 5.47 tbr (J=5 Hz, 1H, NH); 5.37 s (1H, CH₂O); 3.81 m (4H, piperazine); 3.70 qd (J=7 Hz+5 Hz, 2H, CH₂N); 3.67 m (2H, CH₂N); 2.4 m (4H, piperazine); 2.38 m (2H, CH₂piperazine); 1.86 m (2H, CH₂); 1.57 s (6H, CH₃) 1.57 m (2H, CH₂); 1.41 m (2H, CH₂); 1.24 t (J=7 Hz, 3H, CH₃).

EXAMPLE 13 S-Methyl 4-[5-[3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]piperazine-1-carbothioate

15.5 mg of the compound that was produced under 11 was refluxed for 4 hours with 6.2 ml of S-methyl chlorothioformate and 10 μl of triethylamine in 1 ml of tetrahydrofuran. The reaction mixture was concentrated by evaporation in a vacuum. Column chromatography on silica gel with a mixture that consists of hexane/ethyl acetate yields 8 mg of the title compound as a colorless oil.

¹H-NMR (300 MHz, CDCl₃): δ [ppm]=8.03 d (J=8 Hz, 1H, aryl); 7.53 dbr (J=8 Hz, 1H, aryl); 7.52 sbr (1H, aryl); 5.37 s (1H, CH₂O); 3.69 m (2H, CH₂N); 3.56 m (4H, piperazine); 2.43 m (4H, piperazine); 2.38 m (2H, CH₂piperazine); 2.33 s (3H, CH₃); 1.86 m (2H, CH₂); 1.57 s (6H, CH₃); 1.56 m (2H, CH₂); 1.42 m (2H, CH₂).

EXAMPLE 14 4-[5-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]-N,N-diethylpiperazine-1-carboxamide

15.5 mg of the compound that was produced under 11 was refluxed for 4 hours with 9.8 ml of diethylcarbamidoyl chloride and 10 μl of triethylamine in 1 ml of tetrahydrofuran. The reaction mixture was concentrated by evaporation in a vacuum. Column chromatography on silica gel with a mixture that consists of hexane/ethyl acetate yields 6 mg of the title compound as a colorless oil.

¹H-NMR (300 MHz, CDCl₃): δ [ppm]=8.03 d (J=8 Hz, 1H, aryl); 7.53 dbr (J=8 Hz, 1H, aryl); 7.52 sbr (1H, aryl); 5.37 s (1H, CH₂O); 3.69 m (2H, CH₂N); 3.23 m (4H, piperazine); 3.19 q (J=7 Hz, 4H, CH₂N); 2.43 m (4H, piperazine); 2.37 m (2H, CH₂piperazine); 1.86 m (2H, CH₂); 1.59 m (2H, CH₂); 1.58 s (6H, CH₃); 1.41 m (2H, CH₂); 1.11 t (J=7 Hz, 6H, CH₃).

EXAMPLE 15 4-[3-[2-[4-(2-Methoxybenzoyl)piperazin-1-yl]ethyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile

15a) 1,1-Dimethylethyl 4-[2-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-4-imino-5,5-dimethyl-2-thioxoimidazolidin-1-yl]ethyl]piperazine-1-carboxylate

687 g of 4-amino-2-(trifluoromethyl)benzonitrile with 311 μl of thiophosgene in 4 ml of N,N-dimethylformamide was stirred for one hour at room temperature under nitrogen atmosphere. The reaction mixture was diluted with ethyl acetate, washed with water and then concentrated by evaporation in a vacuum. The thus obtained crude isothiocyanate was combined with the cyanoamine that was produced and filtered by two hours of stirring from 743 μl of acetone cyanohydrin with 930 mg of 1,1-dimethylethyl 4-(2-aminoethyl)piperazine-1-carboxylate and 406 mg of a molecular sieve 3 Å in 20 ml of tetrahydrofuran at room temperature, and it was heated to boiling for one hour with 0.57 ml of triethylamine in 40 ml of tetrahydrofuran. After concentration by evaporation in a vacuum, the title compound was obtained as a crude product, which was immediately further reacted.

15b) 1,1-Dimethylethyl 4-[2-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]ethyl]piperazine-1-carboxylate

The crude product that was produced under 15a was stirred with 3.7 ml of 4 molar aqueous hydrochloric acid in 40 ml of methanol overnight at room temperature. The reaction mixture was then poured onto saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate. The organic phase was washed with saturated aqueous sodium chloride solution, dried on sodium sulfate, filtered and concentrated by evaporation in a vacuum. Column chromatography on silica gel with a mixture that consists of hexane/ethyl acetate yields 553 mg of the title compound as a colorless foam.

¹H-NMR (300 MHz, CDCl₃): δ [ppm]=7.95 d (J=8 Hz, 1H, aryl); 7.88 d (J=2 Hz, 1H, aryl); 7.77 ddbr (J=8 Hz+2 Hz, 1H, aryl); 3.85 m (2H, CH₂N); 3.44 m (4H, piperazine); 2.78 m (2H, CH₂N); 2.52 m (4H, piperazine); 1.59 s (6H, CH₃); 1.46 m (9H, ^(t)Bu).

15c) 4-[4,4-Dimethyl-5-oxo-3-[2-(piperazin-1-yl)ethyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile

553 mg of the compound, produced under 15b, was stirred with 809 μl of trifluoroacetic acid in 10 ml of dichloromethane for 24 hours at room temperature. The reaction mixture was concentrated by evaporation in a vacuum and concentrated by evaporation in a vacuum several times with toluene, taken up in methanol, set at a pH of 8 to 9 with anion exchanger (Bio-Rad AG 1-X8, OH form), filtered and concentrated by evaporation in a vacuum. 426 mg of the title compound was obtained as a crude product, which was further reacted in this form.

¹H-NMR (300 MHz, CDCl₃): δ [ppm]=7.95 d (J=8 Hz, 1H, aryl); 7.89 d (J=2 Hz, 1H, aryl); 7.77 ddbr (J=8 Hz+2 Hz, 1H, aryl); 3.85 m (2H, CH₂N); 2.91 m (4H, piperazine); 2.76 m (2H, CH₂N); 2.55 m (4H, piperazine); 1.59 s (6H, CH₃).

15d) 4-[3-[2-[4-(2-Methoxybenzoyl)piperazin-1-yl]ethyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile

20 mg of the compound that was produced under 15c was refluxed with 14 ml of 2-methoxybenzoyl chloride and 13.1 μl of triethylamine in 1 ml of tetrahydrofuran for 4 hours. The reaction mixture was concentrated by evaporation in a vacuum. Column chromatography on silica gel with a mixture that consists of hexane/ethyl acetate yields 16 mg of the title compound as a colorless oil.

¹H-NMR (300 MHz, CDCl₃): δ [ppm]=7.95 d (J=8 Hz, 1H, aryl); 7.88 d (J=2 Hz, 1H, aryl); 7.76 ddbr (J=8 Hz+2 Hz, 1H, aryl); 7.35 ddd (J=8 Hz+7 Hz+2 Hz, 1H, aryl); 7.23 dd (J=7 Hz+2 Hz, 1H, aryl); 6.99 dd (J=7 Hz+7 Hz, 1H, aryl); 6.91 dbr (J=8 Hz, 1H, aryl); 3.85 m (2H, CH₂N); 3.84 m (1H, piperazine); 3.83 s (3H, OCH₃); 3.81 m (1H, piperazine); 3.28 m (2H, piperazine); 2.80 m (2H, CH₂N); 2.67 m (1H, piperazine); 2.55 m (1H, piperazine); 2.47 m (1H, piperazine); 1.59 (6H, CH₃).

The following compounds according to the invention were produced analogously to the previously described compounds.

TABLE 5 Compounds of General Formula I According to the Invention, in which V = Trifluoromethylbenzonitrile, W = Maleimide, n = 1 Synthesis Ex- Analogous am- to ESI- ple Name Example MS 16 4-[3-[(4-Acetylpiperazin-1-yl)methyl]-2,5- 8 420 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 17 4-[2,5-Dihydro-3-[[4-(methoxyacetyl)piperazin- 8 450 1-yl]methyl]-4-methyl-2,5-dioxo-1H-pyrrol-1- yl]-2-(trifluoromethyl)benzonitrile 18 4-[2,5-Dihydro-3-[4-[[(2-methoxyethoxy)- 8 494 acetyl]piperazin-1-yl]methyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 19 4-[2,5-Dihydro-3-[[4-[[2-(2-methoxyethoxy)- 8 538 ethoxy]acetyl]piperazin-1-yl]methyl]-4-methyl- 2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 20 4-[2,5-Dihydro-3-[[4-2-(2-methoxybenzoyl)- 8 512 piperazin-1-yl]methyl]-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 21 4-[2,5-Dihydro-3-methyl-4-[[4- 8 456 (methylsulfonyl)-piperazin-1-yl]methyl]-2,5- dioxo-1H-pyrrol-1-yl]- 2-(trifluoromethyl)benzonitrile 22 4-[3-[[4-(Ethylsulfonyl)piperazin-1-yl]methyl]- 8 470 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1- yl]-2-(trifluoromethyl)benzonitrile 23 4-[2,5-Dihydro-3-[[4-(2- 8 500 methoxyethyl)sulfonyl]-piperazin-1-yl]methyl]- 4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 24 4-[2,5-Dihydro-3-[[4-[[2-[2-(2-methoxy- 8 588 ethoxy)-ethoxy]-ethyl]sulfonyl]piperazin-1- yl]methyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]- 2-(trifluoromethyl)benzonitrile 25 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[[4- 8 518 (phenylsulfonyl)piperazin-1-yl]methyl]-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile

TABLE 6 Compounds of General Formula I According to the Invention, in which V = Trifluoromethylbenzonitrile, W = Maleimide, n = 2 Synthesis Ex- Analogous am- to ESI- ple Name Example MS 26 4-[3-[2-(4-Acetylpiperazin-1-yl)ethyl]-2,5- 7 (4) 434 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 27 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[2-(4-(1- 7 (4) 448 oxopropyl)piperazin-1-yl)ethyl]-1H-pyrrol-1- yl]-2-(trifluoromethyl)benzonitrile 28 4-[3-[2-[4-(Cyclopropylcarbonyl)piperazin-1- 7 (4) 460 yl]ethyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 29 4-[2,5-Dihydro-3-[2-[4- 7 (4) 464 (methoxyacetyl)piperazin-1-yl]ethyl]-4- methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 30 4-[2,5-Dihydro-3-[2-[4-(3-methoxy-1- 7 (4) 478 oxopropyl)piperazin-1-yl]ethyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 31 4-[2,5-Dihydro-3-[2-[4-[(2-methoxyethoxy)- 7 (4) 508 acetyl]piperazin-1-yl]ethyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 32 4-[2,5-Dihydro-3-[2-[4-[[2-(2-methoxyethoxy)- 7 (4) 552 ethoxy]acetyl]piperazin-1-yl]ethyl]-4-methyl- 2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 33 4-[2,5-Dihydro-3-[2-[4-(2-methoxybenzoyl)- 7 (4) 526 piperazin-1-yl]ethyl]-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 34 4-[2,5-Dihydro-3-methyl-4-[2-[4- 7 470 (methylsulfonyl)-piperazin-1-yl]ethyl]-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 35 4-[3-[2-[4-(Ethylsulfonyl)piperazin-1-yl]ethyl]- 7 484 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1- yl]-2-(trifluoromethyl)benzonitrile 36 4-[3-[2-[4-(Cyclopropylsulfonyl)piperazin-1- 7 496 yl]ethyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 37 4-[2,5-Dihydro-3-[2-[4-(2-methoxyethyl)- 7 514 sulfonyl]piperazin-1-yl]ethyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 38 4-[2,5-Dihydro-3-[2-[4-[[2-(2-methoxyethoxy)- 7 558 ethyl]sulfonyl]piperazin-1-yl]ethyl]-4-methyl- 2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 39 4-[2,5-Dihydro-3-[2-[4-[[2-[2-(2- 7 602 methoxyethoxy)-ethoxy]ethyl]sulfonyl]piper- azin-1-yl]ethyl]-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 40 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[2-[4- 7 532 (phenylsulfonyl)piperazin-1-yl]ethyl]-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 41 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[2-[4- 7 546 [(phenylmethyl)sulfonyl]piperazin-1-yl]ethyl]- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 42 4-[2,5-Dihydro-3-methyl-4-[2-[4-[(1-methyl- 7 536 1H-imidazol-4-yl)sulfonyl]piperazin-1- yl]ethyl]-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 43 4-[2-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 7 (6) 477 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]ethyl]-N-(1-methylethyl)piperazine- 1-carboxamide 44 4-[2-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-  7 (12) 479 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]ethyl]-N-ethylpiperazine-1-carbothioamide 45 Methyl 4-[2-[1-[4-cyano-3-(trifluoromethyl)-  7 (13) 450 phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-3-yl]ethyl]piperazine-1-carboxylate 46 S-Methyl 4-[2-[1-[4-cyano-3-(trifluoromethyl)-  7 (13) 466 phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-3-yl]ethyl]piperazine-1-carbothioate 47 4-[2-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 7 499 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]ethyl]-N,N-dimethylpiperazine-1- sulfonamide

TABLE 7 Compounds of General Formula I According to the Invention, in which V = Trifluoromethylbenzonitrile, W = Maleimide, n = 3 Synthesis Ex- Analogous am- to ESI- ple Name Example MS 48 4-[3-[3-(4-Acetylpiperazin-1-yl)propyl]-2,5- 7 (4) 448 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)-benzonitrile 49 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[3-(4-(1- 7 (4) 462 oxopropyl)-piperazin-1-yl)propyl]-1H-pyrrol-1- yl]-2-(trifluoromethyl)-benzonitrile 50 4-[3-[3-[4-(Cyclopropylcarbonyl)piperazin-1- 7 (4) 474 yl]-propyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 51 4-[2,5-Dihydro-3-[3-[4- 7 (4) 478 (methoxyacetyl)piperazin-1-yl]-propyl]-4- methyl-2,5-dioxo-1H-pyrrol-1-yl]- 2-(trifluoromethyl)benzonitrile 52 4-[2,5-Dihydro-3-[3-[4-(3-methoxy-1- 7 (4) 492 oxopropyl)-piperazin-1-yl]propyl]-4-methyl- 2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 53 4-[2,5-Dihydro-3-[3-[4-[(2-methoxyethoxy)- 7 (4) 522 acetyl]piperazin-1-yl]propyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 54 4-[2,5-Dihydro-3-[3-[4-[[2-(2- 7 (4) 566 methoxyethoxy)-ethoxy]-acetyl]piperazin-1- yl]propyl]-4-methyl-2,5-dioxo-1H-pyrrol-1- yl]-2-(trifluoromethyl)-benzonitrile 55 4-[2,5-Dihydro-3-[3-[4-(2-methoxybenzoyl)- 7 (4) 540 piperazin-1-yl]-propyl]-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 56 4-[2,5-Dihydro-3-methyl-4-[3-[4- 7 484 (methylsulfonyl)-piperazin-1-yl]propyl]-2,5- dioxo-1H-pyrrol-1-yl]- 2-(trifluoromethyl)-benzonitrile 57 4-[3-[3-[4-(Ethylsulfonyl)piperazin-1- 7 498 yl]propyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)-benzonitrile 58 4-[3-[3-[4-(Cyclopropylsulfonyl)piperazin-1- 7 510 yl]propyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 59 4-[2,5-Dihydro-3-[3-[4-(2-methoxyethyl)- 7 528 sulfonyl]piperazin-1-yl]propyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 60 4-[2,5-Dihydro-3-[3-[4-[[2-(2-methoxyethoxy)- 7 572 ethoxy]ethyl]-sulfonyl]piperazin-1- yl]propyl]-4-methyl-2,5-dioxo-1H-pyrrol-1- yl]-2-(trifluoromethyl)-benzonitrile 61 4-[2,5-Dihydro-3-[3-[4-[[2-[2-(2- 7 616 methoxyethoxy)-ethoxy]- ethyl]sulfonyl]piperazin-1-yl]propyl]-4- methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 62 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[3-[4- 7 546 (phenyl-sulfonyl)piperazin-1-yl]propyl]-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 63 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[3-[4- 7 560 [(phenylmethyl)-sulfonyl]piperazin-1- yl]propyl]-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 64 4-[2,5-Dihydro-3-methyl-4-[3-[4-[(1-methyl- 7 550 1H-imidazol-4-yl)sulfonyl]piperazin-1- yl]propyl]-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)-benzonitrile 65 4-[3-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 7 (6) 491 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]propyl]-N-(1-methylethyl)-piperazine-1- carboxamide 66 4-[3-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-  7 (12) 493 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]propyl)-N-ethylpiperazine-1-carbothioamide 67 Methyl 4-[3-[1-[4-cyano-3-(trifluoromethyl)-  7 (13) 464 phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-3-yl]propyl]-piperazine-1-carboxylate 68 S-Methyl 4-[3-[1-[4-cyano-3-(trifluoromethyl)-  7 (13) 480 phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-3-yl]propyl]-piperazine-1-carbothioate 69 4-[3-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 7 513 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]propyl]-N,N-dimethylpiperazine-1- sulfonamide

TABLE 8 Compounds of General Formula I According to the Invention, in which V = Trifluoromethylbenzonitrile, W = Maleimide, n = 4 Synthesis Ex- Analogous am- to ESI- ple Name Example MS 70 1,1-Dimethylethyl 4-[4-[1-[4-cyano-3- 1 521 (trifluoromethyl)phenyl]-2,5-dihydro-4-methyl- 2,5-dioxo-1H-pyrrol-3-yl]-butyl]piperazine-1- carboxylate 71 4-[2,5-Dihydro-3-methyl-4-[4-[4-[2- 3 543 (methylsulfanyl)-phenyl]piperazin-1-yl]butyl]- 2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 72 4-[3-[4-[4-(3,5-Dichloropyridin-4-yl)piperazin- 3 566 1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 73 4-[3-[4-[4-(Cyclopentylacetyl)piperazin-1- 4 531 yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 74 4-[3-[4-[4-(2,6-Difluorobenzoyl)piperazin-1- 4 561 yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 75 4-[3-[4-[4-(2,6-Dichlorobenzoyl)piperazin-1- 4 593 yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 76 4-[3-[4-[4-(3-Fluorobenzoyl)piperazin-1- 4 543 yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 77 4-[2,5-Dihydro-3-[4-[4-(3-methoxybenzoyl)- 4 555 piperazin-1-yl]butyl]-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 78 4-[2,5-Dihydro-3-methyl-4-[4-[4-(3- 4 539 methylbenzoyl)-piperazin-1-yl-]butyl]-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 79 4-[3-[4-[4-(4-Fluorobenzoyl)piperazin-1- 4 543 yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 80 4-[2,5-Dihydro-3-methyl-4-[4-[4-[(naphthalen- 4 575 1-yl)-carbonyl]piperazin-1-yl]butyl]-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 81 4-[2,5-Dihydro-3-methyl-4-[4-[4-[(naphthalen- 4 575 2-yl)-carbonyl]piperazin-1-yl]butyl]-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 82 4-[3-[4-[4-(3-Cyanobenzoyl)piperazin-1- 4 550 yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 83 4-[3-[4-[4-(Cyclohexylcarbonyl)piperazin-1- 4 531 yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 84 4-[3-[4-[4-[(Furan-2-yl)carbonyl]piperazin-1- 4 515 yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 85 4-[3-[4-[4-(Cyclopentylcarbonyl)piperazin-1- 4 517 yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 86 4-[2,5-Dihydro-3-methyl-4-[4-[4-[(5- 4 530 methylisoxazol-3-yl)carbonyl]piperazin-1- yl]butyl)-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 87 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[4-[4- 4 539 (phenyl-acetyl)piperazin-1-yl]butyl]-1H-pyrrol- 1-yl]-2-(trifluoromethyl)benzonitrile 88 4-[2,5-Dihydro-3-[4-[4-(2-methoxybenzoyl)- 4 555 piperazin-1-yl]butyl]-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 89 4-[2,5-Dihydro-3-[4-[4-(methoxyacetyl)piper- 4 492 azin-1-yl]-butyl)-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 90 4-[3-[4-[4-(2-Chlorobenzoyl)piperazin-1- 4 559 yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 91 4-[3-[4-[4-(2-Fluorobenzoyl)piperazin-1- 4 543 yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 92 4-[3-[4-(4-Benzoylpiperazin-1-yl)butyl]-2,5- 4 525 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)-benzonitrile 93 4-[3-[4-[4-(Cyclobutylcarbonyl)piperazin-1- 4 503 yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 94 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[4-[4- 4 526 [(pyridin-3-yl)carbonyl]piperazin-1-yl]butyl]- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 95 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[4-[4- 4 526 [(pyridin-4-yl)carbonyl]piperazin-1-yl]butyl]- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 96 4-[3-[4-[4-[4-(Dimethylamino)benzoyl]piper- 4 568 azin-1-yl]butyl-2,5-dihydro-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 97 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[4-[4- 4 571 [(phenyl-sulfanyl)acetyl]piperazin-1-yl]butyl]- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 98 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[4-[4- 4 555 (phenoxy-acetyl)piperazin-1-yl]butyl]-1H- pyrrol-1-yl)-2-(trifluoromethyl)benzonitrile 99 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[4-[4- 4 531 [(thien-2-yl)-carbonyl]piperazin-1-yl]butyl]- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 100 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[4-[4-(3- 4 553 phenyl-1-oxopropyl)piperazin-1-yl]butyl]-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 101 4-[3-[4-[4-[(1,3-Benzodioxol-5-yl)carbonyl]- 4 569 piperazin-1-yl]-butyl]-2,5-dihydro-4-methyl- 2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 102 4-[2,5-Dihydro-3-[4-[4-[(4-methoxyphenyl)- 4 569 acetyl]piperazin-1-yl]butyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 103 4-[2,5-Dihydro-3-methyl-4-[4-[4-(2- 4 539 methylbenzoyl)-piperazin-1-yl]butyl]-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 104 4-[3-[4-[4-(4-Chlorobenzoyl)piperazin-1-yl] 4 559 butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 105 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[4-[4- 4 545 [(thien-2-yl)-acetyl]piperazin-1-yl]butyl]- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 106 4-[3-[4-[4-(3-Chlorobenzoyl)piperazin-1- yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- 4 559 pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 107 4-[3-[4-[4-(4-Cyanobenzoyl)piperazin-1- 4 550 yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 108 4-[2,5-Dihydro-3-[4-[4-(3-methoxy-1- 4 506 oxopropyl)piperazin-1-yl]butyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 109 4-[2,5-Dihydro-3-[4-[4-[(2-methoxyethoxy)- 4 536 acetyl]piperazin-1-yl]butyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl-2- (trifluoromethyl)benzonitrile 110 4-[2,5-Dihydro-3-[4-[4-[[2-(2-methoxyethoxy)- 4 580 ethoxy]-acetyl]piperazin-1-yl]butyl]-4-methyl- 2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl) benzonitrile 111 4-[4-[4-[4-(Cyclopropylsulfonyl)piperazin-1- 5 524 yl]butyl]-2,5-dihydro-3-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 112 4-[2,5-Dihydro-3-[4-[4-(2-methoxyethyl)- 5 542 sulfonyl]piperazin-1-yl]butyl]-4-methyl- 2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 113 4-[2,5-Dihydro-3-[4-[4-[[2-(2- 5 586 methoxyethoxy)ethyl]-sulfonyl]piperazin-1- yl]butyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]- 2-(trifluoromethyl)benzonitrile 114 4-[2,5-Dihydro-3-[4-[4-[[2-[2-(2- 5 630 methoxyethoxy)-ethoxy]- ethyl]sulfonyl]piperazin-1-yl]butyl]-4- methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 115 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 5 527 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]butyl]-N,N-dimethylpiperazine-1- sulfonamide 116 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[4-[4- 5 561 (phenyl-sulfonyl)piperazin-1-yl]butyl]-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 117 4-[2,5-Dihydro-3-methyl-4-[4-[4- 5 499 (methylsulfonyl)-piperazin-1-yl]butyl]-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 118 4-[2,5-Dihydro-3-methyl-4-[4-[4-[(4- 5 575 methylphenyl)-sulfonyl]piperazin-1-yl]butyl]- 2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 119 N-[4-[[4-[4-[1-[4-Cyano-3-(trifluoromethyl)- 5 618 phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-3-yl]butyl]piperazin-1-yl]sulfonyl]- phenyl]acetamide 120 4-[3-[4-[4-[(4-Chlorophenyl)sulfonyl]piperazin- 5 595 1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 121 4-[3-[4-[4-[(4-Cyanophenyl)sulfonyl]piperazin- 5 586 1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 122 4-[2,5-Dihydro-3-methyl-4-[4-[4-[(naphthalen- 5 611 2-yl)-sulfonyl]piperazin-1-yl]butyl-2,5-dioxo- 1H-pyrrol-1-yl-2-(trifluoromethyl)benzonitrile 123 4-[3-[4-[4-[(Quinolin-8-yl)sulfonyl]piperazin-1- 5 612 yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 124 4-[3-[4-[4-[(2-Cyanophenyl)sulfonyl]piperazin- 5 586 1-yl)butyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 125 4-(3-[4-[4-[(3-Cyanophenyl)sulfonyl]piperazin- 5 586 1-yl]butyl)-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl)-2-(trifluoromethyl)benzonitrile 126 4-[3-[4-[4-[(3,5-Dimethylisoxazol-4- 5 580 yl)sulfonyl]-piperazin-1-yl]butyl)-2,5-dihydro- 4-methyl-2,5-dioxo-1H-pyrrol-1-yl)-2- (trifluoromethyl)benzonitrile 127 4-[3-[4-[4-[(5-Chloro-1,3-dimethyl-1H-pyrazol- 5 613 4-yl)sulfonyl]piperazin-1-yl]butyl]-2,5-dihydro- 4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 128 4-[2,5-Dihydro-3-methyl-4-[4-[4-[(1-methyl- 5 565 1H-imidazol-4-yl)sulfonyl)piperazin-1- yl]butyl)-2,5-dioxo-1H-pyrrol-1-yl)-2- (trifluoromethyl)benzonitrile 129 4-[3-[4-[4-(Butylsulfonyl)piperazin-1-yl]butyl)- 5 541 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1- yl]-2-(trifluoromethyl)-benzonitrile 130 4-[4-Cyano-3-(trifluoromethyl)phenyl)-2,5- 6 540 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]butyl]-N-phenylpiperazine-1-carboxamide 131 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl)-2, 6 590 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl)butyl]-N-(naphthalen-1-yl)-piperazine- 1-carboxamide 132 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl)-2, 6 590 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]butyl)-N-(naphthalen-2-yl)-piperazine- 1-carboxamide 133 N-(2-Chlorophenyl)-4-[4-[1-[4-cyano-3- 6 574 (trifluoromethyl)-phenyl]-2,5-dihydro-4- methyl-2,5-dioxo-1H-pyrrol-3-yl]-butyl)piper- azine-1-carboxamide 134 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 608 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl)butyl)-N-[2-(trifluoromethyl)-phenyl)- piperazine-1-carboxamide 135 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 570 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]butyl-N-(3-methoxy-phenyl)piperazine-1- carboxamide 136 N-(4-Chlorophenyl)-4-[4-[1-[4-cyano-3- 6 574 (trifluoromethyl)-phenyl]-2,5-dihydro-4- methyl-2,5-dioxo-1H-pyrrol-3-yl]- butyl]piperazine-1-carboxamide 137 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 632 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]butyl]N-(4-phenoxy-phenyl)piperazine-1- carboxamide 138 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 586 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]butyl]-N-[4-(methylsulfanyl)phenyl]piper- azine-1-carboxamide 139 N-([1,1′-Biphenyl]-2-yl)-4[4-[1-[4-cyano-3- 6 616 (trifluoromethyl)-phenyl]-2,5-dihydro-4- methyl-2,5-dioxo-1H-pyrrol-3-yl]- butyl]piperazine-1-carboxamide 140 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 600 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]butyl]N-(2,5-dimethoxyphenyl)piperazine- 1-carboxamide 141 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 582 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]butyl]-N-[2-(1-methylethyl)phenyl]piper- azine-1-carboxamide 142 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 582 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]butyl]N-(2,4,6-trimethylphenyl)piperazine-1- carboxamide 143 (R)-4-[4-[1-[4-Cyano-3-(trifluoro- 6 568 methyl)phenyl]-2,5-dihydro-4-methyl-2,5- dioxo-1H-pyrrol-3-yl]butyl]-N-(1-phenylethyl)- piperazine-1-carboxamide 144 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 596 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]butyl]N-[2-(1,1-dimethylethyl)phenyl]piper- azine-1-carboxamide 145 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 548 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]butyl]-N-hexylpiperazine-1-carboxamide

TABLE 9 Compounds of General Formula I According to the Invention, in which V = Trifluoromethylbenzonitrile, W = Maleimide, n = 5 Synthesis Ex- Analogous am- to ESI- ple Name Example MS 146 4-(2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4- 3 513 (pyrazin-2-yl)-piperazin-1-yl]pentyl]-1H- pyrrol-1-yl]-2-(trifluoromethyl)-benzonitrile 147 4-[3-[5-[4-(2,4-Difluorophenyl)piperazin-1- 3 547 yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 148 4-[3-[5-[4-[(Furan-2-yl)carbonyl]piperazin-1- 4 529 yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 149 4-[2,5-Dihydro-3-methyl-4-[5-[4-[(5- 4 544 methylisoxazol-3-yl)carbonyl]piperazin-1- yl]pentyl]-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 150 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4- 4 553 (phenylacetyl)-piperazin-1-yl]pentyl]-1H- pyrrol-1-yl]-2-(trifluoromethyl)-benzonitrile 151 4-[2,5-Dihydro-3-[5-[4-(4-methoxybenzoyl)- 4 569 piperazin-1-yl]-pentyl]-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 152 4-[2,5-Dihydro-3-[5-[4-(2-methoxybenzoyl)- 4 569 piperazin-1-yl]-pentyl]-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 153 4-[2,5-Dihydro-3-[5-[4-(methoxyacetyl)piper- 4 507 azin-1-yl]-pentyl]4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 154 4-[3-[5-[4-(2-Chlorobenzoyl)piperazin-1- 4 573 yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 155 4-[3-[5-[4-(2-Fluorobenzoyl)piperazin-1- 4 557 yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 156 4-[3-[5-(4-Benzoylpiperazin-1-yl)pentyl]-2,5- 4 539 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 157 4-[3-[5-[4-(Cyclobutylcarbonyl)piperazin-1- 4 517 yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 158 4-[3-[5-[4-(3,4-Dimethoxybenzoyl)piperazin-1- 4 599 yl]pentyl]-2,5-dihydro-3-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 159 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4- 4 540 [(pyridin-3-yl)-carbonyl]piperazin-1-yl]pentyl]- 1H-pyrrol-1-yl-2-(trifluoromethyl)benzonitrile 160 4-[3-[5-[4-(Cyclopropylcarbonyl)piperazin-1- 4 503 yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 161 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4- 4 540 [(pyridin-4-yl)-carbonyl]piperazin-1-yl]pentyl]- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 162 4-[3-[5-[4-[4-(Dimethylamino)benzoyl]piper- 4 582 azin-1-yl]-pentyl]-2,5-dihydro-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 163 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4- 4 585 [(phenylsulfanyl)acetyl]piperazin-1-yl]pentyl]- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 164 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4- 4 569 (phenoxyacetyl)piperazin-1-yl]pentyl]-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 165 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4- 4 545 [(thien-2-yl)-carbonyl]piperazin-1-yl]pentyl]- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 166 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4-[3- 4 567 phenyl-1-oxopropyl)piperazin-1-yl]pentyl]-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 167 4-[3-[5-[4-[(1,3-Benzodioxol-5-yl)carbonyl]- 4 583 piperazin-1-yl]-pentyl]-2,5-dihydro-4-methyl- 2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 168 4-[2,5-Dihydro-3-[5-[4-[(4-methoxyphenyl)- 4 583 acetyl]piperazin-1-yl)pentyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 169 4-[2,5-Dihydro-3-methyl-4-[5-[4-(2- 4 553 methylbenzoyl)-piperazin-1-yl]pentyl]-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 170 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4- 4 559 [(thien-2-yl)-acetyl]piperazin-1-yl]pentyl]-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 171 4-[3-[5-[4-[(4-Chlorophenoxy)acetyl]piperazin- 4 603 1-yl]pentyl)-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 172 4-[3-[5-[4-(3-Cyclopentyl-1-oxopropyl)piper- 4 559 azin-1-yl]-pentyl]-2,5-dihydro-4-methyl-2,5- dioxo-1H-pyrrol-1-yl-2- (trifluoromethyl)benzonitrile 173 4-[3-[5-[4-(3-Chlorobenzoyl)piperazin-1- 4 573 yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 174 4-[3-[5-[4-(3,3-Dimethyl-1-oxobutyl)piperazin- 4 533 1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 175 4-[2,5-Dihydro-3-methyl-4-[5-[4-(3-methyl-1- 4 519 oxobutyl)-piperazin-1-yl]pentyl]-2,5-dioxo-1H- pyrrol-1-yl)-2-(trifluoromethyl)benzonitrile 176 4-[2,5-Dihydro-4-methyl-2,5-dioxo-3-[5-[4- 4 583 [(phenyl-methoxy)acetyl]piperazin-1- yl]pentyl]-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 177 4-[3-[5-[4-(Cyclopentylacetyl)piperazin-1- 4 545 yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 178 4-[3-[5-[4-(2,6-Difluorobenzoyl)piperazin-1- 4 575 yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 179 4-[3-[5-[4-(2,6-Dichlorobenzoyl)piperazin-1- 4 607 yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 180 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4-[2- 4 607 (trifluoromethyl)benzoyl]piperazin-1- yl]pentyl]-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 181 4-[3-[5-[4-(3-Fluorobenzoyl)piperazin-1- 4 557 yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 182 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4-[3- 4 607 (trifluoromethyl)benzoyl]piperazin-1- yl]pentyl]-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 183 4-[2,5-Dihydro-3-methyl-4-[5-[4-(4- 4 553 methylbenzoyl)-piperazin-1-yl]pentyl)-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 184 4-[2,5-Dihydro-3-methyl-4-[5-[4-[(naphthalen- 4 589 1-yl)-carbonyl]piperazin-1-yl]pentyl]-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 185 4-[2,5-Dihydro-3-methyl-4-[5-[4-[(naphthalen- 4 589 2-yl)-carbonyl]piperazin-1-yl)pentyl]-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 186 4-[3-[5-[4-(3-Cyanobenzoyl)piperazin-1- 4 564 yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 187 4-[3-[5-[4-(Cyclohexylcarbonyl)piperazin-1- 4 545 yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 188 4-[3-[5-(4-Acetylpiperazin-1-yl)pentyl]-2,5- 4 476 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)-benzonitrile 189 4-[2,5-Dihydro-3-[5-[4-(3-methoxy-1- 4 520 oxopropyl)piperazin-1-yl]pentyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 190 4-[2,5-Dihydro-3-[5-(4-[(2-methoxyethoxy)- 4 550 acetyl]piperazin-1-yl]pentyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 191 4-[2,5-Dihydro-3-[5-[4-[[2-(2-methoxyethoxy)- 4 594 ethoxy]-acetyl]piperazin-1-yl]pentyl]-4-methyl- 2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 192 4-[4-[5-[4-(Cyclopropylsulfonyl)piperazin-1- 5 538 yl-]pentyl]-2,5-dihydro-3-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 193 4-[2,5-Dihydro-3-[5-[4-(2-methoxyethyl)- 5 556 sulfonyl]piperazin-1-yl]pentyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 194 4-[2,5-Dihydro-3-[5-[4-[[2-(2-methoxyethoxy)- 5 600 ethyl]-sulfonyl]piperazin-1-yl]pentyl]-4-methyl- 2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 195 4-[2,5-Dihydro-3-[5-[4-[[2-[2-(2-methoxy- 5 644 ethoxy)-ethoxy]-ethyl]sulfonyl]piperazin-1- yl]pentyl]-4-methyl-2,5-dioxo-1H-pyrrol-1- yl]-2-(trifluoromethyl)benzonitrile 196 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 5 541 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]pentyl]-N,N-dimethylpiperazine- 1-sulfonamide 197 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4-[(1- 5 541 methylethyl)-sulfonyl]piperazin-1-yl]pentyl]- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 198 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4- 5 575 (phenylsulfonyl)piperazin-1-yl]pentyl]-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 199 4-[2,5-Dihydro-3-methyl-4-[5-[4- 5 513 (methylsulfonyl)piperazin-1-yl]pentyl]-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)-benzonitrile 200 4-[3-[5-[4-[(4-Chlorophenyl)sulfonyl]piperazin- 5 609 1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 201 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4- 5 589 [(phenylmethyl)-sulfonyl]piperazin-1- yl]pentyl]-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 202 4-[3-[5-[4-[(4-Cyanophenyl)sulfonyl]piperazin- 5 600 1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-yl]-2-(trifluoromethyl)benzonitrile 203 4-[4-[5-[4-[(Quinolin-8-yl)sulfonyl]piperazin-1- 5 626 yl]pentyl]-2,5-dihydro-3-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 204 4-[3-[5-[4-[(2-Fluorophenyl)sulfonyl]piperazin- 5 593 1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 205 4-[3-[5-[4-[(2,5-Dimethoxyphenyl)sulfonyl]- 5 635 piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2, 5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 206 4-[3-[5-[4-[(3-Cyanophenyl)sulfonyl]piperazin- 5 600 1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 207 4-[3-[5-[4-[(2,1,3-Benzothiadiazol-4- 5 633 yl)sulfonyl]piperazin-1-yl]pentyl]-2,5-dihydro- 4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 208 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 534 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]pentyl]-N-(1,1-dimethyl-ethyl)piperazine-1- carboxamide 209 4-[5-[1-(4-Cyano-3-(trifluoromethyl)phenyl]- 6 604 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]pentyl]-N-(naphthalen-1-yl)piperazine-1- carboxamide 210 N-(4-Cyanophenyl)-4-[5-[1-[4-cyano-3- 6 579 (trifluoromethyl)-phenyl]-2,5-dihydro-4- methyl-2,5-dioxo-1H-pyrrol-3-yl]-pentyl]piper- azine-1-carboxamide 211 N-(2-Chlorophenyl)-4-[5-[1-[4-cyano-3- 6 588 (trifluoromethyl)-phenyl]-2,5-dihydro-4- methyl-2,5-dioxo-1H-pyrrol-3-yl]-pentyl]piper- azine-1-carboxamide 212 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 622 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]pentyl]-N-[2-(trifluoromethyl)phenyl]piper- azine-1-carboxamide 213 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl)-2, 6 568 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]pentyl]-N-(2-methyl-phenyl)piperazine-1- carboxamide 214 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 568 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]pentyl]-N-(3-methyl-phenyl)piperazine-1- carboxamide 215 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 572 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]pentyl)-N-(4-fluorophenyl)-piperazine-1- carboxamide 216 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 584 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]pentyl]-N-(4-methoxy-phenyl)piperazine-1- carboxamide 217 N-(3-Cyanophenyl)-4-[5-[1-[4-cyano-3- 6 579 (trifluoromethyl)-phenyl)-2,5-dihydro-4- methyl-2,5-dioxo-1H-pyrrol-3-yl]-pentyl]piper- azine-1-carboxamide 218 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 614 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]pentyl)-N-(3,5-dimethoxy-phenyl)piper- azine-1-carboxamide 219 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 582 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]pentyl]-N-(2-phenylethyl)-piperazine-1- carboxamide 220 N-([1,1′-Biphenyl]-2-yl)-4-[5-[1-[4-cyano-3- 6 630 (trifluoromethyl)-phenyl]-2,5-dihydro-4- methyl-2,5-dioxo-1H-pyrrol-3-yl]-pentyl]piper- azine-1-carboxamide 221 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 596 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]pentyl]-N-[2-(1-methyl-ethyl)phenyl]piper- azine-1-carboxamide 222 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 623 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]pentyl]-N-(2,6-dichloropyridin-4-yl)piper- azine-1-carboxamide 223 (R)-4-[5-[1-[4-Cyano-3-(trifluoro- 6 582 methyl)phenyl]-2,5-dihydro-4-methyl-2,5- dioxo-1H-pyrrol-3-yl]pentyl]-N-(1-phenyl- ethyl)piperazine-1-carboxamide 224 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 654 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]pentyl]-N-[3-[(trifluoromethyl)sulfanyl]- phenyl]piperazine-1-carboxamide 225 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 582 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]pentyl]-N-[(3-methylphenyl)methyl]piper- azine-1-carboxamide 226 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 598 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]pentyl]-N-[(4-methoxy-phenyl)methyl]- piperazine-1-carboxamide 227 1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5- 6 590 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]pentyl]-N-(1,1,3,3-tetramethylbutyl)piper- azine-1-carboxamide

TABLE 10 Compounds of General Formula I According to the Invention, in which V = Trifluoromethylbenzonitrile, W = Maleimide, n = 6 Synthesis Ex- Analogous am- to ESI- ple Name Example MS 228 1,1-Dimethylethyl 4-[6-[1-[4-cyano-3- 1 549 (trifluoromethyl)phenyl]-2,5-dihydro-4-methyl- 2,5-dioxo-1H-pyrrol-3-yl]hexyl]-piperazine-1- carboxylate 229 4-[2,5-Dihydro-3-methyl-4-[6-(4-methylpiper- 3 463 azin-1-yl)hexyl]-2,5-dioxo-1H-pyrrol-1-yl]-2 (trifluoromethyl)-benzonitrile 230 Ethyl 4-[6-[1-[4-cyano-3-(trifluoro- 3 521 methyl)phenyl)-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-3-yl]hexyl]piperazine-1-carboxylate 231 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4- 3 526 (pyridin-2-yl)piperazin-1-yl]hexyl]-1H-pyrrol- 1-yl]-2-(trifluoromethyl)-benzonitrile 232 (Phenylmethyl) 4-[6-[1-[4-cyano-3- 3 583 (trifluoromethyl)phenyl]-2,5-dihydro-4-methyl- 2,5-dioxo-1H-pyrrol-3-yl]hexyl]-piperazine-1- carboxylate 233 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4- 3 527 (pyrimidin-2-yl)-piperazin-1-yl]hexyl]-1H- pyrrol-1-yl]-2-(trifluoromethyl)-benzonitrile 234 4-[2,5-Dihydro-3-[6-[4-(2-methoxyphenyl)- 3 555 piperazin-1-yl]-hexyl]-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 235 4-[2,5-Dihydro-3-methyl-4-[6-[4-(2- 3 570 nitrophenyl)piperazin-1-yl]hexyl]-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)-benzonitrile 236 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4- 3 527 (pyrazin-2-yl)-piperazin-1-yl]hexyl]-1H-pyrrol- 1-yl]-2-(trifluoromethyl)-benzonitrile 237 4-[2,5-Dihydro-3-methyl-4-[6-[4-[2- 3 571 (methylsulfanyl)-phenyl]piperazin-1-yl]hexyl]- 2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 238 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-[3- 3 594 (trifluoromethyl)pyridin-2-yl]piperazin-1- yl]hexyl]-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 239 4-[2,5-Dihydro-3-[6-[4-(2-methoxy- 3 507 ethyl)piperazin-1-yl]-hexyl)-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 240 4-[3-[6-[4-(3,5-Dichloropyridin-4-yl)piperazin- 3 594 1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 241 4-[3-[6-(4-Acetylpiperazin-1-yl)hexyl]-2,5- 4 491 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)-benzonitrile 242 4-[3-[6-[4-[(Furan-2-yl)carbonyl]piperazin- 4 543 1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 243 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4- 4 547 [(tetrahydrofuran-2-yl)carbonyl]piperazin- 1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 244 4-[3-[6-[4-(Cyclopentylcarbonyl)piperazin-1- 4 545 yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 245 4-[2,5-Dihydro-3-methyl-4-[6-[4-[(5- 4 558 methylisoxazol-3-yl)-carbonyl]piperazin-1- yl]hexyl]-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 246 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4- 4 567 (phenylacetyl)-piperazin-1-yl]hexyl]-1H-pyrrol- 1-yl]-2-(trifluoromethyl)-benzonitrile 247 4-[2,5-Dihydro-3-[6-[4-(4-methoxybenzoyl)- 4 583 piperazin-1-yl]-hexyl]-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 248 4-[2,5-Dihydro-3-[6-[4-(2-methoxybenzoyl)- 4 583 piperazin-1-yl]-hexyl]-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 249 4-[2,5-Dihydro-3-[6-[4-(methoxyacetyl)piper- 4 521 azin-1-yl]-hexyl]-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 250 4-[3-[6-[4-(2-Chlorobenzoyl)piperazin-1- 4 587 yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 251 4-[3-[6-[4-(2-Fluorobenzoyl)piperazin-1- 4 571 yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 252 4-[3-[6-(4-Benzoylpiperazin-1-yl)hexyl]-2,5- 4 553 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 253 4-[3-[6-[4-(Cyclobutylcarbonyl)piperazin-1- 4 531 yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 254 4-[3-[6-[4-(3,4-Dimethoxybenzoyl)piperazin-1- 4 613 yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 255 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4- 4 599 [(phenylsulfanyl)acetyl]piperazin-1-yl]hexyl]- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 256 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4- 4 583 (phenoxyacetyl)piperazin-1-yl]hexyl]-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 257 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4- 4 559 [(thien-2-yl)carbonyl]piperazin-1-yl]hexyl]-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 258 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-(3- 4 581 phenyl-1-oxopropyl)piperazin-1-yl]hexyl]-1H- pyrrol-1-yl)-2-(trifluoromethyl)benzonitrile 259 4-[3-[6-[4-[(1,3-Benzodioxol-5-yl)carbonyl]- 4 597 piperazin-1-yl]-hexyl]-2,5-dihydro-4-methyl-2, 5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl) benzonitrile 260 4-[2,5-Dihydro-3-[6-[4-[(4-methoxyphenyl)- 4 597 acetyl)piperazin-1-yl]hexyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 261 4-[2,5-Dihydro-3-methyl-4-[6-[4-(2- 4 567 methylbenzoyl)-piperazin-1-yl]hexyl)-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 262 4-[3-[6-[4-(4-Chlorobenzoyl)piperazin-1- 4 587 yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 263 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4- 4 573 [(thien-2-yl)-acetyl]piperazin-1-yl]hexyl]- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 264 4-[3-[6-[4-[(4-Chlorophenoxy)acetyl]piperazin- 4 617 1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 265 4-[3-[6-[4-(3-Cyclopentyl-1-oxopropyl)piper- 4 573 azin-1-yl]-hexyl]-2,5-dihydro-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 266 4-[3-[6-[4-(3-Chlorobenzoyl)piperazin-1- 4 587 yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 267 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-[4- 4 621 (trifluoromethyl)benzoyl]piperazin-1- yl]hexyl]-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 268 4-[3-[6-[4-(4-cyanobenzoyl)piperazin- 4 578 1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 269 4-[3-[6-[4-(3,3-Dimethyl-1-oxobutyl)piperazin- 4 547 1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 270 4-[2,5-Dihydro-3-methyl-4-[6-[4-(3-methyl-1- 4 533 oxobutyl)-piperazin-1-yl]hexyl]-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 271 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4- 4 597 [(phenyl-methoxy)acetyl]piperazin-1-yl]hexyl]- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 272 4-[3-[6-[4-(Cyclopentylacetyl)piperazin-1- 4 559 yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 273 4-[3-[6-[4-(2,6-Difluorobenzoyl)piperazin-1- 4 589 yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 274 4-[3-[6-[4-(2,6-Dichlorobenzoyl)piperazin-1- 4 621 yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 275 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-[2- 4 621 (trifluoromethyl)benzoyl]piperazin-1-yl]hexyl]- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 276 4-[3-[6-[4-(3-Fluorobenzoyl)piperazin-1- 4 571 yl]hexyl]2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 277 4-[2,5-Dihydro-3-[6-[4-(3-methoxybenzoyl)- 4 583 piperazin-1-yl]-hexyl]-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 278 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-[3- 4 621 (trifluoromethyl)benzoyl]piperazin-1-yl]hexyl]- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 279 4-[2,5-Dihydro-3-methyl-4-[6-[4-(3- 4 567 methylbenzoyl)-piperazin-1-yl]hexyl]-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 280 4-[3-[6-[4-(4-Fluorobenzoyl)piperazin-1- 4 571 yl]hexyl]-2,5-dihydro-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 281 4-[2,5-Dihydro-3-methyl-4-[6-[4-(4- 4 567 methylbenzoyl)-piperazin-1-yl]hexyl)-2,5- dioxo-1H-pyrrol-1-yl)-2- (trifluoromethyl)benzonitrile 282 4-[2,5-Dihydro-3-methyl-4-[6-[4-[(naphthalen- 4 603 1-yl)-carbonyl]piperazin-1-yl]hexyl]-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 283 4-[2,5-Dihydro-3-methyl-4-[6-[4-[(naphthalen- 4 603 2-yl)-carbonyl]piperazin-1-yl]hexyl]-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 284 4-[3-[6-[4-(3-Cyanobenzoyl)piperazin-1- 4 578 yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 285 4-[3-[6-[4-(Cyclohexylcarbonyl)piperazin-1- 4 559 yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 286 4-[3-[6-[4-[[4-(1,1-Dimethyl- 4 639 ethyl)phenoxy]acetyl]-piperazin-1-yl]hexyl]- 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol- 1-yl]-2-(trifluoromethyl)-benzonitrile 287 4-[2,5-Dihydro-3-[6-[4-(3-methoxy-1- 4 534 oxopropyl)piperazin-1-yl]hexyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 288 4-[2,5-Dihydro-3-[6-[4-[(2-methoxyethoxy)- 4 564 acetyl]piperazin-1-yl]hexyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 289 4-[2,5-Dihydro-3-[6-[4-[[2-(2-methoxyethoxy)- 4 608 ethoxy]-acetyl]piperazin-1-yl]hexyl]-4-methyl- 2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 290 4-[4-[6-[4-(Cyclopropylsulfonyl)piperazin-1- 5 552 yl]hexyl]-2,5-dihydro-3-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 291 4-[2,5-Dihydro-3-[6-[4-(2-methoxyethyl)- 5 570 sulfonyl]piperazin-1-yl]hexyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 292 4-[2,5-Dihydro-3-[6-[4-[[2-(2-methoxyethoxy)- 5 614 ethyl]-sulfonyl]piperazin-1-yl]hexyl]-4-methyl- 2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 293 4-[2,5-Dihydro-3-[6-[4-[[2-[2-(2-methoxy- 5 658 ethoxy)-ethoxy]-ethyl]sulfonyl]piperazin-1- yl]hexyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]- 2-(trifluoromethyl])benzonitrile 294 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 5 555 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N, N-dimethyl]piperazine-1- sulfonamide 295 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4- 5 589 (phenyl-sulfonyl)piperazin-1-yl]hexyl]-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 296 4-[2,5-Dihydro-3-methyl-4-[6-[4-(methyl- 5 527 sulfonyl)-piperazin-1-yl]hexyl]-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 297 4-[2,5-Dihydro-3-methyl-4-[6-[4-[(4- 5 603 methylphenyl)-sulfonyl]piperazin-1-yl]hexyl]- 2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 298 N-[4-[[4-[6-[1-[4-Cyano-3-(trifluoromethyl)- 5 646 phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-3-yl]hexyl]piperazin-1-yl]sulfonyl]- phenyl]acetamide 299 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4- 5 603 [(phenylmethyl)-sulfonyl]piperazin-1-yl]hexyl]- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 300 4-[3-[6-[4-[(4-Cyanophenyl)sulfonyl]piperazin- 5 614 1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl)-2-(trifluoromethyl)benzonitrile 301 4-[2,5-Dihydro-3-methyl-4-[6-[4-[(naphthalen- 5 639 2-yl)-sulfonyl]piperazin-1-yl]hexyl]-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 302 4-[3-[6-[4-[[5-(Dimethylamino)naphthalen-2- 5 682 sulfonyl]piperazin-1-yl]hexyl]-2,5-dihydro-4- methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 303 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4- 5 595 [(thien-2-yl)-sulfonyl]piperazin-1- yl]hexyl]-1H-pyrrol-1- yl]-2-(trifluoromethyl)benzonitrile 304 4-[3-[6-[4-[(Quinolin-8-yl)sulfonyl]piperazin-1- 5 640 yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 305 4-[3-[6-[4-[(2-Fluorophenyl)sulfonyl)piperazin- 5 607 1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 306 4-[3-[6-[4-[(2-Chlorophenyl)sulfonyl]piperazin- 5 623 1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 307 4-[3-[6-[4-[(2-Cyanophenyl)sulfonyl]piperazin- 5 614 1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 308 4-[3-[6-[4-[(3-Cyanophenyl)sulfonyl]piperazin- 5 614 1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 309 4-[2,5-Dihydro-3-methyl-4-[6-[4-[[5-[2-methyl- 5 743 5-(trifluoromethyl)-2H-pyrazol-3-yl]thien-2- yl]sulfonyl]-piperazin-1-yl]hexyl]-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 310 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4- 5 740 [[1,2,3,4-tetrahydro-2-(trifluoroacetyl)iso- quinolin-7-yl]sulfonyl]-piperazin-1- yl]hexyl]-1H-pyrrol-1- yl]-2-(trifluoromethyl)benzonitrile 311 4-[3-[6-[4-[(3,5-Dimethylisoxazol-4- 5 608 yl)sulfonyl]piperazin-1-yl]hexyl]-2,5-dihydro- 4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 312 4-[3-[6-[4-[(5-Chloro-1,3-dimethyl-1H- 5 641 pyrazol-4-yl)sulfonyl]-piperazin-1-yl]hexyl]- 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1- yl]-2-(trifluoromethyl)benzonitrile 313 4-[2,5-Dihydro-3-methyl-4-[6-[4-[(1-methyl- 5 593 1H-imidazol-4-yl)sulfonyl]piperazin-1- yl]hexyl]-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)-benzonitrile 314 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 548 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(1,1-dimethylethyl)piperazine- 1-carboxamide 315 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 568 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-phenylpiperazine-1-carboxamide 316 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 618 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(naphthalen-1- yl)piperazine-1-carboxamide 317 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 618 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(naphthalen-2-yl)piperazine- 1-carboxamide 318 N-(4-Cyanophenyl)-4-[6-[1-[4-cyano-3- 6 593 (trifluoromethyl)-phenyl)-2,5-dihydro-4- methyl-2,5-dioxo-1H-pyrrol-3-yl]-hexyl]piper- azine-1-carboxamide 319 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 534 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(1-methylethyl)-piperazine- 1-carboxamide 320 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 636 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[3-(trifluoromethyl)phenyl]piper- azine-1-carboxamide 321 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 586 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(2-fluorophenyl)-piperazine- 1-carboxamide 322 N-(2-Chlorophenyl)-4-[6-[1-[4-cyano-3- 6 602 (trifluoromethyl)-phenyl]-2,5-dihydro-4- methyl-2,5-dioxo-1H-pyrrol-3-yl]-hexyl]piper- azine-1-carboxamide 323 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 598 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(2-methoxy-phenyl)piperazine- 1-carboxamide 324 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 636 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[2-(trifluoromethyl)phenyl]piper- azine-1-carboxamide 325 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 582 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(2-methyl-phenyl)pipera- zine-1-carboxamide 326 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 586 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(3-fluorophenyl)-piperazine- 1-carboxamide 327 N-(3-Chlorophenyl)-4-[6-[1-[4-cyano-3- 6 602 (trifluoromethyl)-phenyl]-2,5-dihydro-4-methyl 2,5-dioxo-1H-pyrrol-3-yl]-hexyl]piperazine-1- carboxamide 328 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 598 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(3-methoxy-phenyl)piperazine- 1-carboxamide 329 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 582 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(3-methylphenyl)piperazine- 1-carboxamide 330 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 586 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(4-fluorophenyl)-piperazine- 1-carboxamide 331 N-(4-Chlorophenyl)-4-[6-[1-[4-cyano-3- 6 602 (trifluoromethyl)-phenyl]-2,5-dihydro-4- methyl-2,5-dioxo-1H-pyrrol-3-yl]-hexyl]piper- azine-1-carboxamide 332 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 598 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(4-methoxy-phenyl)piperazine- 1-carboxamide 333 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 636 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[4-(trifluoromethyl)phenyl]piper- azine-1-carboxamide 334 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 582 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(4-methylphenyl)piperazine- 1-carboxamide 335 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 532 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(prop-2-enyl)-piperazine- 1-carboxamide 336 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2, 6 574 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-cyclohexyl-piperazine- 1-carboxamide 337 4-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5- 6 582 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(phenylmethyl)-piperazine- 1-carboxamide 338 N-(3-Cyanophenyl)-4-[6-[1-[4-cyano-3- 6 593 (trifluoromethyl)-phenyl]-2,5-dihydro-4- methyl-2,5-dioxo-1H-pyrrol-3-yl]- hexyl]piperazine-1-carboxamide 339 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 628 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(3,5-dimethoxy-phenyl)piperazine- 1-carboxamide 340 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 614 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[3-(methylsulfanyl)phenyl]piper- azine-1-carboxamide 341 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 660 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(4-phenoxy-phenyl)piperazine- 1-carboxamide 342 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 614 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[4-(methylsulfanyl)phenyl]piper- azine-1-carboxamide 343 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 610 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[4-(1-methylethyl)phenyl]piper- azine-1-carboxamide 344 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 596 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(2-phenylethyl)-piperazine- 1-carboxamide 345 N-([1,1′-Biphenyl]-2-yl)-4-[6-[1-[4-cyano-3- 6 644 (trifluoromethyl)-phenyl]-2,5-dihydro-4- methyl-2,5-dioxo-1H-pyrrol-3-yl]-hexyl]piper- azine-1-carboxamide 346 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 674 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[4-(phenyl-methoxy)phenyl]piper- azine-1-carboxamide 347 N-(2-Cyanophenyl)-4-[6-[1-[4-cyano-3- 6 593 (trifluoromethyl)-phenyl]-2,5-dihydro-4- methyl-2,5-dioxo-1H-pyrrol-3-yl]-hexyl]piper- azine-1-carboxamide 348 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 602 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[2-(thien-2-yl)-ethyl]piper- azine-1-carboxamide 349 (1R-trans)-4-[6-[1-[4-Cyano-3-(trifluoro- 6 608 methyl)-phenyl]-2,5-dihydro-4-methyl-2,5- dioxo-1H-pyrrol-3-yl]hexyl]-N-(2-phenylcyclo- propyl)-piperazine-1-carboxamide 350 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 604 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(2,6-difluorophenyl)piperazine- 1-carboxamide 351 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 636 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(2,6-dichlorophenyl)piperazine- 1-carboxamide 352 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 628 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(2,4-dimethoxy-phenyl)piperazine- 1-carboxamide 353 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 628 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(2,5-dimethoxy-phenyl)piperazine- 1-carboxamide 354 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 596 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(2,6-dimethyl-phenyl)piperazine- 1-carboxamide 355 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 637 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(trichloroacetyl)-piperazine- 1-carboxamide 356 (S)-4-[6-[1-[4-Cyano-3-(trifluoro- 6 596 methyl)phenyl]-2,5-dihydro-4-methyl- 2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N- (1-phenylethyl)piperazine-1-carboxamide 357 (R)-4-[6-[1-[4-Cyano-3-(trifluoro- 6 646 methyl)phenyl]-2,5-dihydro-4-methyl- 2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[1- (naphthalen-1-yl)ethyl]piperazine-1- carboxamide 358 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 671 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl)hexyl]-N-(2,4,6-trichlorophenyl)piperazine- 1-carboxamide 359 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 610 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[2-(1-methylethyl)phenyl]piper- azine-1-carboxamide 360 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 636 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(3,5-dichlorophenyl)piperazine- 1-carboxamide 361 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 610 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(2,4,6-trimethyl-phenyl)piperazine- 1-carboxamide 362 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 668 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[4-[(trifluoro- methyl)sulfanyl]phenyl]piperazine- 1-carboxamide 363 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 651 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[(2,4-dichlorophenyl)methyl]piper- azine-1-carboxamide 364 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 614 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[2-(methylsulfanyl)phenyl]piper- azine-1-carboxamide 365 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 637 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(2,6-dichloropyridin-4-yl)piper- azine-1-carboxamide 366 (R)-4-[6-[1-[4-Cyano-3-(trifluoro- 6 596 methyl)phenyl]-2,5-dihydro-4-methyl-2,5- dioxo-1H-pyrrol-3-yl]hexyl]-N-(1-phenyl- ethyl)piperazine-1-carboxamide 367 (S)-4-[6-[1-[4-Cyano-3-(trifluoro- 6 646 methyl)phenyl]-2,5-dihydro-4-methyl-2,5- dioxo-1H-pyrrol-3-yl]hexyl]-N-[1-(naphthalen- 1-yl)thyl]piperazine-1-carboxamide 368 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 650 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[1-methyl-1-[3-(1-methyl- ethenyl)phenyl]-ethyl]piperazine- 1-carboxamide 369 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 652 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[2-(trifluoromethoxy)phenyl]piper- azine-1-carboxamide 370 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 626 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(tricyclo[3.3.1.1^(3.7)]dec-1- yl)piperazine-1-carboxamide 371 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 611 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[4-(dimethylamino)phenyl]piper- azine-1-carboxamide 372 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 668 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[3-[(trifluoro- methyl)sulfanyl]phenyl]piperazine- 1-carboxamide 373 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 596 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[(2-methylphenyl)methyl]piper- azine-1-carboxamide 374 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 596 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[(3-methylphenyl)methyl]piper- azine-1-carboxamide 375 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 596 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[(4-methylphenyl)methyl]piper- azine-1-carboxamide 376 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 612 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[(4-methoxyphenyl)methyl]piper- azine-1-carboxamide 377 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 604 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(1,1,3,3-tetramethylbutyl)piper- azine-1-carboxamide

TABLE 11 Compounds of General Formula I According to the Invention, in which V = Trifluoromethylbenzonitrile, W = Maleimide, n = 7 Synthesis Ex- Analogous am- to ESI- ple Name Example MS 378 4-[3-[7-(4-Acetylpiperazin-1-yl)heptyl]- 9 (4)  504 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1- yl]-2-(trifluoromethyl)-benzonitrile 379 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[7-(4-(1- 9 (4)  518 oxopropyl)-piperazin-1-yl)heptyl]-1H-pyrrol-1- yl]-2-(trifluoromethyl)-benzonitrile 380 4-[3-[7-[4-(Cyclopropylcarbonyl)piperazin-1- 9 (4)  530 yl]heptyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 381 4-[2,5-Dihydro-3-[7-[4-(methoxyacetyl)piper- 9 (4)  534 azin-1-yl]-heptyl]-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 382 4-[2,5-Dihydro-3-[7-[4-(3-methoxy-1- 9 (4)  548 oxopropyl)piperazin-1-yl]heptyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 383 4-[2,5-Dihydro-3-[7-[4-[(2-methoxyethoxy)- 9 (4)  578 acetyl]piperazin-1-yl]heptyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 384 4-[2,5-Dihydro-3-[7-[4-[[2-(2-methoxyethoxy)- 9 (4)  622 ethoxy]-acetyl]piperazin-1-yl]heptyl]-4-methyl- 2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 385 4-[2,5-Dihydro-3-[7-[4-(2-methoxybenzoyl)- 9 (4)  596 piperazin-1-yl]-heptyl]-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 386 4-[2,5-Dihydro-3-methyl-4-[7-[4- 9 540 (methylsulfonyl)piperazin-1-yl]heptyl]-2,5- dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 387 4-[3-[7-[4-(Ethylsulfonyl)piperazin-1- 9 554 yl]heptyl]-2,5-dihydro-4-methyl-2,5-dioxo- 1H-pyrrol-1-yl]-2-(trifluoromethyl)-benzonitrile 388 4-[3-[7-[4-(Cyclopropylsulfonyl)piperazin-1- 9 566 yl]heptyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 389 4-[2,5-Dihydro-3-[7-[4-(2-methoxyethyl)- 9 584 sulfonyl]piperazin-1-yl]heptyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 390 4-[2,5-Dihydro-3-[7-[4-[[2-(2-methoxyethoxy)- 9 628 ethyl]-sulfonyl]piperazin-1-yl]heptyl]-4-methyl- 2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 391 4-[2,5-Dihydro-3-[7-[4-[[2-[2-(2- 9 672 methoxyethoxy)ethoxy]-ethyl]sulfonyl]piper- azin-1-yl]heptyl]-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 392 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[7-[4- 9 602 (phenylsulfonyl)piperazin-1-yl]heptyl]-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 393 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[7-[4- 9 616 [(phenylmethyl)-sulfonyl]piperazin-1- yl]heptyl]-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 394 4-[2,5-Dihydro-3-methyl-4-[7-[4-[(1-methyl- 9 606 1H-imidazol-4-yl)sulfonyl]piperazin-1- yl]heptyl]-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 395 4-[7-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 9 (6)  547 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]heptyl]-N-(1-methylethyl)-piperazine-1- carboxamide 396 4-[7-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 9 (12) 549 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]heptyl]-N-ethylpiperazine-1-carbothioamide 397 Methyl 4-[7-[1-[4-cyano-3-(trifluoromethyl)- 9 (13) 520 phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-3-yl]heptyl]-piperazine-1-carboxylate 398 S-Methyl 4-[7-[1-[4-cyano-3-(trifluoromethyl)- 9 (13) 536 phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-3-yl)-heptyl]piperazine-1-carbothioate 399 4-[7-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 9 569 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]heptyl]-N,N-dimethylpiperazine-1- sulfonamide

TABLE 12 Compounds of General Formula I According to the Invention, in which V = Trifluoromethylbenzonitrile, W = Maleimide, n = 8 Synthesis Ex- Analogous am- to ESI- ple Name Example MS 400 4-[3-[8-(4-Acetylpiperazin-1-yl)octyl]-2,5- 9 (4) 518 dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 401 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[8-(4-(1- 9 (4) 532 oxopropyl)-piperazin-1-yl)octyl]-1H-pyrrol-1- yl]-2-(trifluoromethyl)-benzonitrile 402 4-[3-[8-[4-(Cyclopropylcarbonyl)piperazin-1- 9 (4) 544 yl]octyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 403 4-[2,5-Dihydro-3-[8-[4-(methoxyacetyl)piper- 9 (4) 548 azin-1-yl]-octyl]4-methyl-2,5-dioxo-1H-pyrrol- 1-yl]-2-(trifluoromethyl)benzonitrile 404 4-[2,5-Dihydro-3-[8-[4-(3-methoxy-1- 9 (4) 562 oxopropyl)-piperazin-1-yl]octyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 405 4-[2,5-Dihydro-3-[8-[4-[(2-methoxyethoxy)- 9 (4) 592 acetyl]piperazin-1-yl]octyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 406 4-[2,5-Dihydro-3-[8-[4-[[2-(2-methoxyethoxy)- 9 (4) 636 ethoxy]-acetyl]piperazin-1-yl]octyl]-4-methyl- 2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 407 4-[2,5-Dihydro-3-[8-[4-(2-methoxybenzoyl)- 9 (4) 610 piperazin-1-yl]-octyl]-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)-benzonitrile 408 4-[2,5-Dihydro-3-methyl-4-[8-[4-(methyl- 9 554 sulfonyl)-piperazin-1-yl]octyl]-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)-benzonitrile 409 4-[3-[8-[4-(Ethylsulfonyl)piperazin-1-yl]octyl]- 9 568 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1- yl]-2-(trifluromethyl)benzonitrile 410 4-[3-[8-[4-(Cyclopropylsulfonyl)piperazin-1- 9 580 yl]octyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 411 4-[2,5-Dihydro-3-[8-[4-(2-methoxyethyl)- 9 598 sulfonyl]piperazin-1-yl]octyl]-4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 412 4-[2,5-Dihydro-3-[8-[4-[[2-(2-methoxyethoxy)- 9 642 ethyl]sulfonyl]piperazin-1-yl]octyl]-4-methyl- 2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- benzonitrile 413 4-[2,5-Dihydro-3-[8-[4-[[2-[2-(2-methoxy- 9 686 ethoxy)-ethoxy]-ethyl]sulfonyl]piperazin-1- yl]octyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 414 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[8-[4- 9 616 (phenylsulfonyl)piperazin-1-yl]octyl]-1H- pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 415 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[8-[4 9 630 [(phenylmethyl)-sulfonyl]piperazin-1-yl]octyl]- 1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile 416 4-[2,5-Dihydro-3-methyl-4-[8-[4-[(1-methyl- 9 620 1H-imidazol-4-yl)sulfonyl]piperazin-1- yl]octyl]-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)benzonitrile 417 4-[8-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 6 561 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]octyl]-N-(1-methylethyl)-piperazine- 1-carboxamide 418 4-[8-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 9 (12) 563 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]octyl]-N-ethylpiperazine-1-carbothioamide 419 Methyl 4-[8-[1-[4-cyano-3-(trifluoromethyl)- 9 (13) 534 phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-3-yl)octyl]piperazine-1-carboxylate 420 S-Methyl 4-[8-[1-[4-cyano-3-(trifluoromethyl)- 9 (13) 550 phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-3-yl]octyl]piperazine-1-carbothioate 421 4-[8-[1-[4-Cyano-3-(trifluoromethyl)phenyl]- 9 583 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]octyl]-N,N-dimethylpiperazine-1- sulfonamide

TABLE 13 Compounds of General Formula I According to the Invention, in which V = Trifluoromethylphenylacetamide, W = Maleimide, n = 6 Synthesis Ex- Analogous am- to ESI- ple Name Example MS 422 N-[4-[2,5-Dihydro-3-[6-[4-(2-methoxy- 4 615 benzoyl)-piperazin-1-yl]hexyl]4-methyl-2,5- dioxo-1H-pyrrol-1-yl]-2-(trifluoro- methyl)phenyl]acetamide 423 N-[4-[3-[6-[4-(Cyclobutylcarbonyl)piperazin-1- 4 563 yl]hexyl]-2,5 dihydro-4-methyl-2,5-dioxo-1H- pyrrol-1-yl]-2-(trifluoro- methyl)phenyl]acetamide 424 N-[4-[2,5-Dihydro-3-methyl-2,5-dioxo- 4 591 4-[6-[4-[(thien-2-yl)-carbonyl]piperazin-1- yl]hexyl]-1H-pyrrol-1-yl]-2- (trifluoromethyl)phenyl]acetamide 425 N-[4-[3-[6-[4-[4-(Dimethylamino)benzoyl]- 4 628 piperazin-1-yl]-hexyl]-2,5-dihydro-4-methyl-2, 5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)- phenyl]acetamide 426 N-[4-[3-[6-(4-Acetylpiperazin-1-yl)hexyl]-2, 4 523 5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]- 2-(trifluoromethyl)phenyl]acetamide 427 N-[4-[2,5-Dihydro-3-methyl-4-[6-[4- 5 559 (methylsulfonyl)-piperazin-1-yl]hexyl]-2,5- dioxo-1H-pyrrol-1-yl]-2-(trifluoro- methyl)phenyl]-acetamide 428 N-[4-[3-[6-[4-[(2,1,3-Benzothiadiazol-4- 5 679 yl)sulfonyl]-piperazin-1-yl]hexyl]-2,5-dihydro- 4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2- (trifluoromethyl)phenyl]acetamide 429 4-[6-[1-[4-(Acetylamino)-3-(trifluoromethyl)- 6 601 phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H- pyrrol-3-yl]hexyl]-N-(pyridin-4-yl)piperazine- 1-carboxamide

TABLE 14 Compounds of General Formula I According to the Invention, in which V = Nitrotrifluoromethylbenzene, W = Maleimide, n = 6 Synthesis Ex- Analogous am- to ESI- ple Name Example MS 430 3-[6-[4-(Cyclobutylcarbonyl)piperazin-1- 4 551 yl]hexyl]-4-methyl-1-[4-nitro-3-(trifluoro- methyl)phenyl]-1H-pyrrole-2,5-dione 431 3-[6-[4-[4-(Dimethylamino)benzoyl]piperazin- 4 616 1-yl]hexyl]-4-methyl-1-[4-nitro-3-(trifluoro- methyl)-phenyl-1H-pyrrole-2,5-dione 432 3-[6-(4-Acetylpiperazin-1-yl)hexyl]-4-methyl- 4 511 1-[4-nitro-3-(trifluoromethyl)phenyl]-1H- pyrrole-2,5-dione 433 3-Methyl-4-[6-[4-(methylsufonyl)piperazin-1- 5 547 yl]hexyl]-1-[4-nitro-3-(trifluoromethyl)phenyl]- 1H-pyrrole-2,5-dione 434 3-[6-[4-[(2,1,3-Benzothiadiazol-4-yl)sulfonyl]- 5 667 piperazin-1-yl]hexyl]-4-methyl-1-[4-nitro-3- (trifluoromethyl)phenyl]-1H-pyrrole-2,5-dione

TABLE 15 Compounds of General Formula I According to the Invention, in which V = Bistrifluoromethylbenzene, W = Maleimide, n = 6 Synthesis Ex- Analogous am- to ESI- ple Name Example MS 435 1-[3,4-Bis(trifluoromethyl)phenyl]-3-[6-[4-(2- 4 626 methoxy-benzoyl)piperazin-1-yl]hexyl]-4- methyl-1H-pyrrole-2,5-dione 436 3-[6-(4-Acetylpiperazin-1-yl)hexyl)-1-[3,4- 4 534 bis(trifluoromethyl)phenyl]-4-methyl-1H- pyrrole-2,5-dione 437 1-[3,4-Bis(trifluoromethyl)phenyl]-3-[6-[4- 4 574 (cyclobutyl-carbonyl)piperazin-1-yl]hexyl]-4- methyl-1H-pyrrole-2,5-dione 438 1-[3,4-Bis(trifluoromethyl)phenyl]-3-methyl- 4 602 4-[6-[4-[(thien-2-yl)carbonyl]piperazin-1- yl]hexyl]-1H-pyrrole-2,5-dione 439 1-[3,4-Bis(trifluoromethyl)phenyl]-3-[6-[4- 4 639 [4-(dimethylamino)benzoyl]piperazin-1- yl]hexyl]-4-methyl-1H-pyrrole-2,5-dione 440 1-[3,4-Bis(trifluoromethyl)phenyl]-3-methyl- 5 570 4-[6-[4-(methyl-sulfonyl)piperazin-1-yl]hexyl]- 1H-pyrrole-2,5-dione 441 3-[6-[4-[(2,1,3-Benzothiadiazol-4-yl)sulfonyl]- 5 690 piperazin-1-yl]hexyl]-1-[3 ,4-bis(trifluoro- methyl)-phenyl]-4-methyl-1H-pyrrole-2,5-dione

TABLE 16 Compounds of General Formula I According to the Invention, in which V =Fluorotrifluoromethylbenzene, W = Maleimide, n = 6 Synthesis Analogous ESI- Example Name to Example MS 442 1-[3-Fluoro-4-(trifluoromethyl)phenyl]-3-[6-[4-(2- 4 576 methoxy-benzoyl)piperazin-1-yl]hexyl]-4-methyl- 1H-pyrrole-2,5-dione 443 3-[6-[4-(Cyclobutylcarbonyl)piperazin-1-yl]hexyl]- 4 524 1-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl- 1H-pyrrole-2,5-dione 444 1-[3-Fluoro-4-(trifluoromethyl)phenyl]-3-methyl-4- 4 552 [6-[4-(thien-2-yl)carbonyl]piperazin-1-yl]hexyl]- 1H-pyrrole-2,5-dione 445 3-[6-[4-[4-(Dimethylamino)benzoyl]piperazin-1- 4 589 yl]hexyl]-1-[3-fluoro-4-(trifluoromethyl)phenyl]-4- methyl-1H-pyrrole-2,5-dione 446 3-[6-[4-Acetylpiperazin-1-yl)hexyl]-1-[3-fluoro-4- 4 484 (trifluoromethyl)phenyl]-4-methyl-1H-pyrrole-2,5 dione 447 1-[3-Fluoro-4-(trifluoromethyl)phenyl]-3-methyl-4- 5 520 [6-[4-(methylsulfonyl)piperazin-1-yl]hexyl]-1H- pyrrole-2,5-dione 448 3-[6-[4-[(2,1,3-Benzothiadiazol-4-yl)sulfonyl]- 5 640 piperazin-1-yl]hexyl]-1-[3-fluoro-4- (trifluoromethyl)phenyl]-4-methyl-1H-pyrrole-2,5- dione

TABLE 17 Compounds of General Formula I According to the Invention, in which V = Isobenzofuranone, W = Maleimide, n = 4 Synthesis Analogous ESI- Example Name to Example MS 449 3-[4-(4-Acetylpiperazin-1-yl)butyl]-1-(1,3-dihydro- 4 425 1-oxo-isobenzofuran-5-yl)-4-methyl-1H-pyrrole- 2,5-dione 450 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3- 4 440 methyl-4-[4-[4-(1-oxopropyl)piperazin-1-yl]butyl]- 1H-pyrrole-2,5-dione 451 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-[4-[4- 4 500 [(2-methoxyethoxy)acctyl]-piperazin-1-yl]butyl)-4- methyl-1H-pyrrole-2,5-dione 452 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-[4-[4- 4 544 [[2-(2-methoxyethoxy)ethoxy]acetyl]piperazin-1- yl]butyl]-4-methyl-1H-pyrrole-2,5-dione 453 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3- 5 462 methyl-4-[4-[4-(methylsulfonyl)piperazin-1- yl)butyl]-1H-pyrrole-2,5-dione 454 4-[4-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 471 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]butyl]-N-ethyl-piperazine-1-carbothioamide 455 4-[4-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 485 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]butyl]-N-propyl-piperazine-1-carbothioamide 456 4-[4-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 483 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]butyl]-N-(prop-2-enyl)piperazine-1- carbothioamide

TABLE 18 Compounds of General Formula I According to the Invention, in which V = Isobenzofuranone, W = Maleimide, n = 5 Synthesis Analogous ESI- Example Name to Example MS 457 3-[5-(4-Acetylpiperazin-1-yl)pentyl]-1-(1,3- 4 439 dihydro-1-oxo-isobenzofuran-5-yl)-4-methyl-1H- pyrrole-2,5-dione 458 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3- 4 454 methyl-4-[5-[4-(1-oxopropyl)piperazin-1- yl]pentyl]-1H-pyrrole-2,5-dione 459 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-[5-[4- 4 514 [(2-methoxyethoxy)acetyl]piperazin-1-yl]pentyl]-4- methyl-1H-pyrrole-2,5-dione 460 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-[5-[4- 4 558 [[2-(2-methoxyethoxy)ethoxy]acetyl]piperazin-1- yl]pentyl]-4-methyl-1H-pyrrole-2,5-dione 461 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3- 5 476 methyl-4-[5-[4-(methylsulfonyl)piperazin-1- yl]pentyl]-1H-pyrrole-2,5-dione 462 3-[5-[4-(Cyclopropylsulfonyl)piperazin-1- 5 502 yl]pentyl]-1-(1,3-dihydro-1-oxoisobenzofuran-5- yl)-4-methyl-1H-pyrrole-2,5-dione 463 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-[5-[4- 5 608 [[2-[2-(2-methoxyethoxy)ethoxy]ethyl]- sulfonyl]piperazin-1-yl]-pentyl]-4-methyl-1H- pyrrole-2,5-dione 464 4-[5-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 471 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]pentyl]-N-ethyl-piperazine-1-carbothioamide 465 4-[5-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 485 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]pentyl]-N-propylpiperazine-1-carbothioamide 466 4-[5-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 483 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]pentyl]-N-prop-2-enyl)piperazine-1- carbothioamide

TABLE 19 Compounds of General Formula I According to the Invention, in which V = Isobenzofuranone, W = Maleimide, n = 6 Synthesis Analogous ESI- Example Name to Example MS 467 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-[6-[4 4 546 (2-methoxybenzoyl)piperazin-1-yl]hexyl]-4 methyl-1H-pyrrole-2,5-dione 468 3-[6-[4-(Cyclobutylcarbonyl)piperazin-1-yl]hexyl]- 4 494 1-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-4-methyl- 1H-pyrrole-2,5-dione 469 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3- 4 522 methyl-4-[6-[4-[(thien-2-yl)carbonyl]piperazin-1- yl]hexyl]-1H-pyrrole-2,5-dione 470 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-[6-[4- 4 559 [4-(dimethylamino)benzoyl]piperazin-1-yl]hexyl]- 4-methyl-1H-pyrrole-2,5-dione 471 3-[6-(4-Acetylpiperazin-1-yl)hexyl]-1-(1,3- 4 454 dihydro-1-oxoisobenzofuran-5-yl)-4-methyl-1H- pyrrole-2,5-dione 472 4-[4-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 5 519 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N,N-dimethylpiperazine-1-sulfonamide 473 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3- 5 490 methyl-4-[6-[4-(methylsulfonyl)piperazin-1- yl]hexyl]-1H-pyrrole-2,5-dione 474 3-[6-[4-[(2,1,3-Benzothiadiazol-4-yl)sulfonyl]- 5 610 piperazin-1-yl]hexyl]-1-(1,3-dihydro-1- oxoisobenzofuran-5-yl)-4-methyl-1H-pyrrole-2,5- dione 475 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-[6-[4- 5 504 (ethyl-sulfonyl)piperazin-1-yl]hexyl]-4-methyl-1H- pyrrole-2,5-dione 476 4-[6-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 499 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-ethyl-piperazine-1-carbothioamide 477 4-[6-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 513 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-propyl-piperazine-1-carbothioamide 478 4-[6-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 511 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(prop-2-enyl)piperazine-1- carbothioamide 479 4-[6-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 561 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(phenylmethyl)piperazine-1- carbothioamide 480 4-[6-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 575 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-[(4-methylphenyl)methyl]piperazine-1- carbothioamide 481 N-[(4-Chlorophenyl)methyl]-4-[6-[1-(1,3-dihydro- 12 595 1-oxo-isobenzofuran-5-yl)-2,5-dihydro-4-methyl- 2,5-dioxo-1H-pyrrol-3-yl]hexyl]piperazine-1- carbothioamide 482 4-[6-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 547 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-phenylpiperazine-1-carbothioamide 483 4-[6-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 575 2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3- yl]hexyl]-N-(2,6-dimethylphenyl)piperazine-1- carbothioamide

TABLE 20 Compounds of General Formula I According to the Invention, in which V = Methylbenzoxazinone, W = Maleimide, n = 6 Synthesis Analogous ESI- Example Name to Example MS 484 3-[6-[4-(2-Methoxybenzoyl)piperazin-1-yl]hexyl]- 4 573 4-methyl-1-(4-methyl-1-oxo-1H-2,3-benzoxazin-6- yl)-1H-pyrrole-2,5-dione 485 3-[6-[4-(Cyclobutylcarbonyl)piperazin-1-yl]hexyl]- 4 521 4-methyl-1-(4-methyl-1-oxo-1H-2,3-benzoxazin-6- yl)-1H-pyrrole-2,5-dione 486 3-Methyl-1-(4-methyl-1-oxo-1H-2,3-benzoxazin-6- 4 549 yl)-4-[6-[4-[(thien-2-yl)carbonyl]piperazin-1- yl]hexyl]-1H-pyrrole-2,5-dione 487 3-[6-[4-[4-(Dimethylamino)benzoyl]piperazin-1- 4 481 yl]hexyl]-4-methyl-1-(4-methyl-1-oxo-1H-2,3- benzoxazin-6-yl)-1H-pyrrole-2,5-dione 488 3-[6-(4-Acetylpiperazin-1-yl)hexyl]-4-methyl-1-(4- 4 481 methyl-1-oxo-1H-2,3-benzoxazin-6-yl)-1H- pyrrole-2,5-dione 489 3-Methyl-1-(4-methyl-1-oxo-1H-2,3-benzoxazin-6- 5 517 yl)-4-[6-[4-(methylsulfonyl)piperazin-1-yl]hexyl]- 1H-pyrrole-2,5-dione

TABLE 21 Compounds of General Formula I According to the Invention, in which V = Indanone, W = Maleimide, n = 6 Synthesis Analogous ESI- Example Name to Example MS 490 1-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-3-[6-[4-(2- 4 544 methoxy-benzoyl)piperazin-1-yl]hexyl]-4-methyl- 1H-pyrrole-2,5-dione 491 3-[6-[4-(Cyclobutylcarbonyl)piperazin-1-yl]hexyl]- 4 492 1-(2,3-dihydro-1-oxo-1H-inden-5-yl)-4-methyl-1H- pyrrole-2,5-dione 492 1-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-3-methyl-4- 4 520 [6-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]hexyl]- 1H-pyrrole-2,5-dione 493 1-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-3-[6-[4-[4- 4 557 (dimethylamino)benzoyl]piperazin-1-yl]hexyl]-4- methyl-1H-pyrrole-2,5-dione 494 3-[6-[4-Acetylpiperazin-1-yl)hexyl]-1-(2,3- 4 452 dihydro-1-oxo-1H-inden-5-yl)-4-methyl-1H- pyrrole-2,5-dione 495 1-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-3-methyl-4- 5 488 [6-[4-(methylsulfonyl)piperazin-1-yl]hexyl]-1H- pyrrole-2,5-dione 496 3-[6-[4-[(2,1,3-Benzothiadiazol-4- 5 608 yl)sulfonyl]piperazin-1-yl]hexyl]-1-(2,3-dihydro-1- oxo-1H-inden-5-yl)4-methyl-1H-pyrrole-2,5-dione

TABLE 22 Compounds of General Formula I According to the Invention, in which V = Trifluoromethylbenzonitrile, W = Thiohydantoin, n = 2 Synthesis Analogous ESI- Example Name to Example MS 497 4-[3-[2-(4-Acetylpiperazin-1-yl)ethyl]-4,4- 15 (4)  468 dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 498 4-(4,4-Dimethyl-5-oxo-3-[2-[4-(1-oxopropyl)- 15 (4)  482 piperazin-1-yl]-ethyl]-2-thioxoimidazolidin-1-yl]- 2-(trifluoromethyl)-benzonitrile 499 4-[4,4-Dimethyl-3-[2-[4-(2-methyl-1-oxopropyl)- 15 (4)  496 piperazin-1-yl]ethyl]-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)-benzonitrile 500 4-[4,4-Dimethyl-5-oxo-3-[2-[4-(1-oxobutyl)- 15 (4)  496 piperazin-1-yl]-ethyl]-2-thioxoimidazolidin-1-yl]- 2-(trifluoromethyl)-benzonitrile 501 4-[3-[2-[4-(Cyclopropylcarbonyl)piperazin-1- 15 (4)  494 yl]ethyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 502 4-[3-[2-[4-(Cyclobutylcarbonyl)piperazin-1- 15 (4)  508 yl]ethyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin 1-yl]-2-(trifluoromethyl)benzonitrile 503 4-[4,4-Dimethyl-5-oxo-3-[2-[4-[(thien-2-yl)acetyl]- 15 (4)  550 piperazin-1-yl]ethyl]-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)-benzonitrile 504 4-[4,4-Dimethyl-5-oxo-3-[2-[4-[(thien-2- 15 (4)  536 yl)carbonyl]-piperazin-1-yl]ethyl]-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 505 4-[4,4-Dimethyl-5-oxo-3-[2-[4-[(pyridin-4- 15 (4)  531 yl)carbonyl]-piperazin-1-yl]ethyl]-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 506 4-[4,4-Dimethyl-3-[2-[4-(methylsulfonyl)piperazin- 15 (5)  504 1-yl]-ethyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)-benzonitrile 507 4-[3-[2-[4-(Ethylsulfonyl)piperazin-1-yl]ethyl]-4,4- 15 (5)  518 dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)-benzonitrile 508 4-[4,4-Dimethyl-5-oxo-3-[2-[4-(propylsulfonyl)- 15 (5)  532 piperazin-1-yl]ethyl]-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)-benzonitrile 509 4-[4,4-Dimethyl-5-oxo-3-[2-[4-(phenylsulfonyl)- 15 (5)  566 piperazin-1-yl]ethyl]-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)-benzonitrile 510 4-[3-[2-[4-[(4-Cyanophenyl)sulfonyl]piperazin-1- 15 (5)  591 yl]ethyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 511 4-[2-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 15 (12) 513 dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]ethyl]- N-ethylpiperazine-1-carbothioamide 512 4-[2-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 15 (12) 527 dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]ethyl]- N-propylpiperazine-1-carbothioamide 513 4-[2-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5 15 (12) 525 dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]ethyl]- N-(prop-2-enyl)-piperazine-1-carbothioamide 514 S-Methyl 4-[2-[3-[4-cyano-3-(trifluoromethyl)- 15 (13) 500 phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin- 1-yl]ethyl]piperazine-1-carbothioate 515 S-Ethyl 4-[2-[3-[4-cyano-3-(trifluoromethyl)- 15 (13) 514 phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin- 1-yl]ethyl]piperazine-1-carbothioate

TABLE 23 Compounds of General Formula I According to the Invention, in which V = Trifluoromethylbenzonitrile, W = Thiohydantoin, n = 3 Synthesis Analogous ESI- Example Name to Example MS 516 4-[3-[3-[4-(2-Methoxybenzoyl)piperazin-1- 15 (4)  574 yl]propyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 517 4-[3-[3-(4-Acetylpiperazin-1-yl)propyl]-4,4- 15 (4)  482 dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 518 4-[4,4-Dimethyl-5-oxo-3-[3-[4-(1-oxopropyl)- 15 (4)  496 piperazin-1-yl]-propyl]-2-thioxoimidazolidin-1-yl]- 2-(trifluoromethyl)-benzonitrile 519 4-[4,4-Dimethyl-3-[3-[4-(2-methyl-1- 15 (4)  510 oxopropyl)piperazin-1-yl]propyl]-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 520 4-[4,4-Dimethyl-5-oxo-3-[3-[4-(1-oxobutyl)- 15 (4)  510 piperazin-1-yl]-propyl]-2-thioxoimidazolidin-1-yl]- 2-(trifluoromethyl)-benzonitrile 521 4-[3-[3-[4-(Cyclopropylcarbonyl)piperazin-1- 15 (4)  508 yl]propyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 522 4-[3-[3-[4-(Cyclobutylcarbonyl)piperazin-1- 15 (4)  522 yl]propyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 523 4-[4,4-Dimethyl-5-oxo-3-[3-[4-[(thien-2- 15 (4)  564 yl)acetyl]piperazin-1-yl]propyl]-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 524 4-[4,4-Dimethyl-5-oxo-3-[3-[4-[(thien-2- 15 (4)  550 yl)carbonyl]-piperazin-1-yl]propyl]-2- thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 525 4-[4,4-Dimethyl-5-oxo-3-[3-[4-[(pyridin-4- 15 (4)  545 yl)carbonyl]-piperazin-1-yl]propyl]-2- thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 526 4-[3-[3-[4-(3-Methoxy-1-oxopropyl)piperazin-1- 15 (4)  526 yl]propyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 527 4-[3-[3-[4-[(2-Methoxyethoxy)acetyl]piperazin-1- 15 (4)  556 yl]propyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 528 4-[3-[3-[4-[[2-(2-Methoxyethoxy)ethoxy]- 15 (4)  600 acetyl]piperazin-1-yl]propyl]-4,4-dimethyl-5-oxo- 2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 529 4-[4,4-Dimethyl-3-[3-[4-(methylsulfonyl)piperazin- 15 (5)  518 1-yl]-propyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)-benzonitrile 530 4-[3-[3-[4-(Ethylsulfonyl)piperazin-1-yl]propyl)- 15 (5)  532 4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 531 4-[4,4-Dimethyl-5-oxo-3-[3-[4-propylsulfonyl)- 15 (5)  546 piperazin-1-yl]propyl]-2-thioxoimidazolidin-1-yl]- 2-(trifluoromethyl)-benzonitrile 532 4-[3-[3-[4-[(2-Methoxyethyl)sulfonyl]piperazin-1- 15 (5)  562 yl]propyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 533 4-[4,4-Dimethyl-5-oxo-3-[3-[4-(phenylsulfonyl)- 15 (5)  580 piperazin-1-yl]propyl]-2-thioxoimidazolidin-1-yl]- 2-(trifluoromethyl)-benzonitrile 534 4-[3-[3-[4-[(4-Cyanophenyl)sulfonyl]piperazin-1- 15 (5)  605 yl]propyl]4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 535 4-[3-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 15 (12) 527 dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]propyl]- N-ethylpiperazine-1-carbothioamide 536 4-[3-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 15 (12) 541 dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]propyl]- N-propylpiperazine-1-carbothioamide 537 4-[3-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 15 (12) 539 dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]propyl] N-(prop-2-enyl)-piperazine-1-carbothioamide 538 S-Methyl 4-[3-[3-[4-cyano-3-(trifluoromethyl)- 15 (13) 514 phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin- 1-yl]propyl]piperazine-1-carbothioate 539 S-Ethyl 4-[3-[3-[4-cyano-3-(trifluoromethyl)- 15 (13) 528 phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin- 1-yl]propyl]piperazine-1-carbothioate

TABLE 24 Compounds of General Formula I According to the Invention, in which V = Trifluoromethylbenzonitrile, W = Thiohydantoin, n = 4 Synthesis Analogous ESI- Example Name to Example MS 540 4-[3-[4-[4-(2-Methoxybenzoyl)piperazin-1- 4 588 yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 541 4-[4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 4 479 dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]butyl]piperazine-1-carbonitrile 542 4-[3-[4-(4-Acetylpiperazin-1-yl)butyl]-4,4- 4 496 dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 543 rel-4-[3-[(2R,5S)-4-Acetyl-2,5- 4 524 dimethylpiperazin-1-yl]butyl]-4,4-dimethyl-5-oxo- 2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 544 4-[3-[4-(4-Acetylhexahydro-1H-1,4-diazepin-1- 4 510 yl)butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 545 4-[4,4-Dimethyl-5-oxo-3-[4-[4-(1- 4 510 oxopropyl)piperazin-1-yl]butyl]-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 546 4-[4,4-Dimethyl-3-[4-[4-(2-methyl-1- 4 524 oxopropyl)piperazin-1-yl]butyl]-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 547 rel-4-[3-[4-[(2R,5S)-2,5-Dimethyl-4-(2-methyl-1- 4 552 oxopropyl)piperazin-1-yl]butyl]-4,4-dimethyl-5- oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 548 4-[3-[4-[4-(2-Hydroxy-2-methyl-1-oxopropyl)- 4 540 piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2 thioxoimidazolidin-1-yl]-2-(trifluormethyl)- benzonitrile 549 4-[3-[4-[4-(2,2-Dimethyl-1-oxopropyl)piperazin-1- 4 538 yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 550 rel-4-[3-[4-[(2R,5S)-4-(2,2-Dimethyl-1-oxopropyl)- 4 566 2,5-dimethylpiperazin-1-yl]butyl]-4,4-dimethyl-5- oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 551 4-[3-[4-[4-(2,2-Dimethyl-1-oxopropyl)hexahydro- 4 552 1H-1,4-diazepin-1-yl]butyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 552 4-[4,4-Dimethyl-5-oxo-3-[4-[4-(1- 4 524 oxobutyl)piperazin-1-yl]-butyl]-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 553 4-[3-[4-[4-(Cyclopropylcarbonyl)piperazin-1- 4 522 yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 554 rel-4-[3-[4-[(2R,5S)-4-(Cyclopropylcarbonyl)-2,5 4 550 dimethylpiperazin-1-yl]butyl]-4,4-dimethyl-5-oxo 2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl) benzonitrile 555 4-[3-[4-[4-(Cyclobutylcarbonyl)piperazin-1- 4 536 yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 556 4-[4,4-Dimethyl-5-oxo-3-[4-[4-[(thien-2- 4 578 yl)acetyl]piperazin-1-yl]butyl]-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 557 4-[3-[4-[4-(Methoxyacetyl)piperazin-1-yl]butyl]- 4 526 4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 558 4-[3-[4-[4-(3-Methoxy-1-oxopropyl)piperazin-1- 4 540 yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin 1-yl]-2-(trifluoromethyl)benzonitrile 559 4-[3-[4-[Hexahydro-4-(3-methoxy-1-oxopropyl)- 4 554 1H-1,4-diazepin-1-yl]butyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 560 4-[3-[4-[4-[(2-Methoxyethoxy)acetyl]piperazin-1- 4 570 yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 561 4-[3-[4-[4-[[2-(2-Methoxyethoxy)ethoxy]- 4 614 acetyl]piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 562 4-[4,4-Dimethyl-5-oxo-2-thioxo-3-[4-[4- 4 550 (trifluoroacetyl)piperazin-1-yl]butyl]imidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 563 4-[3-[4-[Hexahydro-4-(trifluoroacetyl)-1H-1,4- 4 564 diazepin-1-yl]butyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 564 4-[3-[4-[4-[(1,3-Dimethyl-1H-pyrazol-5- 4 576 yl)carbonyl]-piperazin-1-yl]butyl]-4,4-dimethyl-5- oxo-2-thioxo-imidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 565 4-[3-[4-[4-[Furan-3-yl)carbonyl]piperazin-1- 4 548 yl]butyl]-4A-dimethyl-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 566 4-[3-[4-[4-[(2,5-Dimethylfuran-3 4 576 yl)carbonyl]piperazin-1-yl]butyl]-4,4-dimethyl-5- oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 567 4-[3-[4-[4-[(Isoxazol-5-yl)carbonyl]piperazin-1- 4 549 yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 568 4-[4,4-Dimethyl-3-[4-[4-[(5-methylisoxazol-3- 4 563 yl)carbonyl]piperazin-1-yl]butyl]-5-oxo-2-thioxo- imidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile 569 4-[4,4-Dimethyl-5-oxo-3-[4-[4-[(thien-3- 4 564 yl)carbonyl]-piperazin-1-yl]butyl]-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 570 4-[4,4-Dimethyl-3-[4-[4-[(4-methyl-1,2,3- 4 580 thiadiazol-4-yl)-carbonyl]piperazin-1-yl]butyl]-5- oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 571 4-[3-[4-[4-[(Furan-2-yl)carbonyl]piperazin-1- 548 yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 572 4-[3-[4-[4-[(Furan-2-yl)carbonyl]hexahydro-1H- 4 562 1,4-diazepin-1-yl]butyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 573 4-[4,4-Dimethyl-5-oxo-3-[4-[4-[(thien-2- 4 564 yl)carbonyl]-piperazin-1-yl]butyl]-2- thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 574 4-[3-[4-[Hexahydro-4-[(thien-2-yl)carbonyl)-1H- 4 578 1,4-diazepin-1-yl]butyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 575 4-[4,4-Dimethyl-5-oxo-3-[4-[4-[(pyridin-4- 4 559 yl)carbonyl]-piperazin-1-yl]butyl]-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 576 4-[4,4-Dimethyl-3-[4-[4-(methylsulfonyl)piperazin- 5 532 1-yl]-butyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)-benzonitrile 577 rel-4-[4,4-Dimethyl-3-[4-[(2R,5S)-2,5-dimethyl-4- 5 560 (methylsulfonyl)piperazin-1-yl]butyl]-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 578 4-[3-[4-[Hexahydro-4-(methylsulfonyl)-1H-1,4- 5 546 diazepin-1-yl]butyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 579 4-[3-[4-[4-(Ethylsulfonyl)piperazin-1-yl]butyl]-4,4- 5 546 dimethyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)-benzonitrile 580 4-[4,4-Dimethyl-5-oxo-3-[4-[4-(propylsulfonyl)- 5 560 piperazin-1-yl]butyl]-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)-benzonitrile 581 4-[3-[4-[4-[(2-Methoxyethyl)sulfonyl]piperazin-1- 5 576 yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 582 4-[4,4-Dimethyl-5-oxo-3-[4-[4-(phenylsulfonyl)- 5 594 piperazin-1-yl]butyl]-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)-benzonitrile 583 4-[3-[4-[4-[(4-Cyanophenyl)sulfony]]piperazin-1- 5 619 yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 584 4-[4,4-Dimethyl-3-[4-[4-[(1-methyl-1H-imidazol- 5 598 4-yl)-sulfonyl]piperazin-1-yl]butyl]-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 585 4-[3-[4-[4-[(3,5-Dimethylisoxazol-4-yl)sulfonyl]- 5 613 piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 586 4-[4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 12 541 dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]butyl]- N-ethylpiperazine-1-carbothioamide 587 4-[4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 12 555 dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]butyl]- N-propylpiperazine-1-carbothioamide 588 4-[4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 12 553 dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]butyl]- N-(prop-2-enyl)-piperazine-1-carbothioamide 589 S-Methyl 4-[4-[3-[4-cyano-3-(trifluoromethyl)- 13 528 phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin 1-yl]butyl]piperazine-1-carbothioate 590 S-Methyl 4-[4-[3-[4-cyano-3-(trifluoromethyl)- 13 542 phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin- 1-yl]butyl]hexahydro-1H-1,4-diazepine-1- carbothioate 591 S-Ethyl 4-[4-[3-[4-cyano-3-(trifluoromethyl) 13 542 phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin- 1-yl]butyl]piperazine-1-carbothioate 592 N,N-Dimethyl 4-[4-[3-[4-cyano-3- 14 561 (trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2- thioxoimidazolidin-1-yl]butyl]piperazine-1- sulfonamide

TABLE 25 Compounds of General Formula I According to the Invention, in which V = Trifluoromethylbenzonitrile, W = Thiohydantoin, n = 5 Synthesis Analogous ESI- Example Name to Example MS 593 4-[3-[5-[4-(2-Methoxybenzoyl)piperazin-1- 4 602 yl]pentyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 594 4-[5-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 4 493 dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]pentyl]piperazine-1-carbonitrile 595 4-[3-[5-(4-Acetylpiperazin-1-yl)pentyl]-4,4- 510 dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 596 rel-4-[3-[5-[(2R,6S)-4-Acetyl-2,6- 4 538 dimethylpiperazin-1-yl]pentyl]-4,4-dimethyl-5- oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 597 4-[3-[5-(4-Acetylhexahydro-1H-1,4-diazepin-1- 4 524 yl)pentyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoro- methyl)benzonitrile 598 4-[4,4-Dimethyl-5-oxo-3-[5-[4-[1-oxopropyl)- 4 524 piperazin-1-yl]-pentyl]-2-thioxoimidazolidin-1-yl]- 2-(trifluoromethyl)-benzonitrile 599 4-[4,4-Dimethyl-3-[5-[4-(2-methyl-1-oxopropyl)- 4 538 piperazin-1-yl]pentyl]-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)-benzonitrile 600 4-[3-[5-[Hexahydro-4-(2-methyl-1-oxopropyl-1H- 4 552 1,4-diazepin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 601 4-[3-[5-[4-(2-Hydroxy-2-methyl-1-oxopropyl)- 4 554 piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 602 4-[3-[5-[4-(2,2-Dimethyl-1-oxopropyl)piperazin-1- 4 552 yl]pentyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 603 4-[3-[5-[4-(2,2-Dimethyl-1-oxopropyl)hexahydro- 4 566 1H-1,4-diazepin-1-yl]pentyl]-4,4-dimethyl-5-oxo- 2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 604 4-[4,4-Dimethyl-5-oxo-3-[5-[4-(1-oxobutyl)- 4 538 piperazin-1-yl]-pentyl)-2-thioxoimidazolidin-1-yl]- 2-(trifluoromethyl)-benzonitrile 605 4-[3-[5-[4-(Cyclopropylcarbonyl)piperazin-1- 4 536 yl]pentyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 606 4-[3-[5-[4-(Cyclobutylcarbonyl)piperazin-1- 4 550 yl]pentyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 607 4-[4,4-Dimethyl-5-oxo-3-[5-[4-[(thien-2- 4 592 yl)acetyl]piperazin-1-yl]pentyl]-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 608 4-[3-[5-[4-(Methoxyacetyl)piperazin-1-yl]pentyl]- 4 540 4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 609 4-[3-[5-[4-(3-Methoxy-1-oxopropyl)piperazin-1- 4 554 yl]pentyl]4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 610 4-[3-[5-[4-[(2-Methoxyethoxy)acetyl]piperazin-1- 4 584 yl]pentyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 611 4-[3-[5-[4-[[2-(2-Methoxyethoxy)ethoxy]- 4 628 acetyl]piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo- 2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 612 4-[4,4-Dimethyl-5-oxo-2-thioxo-3-[5-[4- 4 564 (trifluoroacetyl)piperazin-1-yl]pentyl]imidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 613 4-[3-[5-[4-[(1,3-Dimethyl-1H-pyrazol-5- 4 590 yl)carbonyl)-piperazin-1-yl]pentyl]-4,4-dimethyl-5- oxo-2-thioxo-imidazolidin-1-yl)-2- (trifluoromethyl)benzonitrile 614 4-[3-[5-[4-[(Furan-3-yl)carbonyl]piperazin-1- 4 562 yl]pentyl)-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 615 4-[3-[5-[4-[(Furan-3-yl)carbonyl]hexahydro-1H- 4 576 1,4-diazepin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 616 4-[3-[5-[4-[(2,5-Dimethylfuran-3- 4 590 yl)carbonyl)piperazin-1-yl)pentyl]-4,4-dimethyl-5- oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)- benzonitrile 617 4-[3-[5-[4-[(Isoxazol-5-yl)carbonyl]piperazin-1- 4 563 yl)pentyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 618 4-[4,4-Dimethyl-3-[5-[4-[(5-methylisoxazol-3 4 577 yl)carbonyl)-piperazin-1-yl]pentyl]-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 619 4-[4,4-Dimethyl-5-oxo-3-[5-[4-[(thien-3- 4 578 yl)carbonyl)-piperazin-1-yl]pentyl)-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 620 4-[3-[5-[Hexahydro-4-[(thien-3-yl)carbonyl]-1H- 4 592 1,4-diazepin-1-yl]pentyl]4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl)-2-(trifluoromethyl)- benzonitrile 621 4-[4,4-Dimethyl-3-[5-[4-[(4-methyl-1,2,3- 4 594 thiadiazol-4-yl)-carbonyl)piperazin-1-yl]pentyl]-5- oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 622 4-[3-[5-[4-[(Furan-2-yl)carbonyl)hexahydro-1H- 4 576 1,4-diazepin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl)-2-(trifluoromethyl)- benzonitrile 623 4-[4,4-Dimethyl-5-oxo-3-[5-[4-[(thien-2- 4 578 yl)carbonyl]-piperazin-1-yl]pentyl)-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 624 4-[3-[5-[Hexahydro-4-[(thien-2-yl)carbonyl)-1H- 4 592 1,4-diazepin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl)-2-(trifluoromethyl)- benzonitrile 625 4-[4,4-Dimethyl-5-oxo-3-[5-[4-[pyridin-4- 4 573 yl)carbonyl)-piperazin-1-yl)pentyl)-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 626 4-[4,4-Dimethyl-3-[5-[4-(methylsulfonyl)piperazin- 5 546 1-yl]-pentyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)-benzonitrile 627 rel-4-[3-[5-[(2R,6S)-2,6-Dimethyl-4 5 574 (methylsulfonyl)piperazin-1-yl]pentyl]-4,4- dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 628 4-[3-[5-[Hexahydro-4-(methylsulfonyl)-1H-1,4- 5 560 diazepin-1-yl]pentyl]4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl)-2-(trifluoromethyl)- benzonitrile 629 4-[3-[5-[4-(Ethylsulfonyl)piperazin-1-yl]pentyl]- 5 560 4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 630 4-[4,4-Dimethyl-5-oxo-3-[5-[4-propylsulfonyl)- 5 574 piperazin-1-yl]pentyl]-2-thioxoimidazolidin-1-yl]- 2-(trifluoromethyl)-benzonitrile 631 4-[4,4-Dimethyl-5-oxo-3-[5-[4-(phenylsulfonyl)- 5 608 piperazin-1-yl]pentyl)-2-thioxoimidazolidin-1-yl)- 2-(trifluoromethyl)-benzonitrile 632 4-[3-[5-[4-[(4-Cyanophenyl)sulfonyl]piperazin-1- 5 633 yl]pentyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 633 4-[3-[5-[4-[(2-Methoxyethoxy)sulfonyl]piperazin- 5 590 1-yl]-pentyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 634 4-[3-[5-[4-[[2-(2-Methoxyethoxy)ethyl]- 5 634 sulfonyl]piperazin-1-yl]pentyl]-4,4-dimethyl-5- oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 635 4-[3-[5-[4-[[2-[2-(2-Methoxyethoxy)ethoxy]ethyl] 5 678 sulfonyl]-piperazin-1-yl]pentyl]-4,4-dimethyl-5- oxo-2-thioxo-imidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 636 4-[4,4-Dimethyl-3-[5-[4-[(1-methyl-1H-imidazol- 5 612 4-yl)-sulfonyl]piperazin-1-yl]pentyl]-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 637 4-[3-[5-[4-[(3,5-Dimethylisoxazol-4 5 627 yl)sulfonyl]piperazin-1-yl]pentyl]-4,4-dimethyl-5- oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 638 4-[5-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 12 555 dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]- N-ethylpiperazine-1-carbothioamide 639 4-[5-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 12 569 dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]- N-propylpiperazine-1-carbothioamide 640 4-[5-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 12 567 dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]- N-(prop-2-enyl)-piperazine-1-carbothioamide 641 S-Methyl 4-[5-[3-[4-cyano-3-(trifluoromethyl)- 13 542 phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin- 1-yl]pentyl]piperazine-1-carbothioate 642 S-Methyl 4-[5-[3-[4-cyano-3-(trifluoromethyl)- 13 556 phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin- 1-yl]pentyl]hexahydro-1H-1,4-diazepin-1- carbothioate 643 S-Ethyl 4-[5-[3-[4-cyano-3-(trifluoromethyl)- 13 556 phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin- 1-yl]pentyl]piperazine-1-carbothioate 644 N,N-Dimethyl 4-[5-[3-[4-cyano-3- 14 575 (trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2- thioxoimidazolidin-1-yl]pentyl]piperazine-1- sulfonamide

TABLE 26 Compounds of General Formula I According to the Invention, in which V = Trifluoromethylbenzonitrile, W = Thiohydantoin, n = 6 Synthesis Analogous ESI- Example Name to Example MS 645 4-[4,4-Dimethyl-3-[6-(4-methylpiperazin-1- 3 496 yl)hexyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 646 4-[4,4-Dimethyl-3-[6-[4-(1-methylethyl)piperazin- 3 524 1-yl]-hexyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)-benzonitrile 647 4-[3-[6-[4-(2-Methoxybenzoyl)piperazin-1- 4 616 yl]hexyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 648 4-[6-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 4 507 dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]hexyl]piperazine-1-carbonitrile 649 4-[3-[6-(4-Acetylpiperazin-1-yl)hexyl]-4,4- 4 524 dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 650 rel-4-[3-[6-[(2R,5S)-4-Acetyl-2,5-dimethyl- 4 552 piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 651 rel-4-[3-[6-[(2R,6S)-4-Acetyl-2,6-dimethyl 4 552 piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 652 4-[4,4-Dimethyl-5-oxo-3-[6-[4-(1-oxopropyl)- 4 538 piperazin-1-yl]-hexyl]-2-thioxoimidazolidin-1-yl]- 2-(trifluoromethyl)-benzonitrile 653 4-[4,4-Dimethyl-3-[6-[4-(2-methyl-1- 4 552 oxopropyl)piperazin-1-yl]hexyl]-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 654 rel-4-[3-[6-[(2R,5S)-2,5-Dimethyl-4-(2-methyl-1- 4 580 oxopropyl)piperazin-1-yl]hexyl]-4,4-dimethyl-5- oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoomethyl)- benzonitrile 655 4-[3-[6-[Hexahydro-4-(2-methyl-1-oxopropyl)-1H- 4 566 1,4-diazepin-1-yl]hexyl]4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 656 4-[3-[6-[4-(2-Hydroxy-2-methyl-1-oxopropyl)- 4 568 piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 657 4-[3-[6-[4-(2,2-Dimethyl-1-oxopropyl)piperazin-1- 4 566 yl]hexyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 658 rel-4-[3-[6-[(2R,5S)-4-2,2-Dimethyl-1-oxopropyl)- 4 594 2,5-dimethylpiperazin-1-yl]hexyl]-4,4-dimethyl-5- oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 659 rel-4-[3-[6-[(2R,6S)4-(2,2-Dimethyl-1-oxopropyl)- 4 594 2,6-dimethylpiperazin-1-yl]hexyl]-4,4-dimethyl-5- oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 660 4-[4,4-Dimethyl-5-oxo-3-[6-[4-(1- 4 552 oxobutyl)piperazin-1-yl]-hexyl]-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 661 4-[3-[6-[4-(Cyclopropylcarbonyl)piperazin-1- 4 550 yl]hexyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 662 rel-4-[3-[6-[(2R,5S)-4-(Cyclopropylcarbonyl)-2,5- 4 578 dimethylpiperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo- 2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 663 4-[3-[6-[4-(Cyclobutylcarbonyl)piperazin-1- 4 564 yl]hexyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 664 4-[3-[6-[4-(Methoxyacetyl)piperazin-1-yl]hexyl]- 4 554 4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 665 4-[3-[6-[4-(3-Methoxy-1-oxopropyl)piperazin-1- 4 568 yl]hexyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 666 rel-4-[3-[6-[(2R,5S)-4-(3-Methoxy-1-oxopropyl)- 4 596 2,5-dimethylpiperazin-1-yl]hexyl]-4,4-dimethyl-5- oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 667 4-[3-[6-[Hexahydro-4-(3-methoxy-1-oxopropyl)- 4 582 1H-1,4-diazepin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 668 4-[3-[6-[4-[(2-Methoxyethoxy)acetyl]piperazin-1- 4 598 yl]hexyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 669 4-[3-[6-[4-[[2-(2-Methoxyethoxy)ethoxy]- 4 642 acetyl]piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 670 4-[4,4-Dimethyl-5-oxo-2-thioxo-3-[6-[4- 4 578 (trifluoroacetyl)piperazin-1-yl]hexyl]imidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 671 rel-4-[3-[6-[(2R,5S)-2,5-Dimethyl-4- 4 606 (trifluoroacetyl)piperazin-1-yl]hexyl]-4,4-dimethyl- 5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 672 4-[4,4-Dimethyl-5-oxo-3-[6-[4-[(thien-2- 4 606 yl)acetyl]piperazin-1-yl]hexyl]-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 673 rel-4-[3-[6-[(2R,5S)-4-[(Furan-3-yl)carbonyl)-2,5- 4 604 dimethylpiperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo- 2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 674 rel-4-[3-[6-[(2R,5S)-4-[(Isoxazol-5-yl)carbonyl]- 4 605 2,5-dimethylpiperazin-1-yl]hexyl)-4,4-dimethyl-5- oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 675 4-[3-[6-[4-[(Furan-2-yl)carbonyl]piperazin-1- 4 576 yl]hexyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 676 rel-4-[3-[6-[(2R,5S)-4-[(Furan-2-yl)carbonyl]-2,5- 4 604 dimethylpiperazin-1 -yl]hexyl]-4,4-dimethyl-5-oxo- 2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 677 4-[3-[6-[4-[(Furan-2-yl)carbonyl]hexahydro-1H- 4 590 1,4-diazepin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 678 4-[4,4-Dimethyl-5-oxo-3-[6-[4-[(thien-2- 4 592 yl)carbonyl]-piperazin-1-yl]bexyl]-2 thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 679 rel-4-[3-[6-[(2R,5S)-2,5-Dimethyl-4-[(thien-2 4 620 yl)carbonyl]piperazin-1-yl]hexyl]-4,4-dimethyl-5- oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 680 4-[3-[6-[Hexahydro-4-[(thien-2-yl)carbonyl]-1H- 4 606 1,4-diazepin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 681 4-[4,4-Dimethyl-5-oxo-3-[6-[4-[(pyridin-4- 4 587 yl)carbonyl]-piperazin-1-yl]hexyl]-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 682 4-[4,4-Dimethyl-3-[6-[4-(methylsulfonyl)piperazin- 5 560 1-yl]-hexyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)-benzonitrile 683 rel-4-[3-[6-[(2R,5S)-2,5-Dimethyl-4- 5 588 (methylsulfonyl)piperazin-1-yl]hexyl]-4,4- dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 684 rel-4-[3-[6-[(2R,6S)-2,6-Dimethyl-4- 5 588 (methylsulfonyl)piperazin-1-yl]hexyl]-4,4- dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 685 4-[3-[6-[Hexahydro-4-(methylsulfonyl)-1H-1,4- 5 574 diazepin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 686 4-[3-[6-[4-(Ethylsulfonyl)piperazin-1-yl]hexyl]- 5 574 4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 687 rel-4-[3-[6-[(2R,5S)4-(Ethylsulfonyl)-2,5- 5 602 dimethylpiperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo- 2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 688 4-[4,4-Dimethyl-5-oxo-3-[6-[4-propylsulfonyl)- 5 588 piperazin-1-yl]hexyl]-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 689 4-[4,4-Dimethyl-3-[6-[4-[(1-methylethyl)- 5 588 sulfonyl]piperazin-1-yl]hexyl]-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 690 4-[3-[6-[4-[(2-Methoxyethyl)sulfonyl]piperazin-1- 5 604 yl]hexyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 691 4-[4,4-Dimethyl-5-oxo-3-[6-[4-(phenylsulfonyl)- 5 622 piperazin-1-yl]hexyl]-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 692 4-[3-[6-[4-[(4-Cyanophenyl)sulfonyl]piperazin-1- 5 647 yl]hexyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 693 4-[6-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 12 569 dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]- N-ethylpiperazine-1-carbothioamide 694 4-[6-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 12 583 dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]- N-propylpiperazine-1-carbothioamide 695 4-[6-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 12 581 dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]- N-(prop-2-enyl)-piperazine-1-carbothioamide 696 S-Methyl 4-[6-[3-[4-cyano-3-(trifluoromethyl)- 13 556 phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin- 1-yl]hexyl]piperazine-1-carbothioate 697 S-Methyl 4-[6-[3-[4-cyano-3-(trifluoromethyl)- 13 570 phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin- 1-yl]hexyl]hexahydro-1H-1,4-diazepine-1- carbothioate 698 S-Ethyl 4-[6-[3-[4-cyano-3-(trifluoromethyl)- 13 570 phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin- 1-yl]hexyl]piperazine-1-carbothioate

TABLE 27 Compounds of General Formula I According to the Invention, in which V = Trifluoromethylbenzonitrile, W = Thiohydantoin, n = 7 Synthesis Analogous ESI- Example Name to Example MS 699 4-[4,4-Dimethyl-3-[7-(4-methylpiperazin-1- 3 510 yl)heptyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 700 4-[7-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 4 521 dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]heptyl]piperazine-1-carbonitrile 701 4-[3-[7-(4-Acetylpiperazin-1-yl)heptyl]-4,4- 4 538 dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 702 rel-4-[3-[7-[(2R,6S)-4-Acetyl-2,6-dimethyl- 4 566 piperazin-1-yl]heptyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 703 4-[3-[7-[4-(2-Hydroxy-2-methyl-1-oxopropyl)- 4 582 piperazin-1-yl]heptyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 704 4-[3-[7-[4-(2,2-Dimethyl-1-oxopropyl)piperazin-1- 4 580 yl]heptyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 705 rel-4-[3-[7-[(2R,6S)-4-(2,2-Dimethyl-1-oxopropyl)- 4 608 2,6-dimethylpiperazin-1-yl]heptyl]-4,4-dimethyl-5- oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 706 4-[3-[7-[4-(Methoxyacetyl)piperazin-1-yl]heptyl]- 4 568 4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 707 4-[4,4-Dimethyl-5-oxo-2-thioxo-3-[7-[4- 4 592 (trifluoroacetyl)piperazin-1-yl]heptyl]imidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 708 rel-4-[3-[7-[(2R,6S)-2,6-Dimethyl-4- 4 620 (trifluoroacetyl)piperazin-1-yl]heptyl]-4,4- dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 709 4-[4,4-Dimethyl-3-[7-[4-(methylsulfonyl)piperazin- 5 574 1-yl]heptyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 710 rel-4-[3-[7-[(2R,6S)-2,6-Dimethyl-4- 5 602 (methylsulfonyl)piperazin-1-yl]heptyl]-4,4- dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 711 4-[3-[7-[4-[(2-Methoxyethyl)sulfonyl]piperazin-1- 5 618 yl]heptyl)-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile

TABLE 28 Compounds of General Formula I According to the Invention, in which V = Trifluoromethylbenzonitrile, W = Thiohydantoin, n = 8 Synthesis Analogous ESI- Example Name to Example MS 712 4-[8-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 4 535 dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]octyl]piperazine-1-carbonitrile 713 rel-4-[3-[8-[(2R,6S)-4-Acetyl-2,6- 4 580 dimethylpiperazin-1-yl]octyl]-4,4-dimethyl-5-oxo- 2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 714 4-[4,4-Dimethyl-3-[8-[4-(2-methyl-1-oxopropyl)- 4 580 piperazin-1-yl]octyl]-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)-benzonitrile 715 4-[3-[8-[4-(2-Hydroxy-2-methyl-1-oxopropyl)- 4 596 piperazin-1-yl]octyl]-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 716 rel-4-[3-[8-[(2R,6S)-4-(2,2-Dimethyl-1-oxopropyl)- 4 622 2,6-dimethylpiperazin-1-yl]octyl]-4,4-dimethyl-5- oxo-2-thioxoimidazolidin-1-yl]-2- (trifluormethyl)benzonitril 717 4-[3-[8-[4-(Cyclopropylcarbonyl)piperazin-1- 4 578 yl]octyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 718 4-[3-[8-[4-(Cyclobutylcarbonyl)piperazin-1- 4 592 yl]octyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 719 4-[3-[8-[4-(Methoxyacetyl)piperazin-1-yl]octyl]- 4 582 4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 720 4-[4,4-Dimethyl-5-oxo-2-thioxo-3-[8-[4- 4 606 (trifluoroacetyl)piperazin-1-yl]octyl]imidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 721 4-[4,4-Dimethyl-5-oxo-3-[8-[4-[(thien-2- 4 620 yl)carbonyl]-piperazin-1-yl]octyl]-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 722 4-[4,4-Dimethyl-5-oxo-3-[8-[4-[(pyridin-4- 4 615 yl)carbonyl]-piperazin-1-yl]octyl]-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 723 4-[4,4-Dimethyl-3-[8-[4-(methylsulfonyl)piperazin- 5 588 1-yl]-octyl)-5-oxo-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)-benzonitrile 724 4-[4,4-Dimethyl-5-oxo-3-[8-[4-(propylsulfonyl)- 5 616 piperazin-1-yl]octyl]-2-thioxoimidazolidin-1-yl]-2- (trifluoromethyl)benzonitrile 725 4-[4,4-Dimethyl-3-[8-[4-[(1-methylethyl)- 5 616 sulfonyl]piperazin-1-yl]octyl]-5-oxo-2- thioxoimidazolidin-1-yl]-2-(trifluoromethyl)- benzonitrile 726 4-[3-[8-[4-[(2-Methoxyethyl)sulfonyl]piperazin-1- 5 632 yl]octyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 727 4-[3-[8-[4-[(4-Cyanophenyl)sulfonyl]piperazin-1- 5 675 yl]octyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin- 1-yl]-2-(trifluoromethyl)benzonitrile 728 4-[8-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- 12 597 dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]octyl]- N-ethylpiperazine-1-carbothioamide 729 4-[8-[3-[4-Cyano-3-(trifluoromethyl)phenyl)-5,5- 12 609 dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]octyl]- N-(prop-2-enyl)-piperazine-1-carbothioamide 730 S-Methyl 4-[8-[3-[4-cyano-3-(trifluoromethyl)- 13 584 phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin- 1-yl]octyl]piperazine-1-carbothioate 731 N,N-Dimethyl 4-[8-[3-[4-cyano-3- 14 617 (trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2 thioxoimidazolidin-1-yl]octyl)piperazine-1- sulfonamide

TABLE 29 Compounds of General Formula I According to the Invention, in which V = Isobenzofuranone, W = Thiohydantoin, n = 3 Synthesis Analogous ESI- Example Name to Example MS 732 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 15 (4)  513 dimethyl-1-[3-[4-[(thien-2-yl)carbonyl]piperazin-1- yl]propyl]-2-thioxoimidazolidin-4-one 733 3-[1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[3-[4- 15 (4)  550 [4-(dimethylamino)benzoyl]piperazin-1-yl]propyl]- 5,5-dimethyl-2-thioxoimidazolidin-4-one 734 N-[(4-Chlorophenyl)methyl]-4-[3-[3-(1,3-dihydro- 15 (12) 586 1-oxo-isobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2- thioxo-imidazolidin-1-yl]propyl]piperazine-1- carbothioamide 735 S-Ethyl 4-[3-[3-(1,3-dihydro-1-oxoisobenzofuran- 15 (13) 491 5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]propyl]piperazine-1-carbothioate 736 4-[3-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 15 (14) 502 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]propyl)-N,N-diethylpiperazine-1-carboxylic acid amide

TABLE 30 Compounds of General Formula I According to the Invention, in which V = Isobenzofuranone, W = Thiohydantoin, n = 4 Synthesis Analogous ESI- Example Name to Example MS 737 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 4 527 dimethyl-1-[4[4-[(thien-2-yl)carbonyl]piperazin-1- yl]butyl]-2-thioxo-imidazolidin-4-one 738 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[4-[4- 4 551 (2-methoxybenzoyl)piperazin-1-yl]butyl]-5,5- dimethyl-2-thioxoimidazolidin-4-one 739 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[4-[4- 4 564 [4-(dimethylamino)benzoyl]piperazin-1-yl]butyl]- 5,5-dimethyl-2-thioxoimidazolidin-4-one 740 1-[4-[4-[(2,1,3-Benzothiadiazol-4-yl)sulfonyl]- 5 615 piperazin-1-yl]butyl]-3-(1,3-dihydro-1- oxoisobenzofuran-5-yl)-5,5-dimethyl-2- thioxoimidazolidin-4-one 741 N-(2,6-Dichloropyridin-4-yl)-4-[4-[3-(1,3-dihydro- 6 606 1-oxo-isobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2- thioxo-imidazolidin-1-yl]butyl]piperazine-1- carboxylic acid amide 742 S-Methyl 4-[4-[3-(1,3-dihydro-1-oxoisobenzofuran- 13 491 5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]butyl]-piperazine-1-carbothioate 743 S-Ethyl 4-[4-[3-(1,3-dihydro-1-oxoisobenzofuran- 13 505 5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]butyl]piperazine-1-carbothioate

TABLE 31 Compounds of General Formula I According to the Invention, in which V = Isobenzofuranone, W = Thiohydantoin, n = 5 Synthesis Analogous ESI- Example Name to Example MS 744 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 4 501 dimethyl-1-[5-[4-(2-methyl-1-oxopropyl)piperazin- 1-yl]pentyl]-2-thioxoimidazolidin-4-one 745 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 4 555 dimethyl-1-[5-[4-[(thien-2-yl)acetyl]piperazin-1- yl]pentyl]-2-thioxo-imidazolidin-4-one 746 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 4 541 dimethyl-1-[5-[4-[(thien-2-yl)carbonyl]piperazin-1- yl]pentyl]-2-thioxo-imidazolidin-4-one 747 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[5-[4- 5 523 ethyl-sulfonyl)piperazin-1-yl]pentyl]-5,5-dimethyl- 2-thioxo-imidazolidin-4-one 748 4-[[4-[5-[3-(1,3-Dihydro-1-oxoisobenzofuran-5- 5 596 yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]pentyl]piperazin-1-yl]sulfonyl]benzonitrile 749 S-Ethyl 4-[5-[3-(1,3-dihydro-1-oxoisobenzofuran- 13 519 5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]pentyl]piperazine-1-carbothioate

TABLE 32 Compounds of General Formula I According to the Invention, in which V = Isobenzofuranone, W = Thiohydantoin, n = 6 Synthesis Analogous ESI- Example Name to Example MS 750 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[6-[4- 4 579 (2-methoxybenzoyl)piperazin-1-yl]hexyl]-5,5 dimethyl-2-thioxoimidazolidin-4-one 751 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[6-[4- 4 592 [4-(dimethylamino)benzoyl]piperazin-1-yl]hexyl]- 5,5-dimethyl-2-thioxoimidazolidin-4-one 752 3-[[4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5- 4 574 yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]hexyl]piperazin-1-yl]carbonyl]benzonitrile 753 1-[6-(4-Acetylpiperazin-1-yl)hexyl]-3-(1,3- 4 487 dihydro-1-oxo-isobenzofuran-5-yl)-5,5-dimethyl-2- thioxoimidazolidin-4-one 754 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 4 501 dimethyl-1-[6-[4-(1-oxopropyl)piperazin-1- yl]hexyl]-2-thioxoimidazolidin-4-one 755 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 4 515 dimethyl-1-[6-[4-(2-methyl-1-oxopropyl)- piperazin-1-yl]hexyl]-2-thioxoimidazolidin-4-one 756 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 4 515 dimethyl-1-[6-[4-(1-oxobutyl)piperazin-1- yl]hexyl]-2-thioxo-imidazolidin-4-one 757 1-[6-[4-(Cyclopropylcarbonyl)piperazin-1- 4 513 yl]hexyl]-3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)- 5,5-dimethyl-2-thioxoimidazolidin-4-one 758 1-[6-[4-(Cyclobutylcarbonyl)piperazin-1-yl]hexyl]- 4 527 3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5- dimethyl-2-thioxo-imidazolidin-4-one 759 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 4 550 dimethyl-1-[6-[4-[(pyridin-4-yl)carbonyl]piperazin- 1-yl]hexyl]-2-thioxo-imidazolidin-4-one 760 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 4 555 dimethyl-1-[6-[4-[(thien-2-yl)carbonyl]piperazin-1- yl]hexyl]-2-thioxo-imidazolidin-4-one 761 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 4 569 dimethyl-1-[6-[4-[(thien-2-yl)acetyl]piperazin-1- yl]hexyl]-2-thioxo-imidazolidin-4-one 762 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 5 523 dimethyl-1-[6-[4-(methylsulfonyl)piperazin-1- yl]hexyl]-2-thioxo-imidazolidin-4-one 763 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[6-[4- 5 537 (ethylsulfonyl)piperazin-1-yl]hexyl]-5,5-dimethyl- 2-thioxo-imidazolidin-4-one 764 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 5 551 dimethyl-1-[6-[4-(propylsulfonyl)piperazin-1- yl]hexyl]-2-thioxo-imidazolidin-4-one 765 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 5 585 dimethyl-1-[6-[4-(phenylsulfonyl)piperazin-1- yl]hexyl]-2-thioxo-imidazolidin-4-one 766 4-[[4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5- 5 610 yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]hexyl]piperazin-1-yl]sulfonyl]benzonitrile 767 1-[6-[4-[(2,1,3-Benzothiadiazol-4-yl)sulfonyl]- 5 643 piperazin-1-yl]hexyl]-3-(1,3-dihydro-1- oxoisobenzofuran-5-yl)-5,5-dimethyl-2- thioxoimidazolidin-4-one 768 4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 6 610 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]hexyl]-N-[3-(methylsulfonyl)phenyl]piperazine- 1-carboxylic acid amide 769 4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 6 582 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]hexyl)-N-(3-fluorophenyl)piperazine-1- carboxylic acid amide 770 4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 6 582 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]hexyl]-N-(4-fluorophenyl)piperazine-1- carboxylic acid amide 771 4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 532 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]hexyl]-N-ethyl-piperazine-1-carbothioamide 772 4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 546 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]hexyl]-N-propyl-piperazine-1-carbothioamide 773 4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 544 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]hexyl]-N-(prop-2-enyl)piperazine-1 carbothioamide 774 4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 580 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]hexyl]-N-phenyl-piperazine-1-carbothioamide 775 4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 594 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]hexyl]-N-(phenylmethyl)piperazine-1- carbothioamide 776 S-Methyl 4-[6-[3-(1,3-dihydro-1-oxoisobenzofuran- 13 519 5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]hexyl]-piperazine-1-carbothioate 777 S-Ethyl 4-[6-[3-(1,3-dihydro-1-oxoisobenzofuran- 13 533 5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]hexyl]piperazine-1-carbothioate 778 4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 14 544 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]hexyl]-N,N-diethylpiperazine-1-carboxylic acid amide

TABLE 33 Compounds of General Formula I According to the Invention, in which V = Isobenzofuranone, W = Thiohydantoin, n = 7 Synthesis Analogous ESI- Example Name to Example MS 779 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[7-[4- 4 593 (2-methoxybenzoyl)piperazin-1-yl]heptyl]-5,5- dimethyl-2-thioxoimidazolidin-4-one 780 1-[7-(4-Acetylpiperazin-1-yl)heptyl]-3-(1,3 4 501 dihydro-1-oxo-isobenzofuran-5-yl)-5,5-dimethyl-2- thioxoimidazolidin-4-one 781 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 4 515 dimethyl-1-[7-[4-(1-oxopropyl)piperazin-1- yl]heptyl]-2-thioxo-imidazolidin-4-one 782 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 4 529 dimethyl-1-[7-[4-(2-methyl-1-oxopropyl)piperazin- 1-yl]heptyl]-2-thioxoimidazolidin-4-one 783 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 4 529 dimethyl-1-[7-[4-(1-oxobutyl)piperazin-1- yl]heptyl]-2-thioxo-imidazolidin-4-one 784 1-[7-[4-(Cyclopropylcarbonyl)piperazin-1- 4 527 yl]heptyl]-3-(1,3-dihydro-1-oxoisobenzofuran-5- yl)-5,5-dimethyl-2-thioxo-imidazolidin-4-one 785 1-(7-[4-(Cyclobutylcarbonyl)piperazin-1- 4 541 yl]heptyl]-3-(1,3-dihydro-1-oxoisobenzofuran-5- yl)-5,5-dimethyl-2-thioxo-imidazolidin-4-one 786 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 4 569 dimethyl-1-[7-[4-[(thien-2-yl)carbonyl]piperazin-1- yl]heptyl]-2-thioxo-imidazolidin-4-one 787 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 4 583 dimethyl-1-[7-[4-[(thien-2-yl)acetyl]piperazin-1- yl]heptyl]-2-thioxo-imidazolidin-4-one 788 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 5 537 dimethyl-1-[7-[4-(methylsulfonyl)piperazin-1- yl]heptyl]-2-thioxo-imidazolidin-4-one 789 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[7-[4- 5 551 (ethyl-sulfonyl)piperazin-1-yl]heptyl]-5,5- dimethyl-2-thioxo-imidazolidin-4-one 790 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 5 565 dimethyl-1-[7-[4-(propylsulfonyl)piperazin-1- yl]heptyl]-2-thioxo-imidazolidin-4-one 791 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 5 599 dimethyl-1-[7-[4-(phenylsulfonyl)piperazin-1- yl]heptyl]-2-thioxo-imidazolidin-4-one 792 4-[7-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 546 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]heptyl]-N-ethyl-piperazine-1-carbothioamide 793 4-[7-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 560 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]heptyl]-N-propyl-piperazine-1-carbothioamide 794 4-[7-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 558 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]heptyl]-N-prop-2-enyl)piperazine-1- carbothioamide 795 S-Methyl 4-[7-[3-(1,3-dihydro-1-oxoisobenzofuran- 13 533 5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]heptyl]-piperazine-1-carbothioate 796 S-Ethyl 4-[7-[3-(1,3-dihydro-1-oxoisobenzofuran- 13 547 5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]heptyl]piperazine-1-carbothioate

TABLE 34 Compounds of General Formula I According to the Invention, in which V = Isobenzofuranone, W = Thiohydantoin, n = 8 Synthesis Analogous ESI- Example Name to Example MS 797 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[8-[4- 4 607 (2-methoxybenzoyl)piperazin-1-yl]octyl]-5,5- dimethyl-2-thioxoimidazolidin-4-one 798 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[8-[4- 4 620 [4-(dimethylamino)benzoyl]piperazin-1-yl]octyl]- 5,5-dimethyl-2-thioxoimidazolidin-4-one 799 1-[8-(4-Acetylpiperazin-1-yl)octyl]-3-(1,3-dihydro- 4 515 1-oxo-isobenzofuran-5-yl)-5,5-dimethyl-2- thioxoimidazolidin-4-one 800 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 4 529 dimethyl-1-[8-[4-(1-oxopropyl)piperazin-1- yl]octyl]-2-thioxo-imidazolidin-4-one 801 1-[8-[4-(Cyclopropylcarbonyl)piperazin-1- 4 541 yl]octyl]-3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)- 5,5-dimethyl-2-thioxo-imidazolidin-4-one 802 1-[8-[4-(Cyclobutylcarbonyl)piperazin-1-yl]octyl]- 4 555 3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5- dimethyl-2-thioxo-imidazolidin-4-one 803 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 4 583 dimethyl-1-[8-[4-[(thien-2-yl)carbonyl]piperazin-1- yl]octyl]-2-thioxo-imidazolidin-4-one 804 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 4 597 dimethyl-1-[8-[4-[(thien-2-yl)acetyl]piperazin-1- yl]octyl]-2-thioxo-imidazolidin-4-one 805 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 4 578 dimethyl-1-[8-[4-[(pyridin-4-yl)carbonyl]piperazin- 1-yl]octyl]-2-thioxo-imidazolidin-4-one 806 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 5 551 dimethyl-1-[8-[4-(methylsulfonyl)piperazin-1- yl]octyl]-2-thioxo-imidazolidin-4-one 807 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[8-[4- 5 565 (ethylsulfonyl)piperazin-1-yl]octyl]-5,5-dimethyl- 2-thioxo-imidazolidin-4-one 808 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 5 579 dimethyl-1-[8-[4-(propylsulfonyl)piperazin-1- yl]octyl]-2-thioxo-imidazolidin-4-one 809 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 5 619 dimethyl-2-thioxo-1-[8-[4-[(2,2,2-trifluoroethyl)- sulfonyl]piperazin-1-yl]-octyl]imidazolidin-4-one 810 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5- 5 613 dimethyl-1-[8-[4-(phenylsulfonyl)piperazin-1- yl]octyl]-2-thioxo-imidazolidin-4-one 811 4-[8-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 6 638 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]octyl]-N-[3-(methylsulfanyl)phenyl]piperazine- 1-carboxylic acid amide 812 4-[8-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 6 610 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]octyl]-N-(3-fluorophenyl)piperazine-1- carboxylic acid amide 813 4-[8-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 560 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]octyl)-N-ethylpiperazine-1-carbothioamide 814 4-[8-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 574 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]octyl]-N-propylpiperazine-1-carbothioamide 815 4-[8-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 572 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]octyl]-N-(prop-2-enyl)piperazine-1- carbothioamide 816 4-[8-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 12 622 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]octyl]-N-(phenylmethyl)piperazine-1- carbothioamide 817 4-[8-[3-(1,3-Dihydro-1-oxoisoberzofuran-5-yl)- 12 608 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]octyl]-N-(phenyl-piperazine-1-carbothioamide 818 S-Methyl 4-[8-[3-(1,3-dihydro-1-oxoisobenzofuran- 13 547 5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]octyl]-piperazine-1-carbothioate 819 S-Ethyl 4-[8-[3-(1,3-dihydro-1-oxoisobenzofuran- 13 561 5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]octyl]piperazine-1-carbothioate 820 4-[8-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)- 14 572 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]octyl]-N,N-diethylpiperazine-1-carboxylic acid amide

TABLE 35 Compounds of General Formula I According to the Invention, in which V = Methylbenzoxazinone, W = Thiohydantoin, n = 5 Synthesis Analogous ESI- Example Name to Example MS 821 6-[4,4-Dimethyl-5-oxo-3-[5-[4-(methylsulfonyl)- 5 536 piperazin-1-yl]pentyl]-2-thioxoimidazolidin-1-yl]- 4-methyl-1H-2,3-benzoxazin-1-one

TABLE 36 Compounds of General Formula I According to the Invention, in which V = Methylbenzoxazinone, W = Thiohydantoin, n = 6 Synthesis Analogous ESI- Example Name to Example MS 822 6-[4,4-Dimethyl-5-oxo-3-[6-[4-(methylsulfonyl)- 5 550 piperazin-1-yl]hexyl]-2-thioxoimidazolidin-1-yl]-4- methyl-1H-2,3-benzoxazin-1-one

TABLE 37 Compounds of General Formula I According to the Invention, in which V = Indanone, W = Thiohydantoin, n = 6 Synthesis Analogous ESI- Example Name to Example MS 823 1-[6-(4-Acetylpiperazin-1-yl)hexyl]-3-(2,3- 4 485 dihydro-1-oxo-1H-inden-5-yl)-5,5-dimethyl-2- thioxoimidazolidin-4-one 824 3-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-5,5- 4 513 dimethyl-1-[6-[4-(2-methyl-1-oxopropyl)piperazin- 1-yl]hexyl]-2-thioxoimidazolidin-4-one 825 3-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-5,5- 4 553 dimethyl-1-[6-[4-[(thien-2-yl)carbonyl]piperazin-1- yl]hexyl]-2-thioxoimidazolidin-4-one 826 3-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-5,5- 4 548 dimethyl-1-[6-[4-[(pyridin-4-yl)carbonyl]piperazin- 1-yl]hexyl]-2-thioxoimidazolidin-4-one 827 3-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-5,5- 5 521 dimethyl-1-[6-[4-(methylsulfonyl)piperazin-1- yl]hexyl]-2-thioxoimidazolidin-4-one 828 3-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-5,5- 5 549 dimethyl-1-[6-[4-(propylsulfonyl)piperazin-1- yl]hexyl]-2-thioxoimidazolidin-4-one 829 4-[6-[3-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-5,5- 12 530 dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]- N-ethylpiperazine-1-carbothioamide 830 S-Methyl 4-[6-[3-(2,3-dihydro-1-oxo-1H-inden-5- 13 517 yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1- yl]hexyl]piperazine-1-carbothioate

The entries disclosures of all applications, patents and publications, cited herein and of corresponding Germany Application No. 101 59 035.0, filed Nov. 23, 2001, and Germany Application No. 102 38 742.7 of Aug. 19, 2002, and U.S. Provisional Application Serial No. 406,650, filed Aug. 29, 2002 and U.S. Provisional Application No. 60/383,785, filed May 30, 2002 are incorporated by references herein.

The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. 

1. A compound of formula I, in which

V stands for a substituted, aromatic radical of formula II,

in which A stands for an acetyl group, an acetylamino group, a cyano group, a nitro group, a trifluoromethyl group, or a halogen, B stands for a hydrogen atom, a halogen or a trifluoromethyl group, or A and B together stand for a cyclic group of formula III or IV that is bonded to the aromatic ring, whereby E stands for a methylene group or an oxygen atom,

W stands for a group of formula V,

in which T is carbon or nitrogen, if T is carbon, a double bond is present between Q and T, and Q means a group ═C(CH₃)— and U means oxygen, and n is one of the integral values 1, 2, 3, 4, 5, 6, 7, or 8, or if T is nitrogen, a single bond is present between Q and T, and Q means a group —(CH₃)₂— and U means sulfur, and n is one of the integral values 2, 3, 4, 5, 6, 7, or 8, i and j, independently of one another, stand for the values 1 and 2, whereby i+j is 2 or 3, R and R′, independently of one another, are a hydrogen atom or a methyl group, Y stands for a bond between the heterocyclic nitrogen and Z, for a carbonyl group —C(O)—, for a sulfonyl group —S(O)₂—, for an iminocarbonyl group —C(O)N(Z′)—, for an iminosulfonyl group —S(O)₂N(Z′)—, for an imino(thioxomethyl) group —C(S)N(Z′)—, for an oxycarbonylimino(thioxomethyl) group —C(S)N(Z′)C(O)O—, for an oxycarbonyl group —C(O)O—, or for a sulfanylcarbonyl group —C(O)S—, and Z and Z′, independently of one another, stand for a hydrogen atom, a branched or unbranched C₁-C₈-alkyl group, a C₃-C₆-cycloalkyl group that is optionally substituted with a phenyl radical, a (C₃-C₆-cycloalkyl)-C₁-C₄-alkylene group, a branched or unbranched C₂-C₅-alkenyl group, a C₃-C₅-alkynyl group, a C₁-C₄-alkoxy group, a cyano group, a phenylsulfanyl group, a hydroxy-C₁-C₄-alkylene group, a (2-methoxyethoxy)methyl group, a [2-(2-methoxyethoxy)ethoxy]methyl group, a 2-(2-methoxyethoxy)ethyl group, a 2-[2-(2-methoxyethoxy)ethoxy]ethyl group, a C₁-C₄-alkoxy-C₁-C₄-alkylene group, a C₁-C₄-alkoxycarbonyl-C₁-C₄-alkylene group, an adamantyl group, a trichloroacetyl group; an aryl, heteroaryl, heterocyclyl, aryl-C₁-C₄-alkylene, heteroaryl-C₁-C₄-alkylene, aryloxy-C₁-C₄-alkylene, heteroaryloxy-C₁-C₄-alkylene, or aryl-C₁-C₄-alkylenoxy-C₁-C₄-alkylene group that is unsubstituted or that is substituted with up to three branched or unbranched C₁-C₄-alkyl, C₂-C₆-alkenyl, C₃-C₆-cycloalkyl, phenyl, cyano, halogen, methoxy, ethoxy, phenoxy, benzyloxy, methylsulfanyl, ethylsulfanyl, benzylsulfanyl, phenylsulfanyl, dimethylamino, acetylamino, trifluoromethyl, trifluoromethoxy, trifluoromethylsulfanyl, acetyl, (1-iminoethyl) or nitro groups, or a radical of formula C_(p)F_(q)H_(r) with p=1, 2, 3, 4, q>1 and q+r=2p+1, or a pharmacologically compatible salt thereof.
 2. A compound of formula I according to claim 1, wherein i=j=1.
 3. A compound of formula I according to claim 1, wherein R and R′ mean H.
 4. A compound of formula I according to claim 1, wherein T=carbon.
 5. A compound of formula I according to claim 1, wherein T=nitrogen.
 6. A compound of formula I according to claim 4, wherein i=j=1, n=1, 2, 3, 4, 5, 6, 7 or 8, R and R′ are hydrogen, A stands for an acetyl group, an acetylamino group, a cyano group, a nitro group, a trifluoromethyl group or a halogen, and B stands for a hydrogen atom, a halogen or a trifluoromethyl group, or A and B together stand for a cyclic group of formula III or IV that is bonded to the aromatic ring, whereby E stands for a methylene group or an oxygen atom


7. A compound of formula I according to claim 5, wherein i=j=1, n=2, 3, 4, 5, 6, 7 or 8, R and R′ are hydrogen, A stands for an acetyl group, an acetylamino group, a cyano group, a nitro group, a trifluoromethyl group or a halogen, and B stands for a hydrogen atom, a halogen or a trifluoromethyl group, or A and B together stand for a cyclic group of formula III or IV that is bonded to the aromatic ring, whereby E stands for a methylene group or an oxygen atom


8. A compound according to claim 1, selected from the group consisting of: 1,1-Dimethylethyl 4-[5-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]piperazine-1-carboxylate; 4-[2,5-Dihydro-3-methyl-4-[5-[4-[2-(methylsulfanyl)phenyl]piperazin-1-yl]pentyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(4-Cyanobenzoyl)piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[(3-Fluorophenyl)sulfonyl]piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-[4-(dimethylamino)phenyl]piperazine-1-carboxamide; 4-[2,5-Dihydro-3-methyl-4-[3-[4-(1-methylethylsulfonyl)piperazin-1-yl]propyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[[4-(1-methylethylsulfonyl)piperazin-1-yl]methyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[7-[4-(1-methylethylsulfonyl)piperazin-1-yl]heptyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 1,1-Dimethylethyl 4-[5-[3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]piperazine-1-carboxylate; 4-[5-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]-N-ethylpiperazine-1-carbothioamide; S-Methyl 4-[5-[3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]piperazine-1-carbothioate; 4-[5-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]-N,N-diethylpiperazine-1-carboxamide; 4-[3-[2-[4-(2-Methoxybenzoyl)piperazin-1-yl]ethyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[(4-Acetylpiperazin-1-yl)methyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[[4-(methoxyacetyl)piperazin-1-yl]methyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[4-[[(2-methoxyethoxy)acetyl]piperazin-1-yl]methyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[[4-[[2-(2-methoxyethoxy)ethoxy]acetyl]piperazin-1-yl]methyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[[4-(2-methoxybenzoyl)piperazin-1-yl]methyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[[4-(methylsulfonyl)piperazin-1-yl]methyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[[4-(Ethylsulfonyl)piperazin-1-yl]methyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[[4-(2-methoxyethyl)sulfonyl]-piperazin-1-yl]methyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[[4-[[2-[2-(2-methoxyethoxy)ethoxy]ethyl]sulfonyl]piperazin-1-yl]methyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[[4-(phenylsulfonyl)piperazin-1-yl]methyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[2-(4-Acetylpiperazin-1-yl)ethyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[2-(4-(1-oxopropyl)piperazin-1-yl)ethyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[2-[4-(Cyclopropylcarbonyl)piperazin-1-yl]ethyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[2-[4-(methoxyacetyl)piperazin-1-yl]ethyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[2-[4-(3-methoxy-1-oxopropyl)piperazin-1-yl]ethyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[2-[4-[(2-methoxyethoxy)acetyl]piperazin-1-yl]ethyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[2-[4-[[2-(2-methoxyethoxy)ethoxy]acetyl]piperazin-1-yl]ethyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[2-[4-(2-methoxybenzoyl)piperazin-1-yl]ethyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[2-[4-(methylsulfonyl)piperazin-1-yl]ethyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[2-[4-(Ethylsulfonyl)piperazin-1-yl]ethyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[2-[4-(Cyclopropylsulfonyl)piperazin-1-yl]ethyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[2-[4-(2-methoxyethyl)sulfonyl]piperazin-1-yl]ethyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[2-[4-[[2-(2-methoxyethoxy)ethyl]sulfonyl]piperazin-1-yl]ethyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[2-[4-[[2-[2-(2-methoxyethoxy)ethoxy]ethyl]sulfonyl]-piperazin-1-yl]ethyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[2-[4-(phenylsulfonyl)piperazin-1-yl]ethyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[2-[4-[(phenylmethyl)sulfonyl]piperazin-1-yl]ethyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[2-[4-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperazin-1-yl]ethyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]ethyl]-N-(1-methylethyl)piperazine-1-carboxamide; 4-[2-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]ethyl]-N-ethylpiperazine-1-carbothioamide; Methyl 4-[2-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]ethyl]piperazine-1-carboxylate; S-Methyl 4-[2-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]ethyl]piperazine-1-carbothioate; 4-[2-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]ethyl]-N,N-dimethylpiperazine-1-sulfonamide; 4-[3-[3-(4-Acetylpiperazin-1-yl)propyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[3-(4-(1-oxopropyl)piperazin-1-yl)propyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[3-[4-(Cyclopropylcarbonyl)piperazin-1-yl]propyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[3-[4-(methoxyacetyl)piperazin-1-yl]propyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[3-[4-(3-methoxy-1-oxopropyl)piperazin-1-yl]propyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[3-[4-[(2-methoxyethoxy)acetyl]piperazin-1-yl]propyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[3-[4-[[2-(2-methoxyethoxy)ethoxy]acetyl]piperazin-1-yl]propyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[3-[4-(2-methoxybenzoyl)piperazin-1-yl]propyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[3-[4-(methylsulfonyl)piperazin-1-yl]propyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[3-[4-(Ethylsulfonyl)piperazin-1-yl]propyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[3-[4-(Cyclopropylsulfonyl)piperazin-1-yl]propyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[3-[4-(2-methoxyethyl)sulfonyl]piperazin-1-yl]propyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[3-[4-[[2-(2-methoxyethoxy)ethyl]sulfonyl]piperazin-1-yl]propyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[3-[4-[[2-[2-(2-methoxyethoxy)ethoxy]ethyl]-sulfonyl]piperazin-1-yl]propyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[3-[4-(phenyl-sulfonyl)piperazin-1-yl]propyl-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[3-[4-[(phenylmethyl)sulfonyl]piperazin-1-yl]propyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[3-[4-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-piperazin-1-yl]propyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]propyl]-N-(1-methylethyl)-piperazine-1-carboxamide; 4-[3-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]propyl]-N-ethylpiperazine-1-carbothioamide; Methyl 4-[3-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]propyl]piperazine-1-carboxylate; S-Methyl 4-[3-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]propyl]piperazine-1-carbothioate; 4-[3-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]propyl]-N,N-dimethylpiperazine-1-sulfonamide; 1,1-Dimethylethyl-4-[4-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]piperazine-1-carboxylate; 4-[2,5-Dihydro-3-methyl-4-[4-[4-[2-(methylsulfanyl)phenyl]piperazin-1-yl]butyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(3,5-Dichloropyridin-4-yl)piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(Cyclopentylacetyl)piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(2,6-Difluorobenzoyl)piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(2,6-Dichlorobenzoyl)piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-(4-(3-Fluorobenzoyl)piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[4-[4-(3-methoxybenzoyl)piperazin-1-yl]butyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[4-[4-[4-(3-methylbenzoyl)piperazin-1-yl]butyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(4-Fluorobenzoyl)piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl[4-[4-[(naphthalen-1-yl)carbonyl]piperazin-1-yl]butyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[4-[4-[(naphthalen-2-yl)-carbonyl]piperazin-1-yl]butyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(3-Cyanobenzoyl)piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(Cyclohexylcarbonyl)piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-[(Furan-2-yl)carbonyl]piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(Cyclopentylcarbonyl)piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[4-[4-[(5-methylisoxazol-3-yl)carbonyl]piperazin-1-yl]butyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[4-[4-(phenylacetyl)piperazin-1-yl]butyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[4-[4-(2-methoxybenzoyl)piperazin-1-yl]butyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[4-[4-(methoxyacetyl)piperazin-1-yl]butyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(2-Chlorobenzoyl)piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(2-Fluorobenzoyl)piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-(4-Benzoylpiperazin-1-yl)butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(Cyclobutylcarbonyl)piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[4-[4-[(pyridin-3-yl)carbonyl]piperazin-1-yl]butyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[4-[4-[(pyridin-4-yl)carbonyl]piperazin-1-yl]butyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-[4-(Dimethylamino)benzoyl]piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[4-[4-[(phenylsulfanyl)acetyl]piperazin-1-yl]butyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[4-[4-(phenoxyacetyl)piperazin-1-yl]butyl]-1H-pyrrol-1-yl)-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[4-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]butyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[4-[4-(3-phenyl-1-oxopropyl)piperazin-1-yl]butyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-[(1,3-Benzodioxol-5-yl)carbonyl]piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[4-[4-[(4-methoxyphenyl)acetyl]piperazin-1-yl]butyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[4-[4-(2-methylbenzoyl)piperazin-1-yl]butyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(4-Chlorobenzoyl)piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[4-[4-[(thien-2-yl)acetyl]piperazin-1-yl]butyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(3-Chlorobenzoyl)piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(4-Cyanobenzoyl)piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[4-[4-(3-methoxy-1-oxopropyl)piperazin-1-yl]butyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[4-[4-[(2-methoxyethoxy)acetyl]piperazin-1-yl]butyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[4-[4-[[2-(2-methoxyethoxy)ethoxy]acetyl]piperazin-1-yl]butyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4-[4-[4-(Cyclopropylsulfonyl)piperazin-1-yl]butyl]-2,5-dihydro-3-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[4-[4-(2-methoxyethyl)sulfonyl]piperazin-1-yl]butyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[4-[4-[[2-(2-methoxyethoxy)ethyl]sulfonyl]piperazin-1-yl]butyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[4-[4-[[2-[2-(2-methoxyethoxy)ethoxy]-ethyl]sulfonyl]piperazin-1-yl]butyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]-N,N-dimethylpiperazine-1-sulfonamide; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[4-[4-(phenylsulfonyl)piperazin-1-yl]butyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[4-[4-(methylsulfonyl)piperazin-1-yl]butyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[4-[4-[(4-methylphenyl)sulfonyl]piperazin-1-yl]butyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; N-[4-[[4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]piperazin-1-y]sulfonyl]phenyl]acetamide; 4-[3-[4-[4-[(4-Chlorophenyl)sulfonyl]piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-[(4-Cyanophenyl)sulfonyl]piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[4-[4-[(naphthalen-2-yl)sulfonyl]piperazin-1-yl]butyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-[(Quinolin-8-yl)sulfonyl]piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-[(2-Cyanophenyl)sulfonyl]piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-(3-[4-[4-[(3-Cyanophenyl)sulfonyl]piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-[(3,5-Dimethylisoxazol-4-yl)sulfonyl]piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-[(5-Chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[4-[4-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-piperazin-1-yl]butyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(Butylsulfonyl)piperazin-1-yl]butyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]-N-phenylpiperazine-1-carboxamide; 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]-N-(naphthalen-1-yl)piperazine-1-carboxamide; 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]-N-naphthalen-2-yl)piperazine-1-carboxamide; N-(2-Chlorophenyl)-4-[4-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]piperazine-1-carboxamide; 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]-N-[2-(trifluoromethyl)phenyl]piperazine-1-carboxamide; 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]-N-(3-methoxyphenyl)piperazine-1-carboxamide; N-(4-Chlorophenyl)-4-[4-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]piperazine-1-carboxamide; 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]-N-(4-phenoxyphenyl)piperazine-1-carboxamide; 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]-N-[4-(methylsulfanyl)phenyl]piperazine-1-carboxamide; N-[(1,1′-Biphenyl]-2-yl)-4-[4-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]piperazine-1-carboxamide; 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]-N-(2,5-dimethoxyphenyl)piperazine-1-carboxamide; 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]-N-[2-(1-methylethyl)phenyl]piperazine-1-carboxamide; 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]-N-(2,4,6-trimethylphenyl)piperazine-1-carboxamide; (R)-4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]-N-(1-phenylethyl)piperazine-1-carboxamide; 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]-N-[2-(1,1-dimethylethyl)phenyl]piperazine-1-carboxamide; 4-[4-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]-N-hexylpiperazine-1-carboxamide; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4-(pyrazin-2-yl)piperazin-1-yl]pentyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(2,4-Difluorophenyl)piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[(Furan-2-yl)carbonyl]piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[5-[4-[(5-methylisoxazol-3-yl)carbonyl]piperazin-1-yl]pentyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4-(phenylacetyl)piperazin-1-yl]pentyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[5-[4-(4-methoxybenzoyl)piperazin-1-yl]pentyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[5-[4-(2-methoxybenzoyl)piperazin-1-yl]pentyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[5-[4-(methoxyacetyl)piperazin-1-yl]pentyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(2-Chlorobenzoyl)piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(2-Fluorobenzoyl)piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-(4-Benzoylpiperazin-1-yl)pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(Cyclobutylcarbonyl)piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(3,4-Dimethoxybenzoyl)piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4-[(pyridin-3-yl)carbonyl]piperazin-1-yl]pentyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(Cyclopropylcarbonyl)piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4-[(pyridin-4-yl)carbonyl]piperazin-1-yl]pentyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[4-(Dimethylamino)benzoyl]piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4-[(phenylsulfanyl)acetyl]piperazin-1-yl]pentyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4-(phenoxyacetyl)piperazin-1-yl]pentyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]pentyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4-(3-phenyl-1-oxopropyl)piperazin-1-yl]pentyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[(1,3-Benzodioxol-5-yl)carbonyl]piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[5-[4-[(4-methoxyphenyl)acetyl]piperazin-1-yl]pentyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[5-[4-(2-methylbenzoyl)piperazin-1-yl]pentyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4-[(thien-2-yl)acetyl]piperazin-1-yl]pentyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[(4-Chlorophenoxy)acetyl]piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(3-Cyclopentyl-1-oxopropyl)piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(3-Chlorobenzoyl)piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(3,3-Dimethyl-1-oxobutyl)piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[5-[4-(3-methyl-1-oxobutyl)piperazin-1-yl]pentyl]-2,5-dioxo-1H-pyrrol-1-yl)-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-4-methyl-2,5-dioxo-3-[5-[4-[(phenylmethoxy)acetyl]piperazin-1-yl]pentyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(Cyclopentylacetyl)piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(2,6-Difluorobenzoyl)piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(2,6-Dichlorobenzoyl)piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pentyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(3-Fluorobenzoyl)piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4-[3-(trifloromethyl)benzoyl]piperazin-1-yl]pentyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[5-[4-(4-methylbenzoyl)piperazin-1-yl]pentyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[5-[4-[(naphthalen-1-yl)carbonyl]piperazin-1-yl]pentyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[5-[4-[(naphthalen-2-yl)carbonyl]piperazin-1-yl]pentyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(3-Cyanobenzoyl)piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(Cyclohexylcarbonyl)piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-(4-Acetylpiperazin-1-yl)pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[5-[4-(3-methoxy-1-oxopropyl)piperazin-1-yl]pentyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[5-[4-[(2-methoxyethoxy)acetyl]piperazin-1-yl]pentyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[5-(4-[[2-(2-methoxyethoxy)ethoxy]acetyl]piperazin-1-yl]pentyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4-[5-[4-(Cyclopropylsulfonyl)piperazin-1-yl]pentyl]-2,5-dihydro-3-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[5-[4-(2-methoxyethyl)sulfonyl]piperazin-1-yl]pentyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[5-[4-[[2-(2-methoxyethoxy)ethyl]sulfonyl]piperazin-1-yl]pentyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[5-[4-[[2-[2-(2-methoxyethoxy)ethoxy]-ethyl]sulfonyl]piperazin-1-yl]pentyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N,N-dimethylpiperazine-1-sulfonamide; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4-[(1-methylethyl)sulfonyl]piperazin-1-yl]pentyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4-(phenylsulfonyl)piperazin-1-yl]pentyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[5-[4-(methylsulfonyl)piperazin-1-yl]pentyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[(4-Chlorophenyl)sulfonyl]piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[5-[4-[(phenylmethyl)sulfonyl]piperazin-1-yl]pentyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[(4-Cyanophenyl)sulfonyl]piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4-[5-[4-[(Quinolin-8-yl)sulfonyl]piperazin-1-yl]pentyl]-2,5-dihydro-3-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[(2-Fluorophenyl)sulfonyl]piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[(2,5-Dimethoxyphenyl)sulfonyl]piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[(3-Cyanophenyl)sulfonyl]piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[(2,1,3-Benzothiadiazol-4-yl)sulfonyl]piperazin-1-yl]pentyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-(1,1-dimethylethyl)piperazine-1-carboxamide; 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-(naphthalen-1-yl)piperazine-1-carboxamide; N-(4-Cyanophenyl)-4-[5-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]piperazine-1-carboxamide; N-(2-Chlorophenyl)-4-[5-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]piperazine-1-carboxamide; 4-[5-[1-[4Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-[2-(trifluoromethyl)phenyl]piperazine-1-carboxamide; 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-(2-methylphenyl)piperazine-1-carboxamide; 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-(3-methylphenyl)piperazine-1-carboxamide; 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-(4-fluorophenyl)piperazine-1-carboxamide; 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-(4-methoxyphenyl)piperazine-1-carboxamide; N-(3-Cyanophenyl)-4-[5-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]piperazine-1-carboxamide; 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-(3,5-dimethoxyphenyl)piperazine-1-carboxamide; 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-(2-phenylethyl)piperazine-1-carboxamide; N-([1,1′-Biphenyl]-2-yl)-4-[5-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]piperazine-1-carboxamide; 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-[2-(1-methylethyl)phenyl]piperazine-1-carboxamide; 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-(2,6-dichloropyridin-4-yl)piperazine-1-carboxamide; (R)-4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-(1-phenylethyl)piperazine-1-carboxamide; 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-[3-[(trifluoromethyl)sulfanyl]phenyl]piperazine-1-carboxamide; 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-[(3-methylphenyl)methyl]piperazine-1-carboxamide; 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-[(4-methoxyphenyl)methyl]piperazine-1-carboxamide; 4-[5-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-(1,1,3,3-tetramethylbutyl)piperazine-1-carboxamide; 1,1-Dimethylethyl 4-[6-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]piperazine-1-carboxylate; 4-[2,5-Dihydro-3-methyl-4-[6-(4-methylpiperazin-1-yl)hexyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; Ethyl 4-[6-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]piperazine-1-carboxylate; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-(pyridin-2-yl)piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; (Phenylmethyl) 4-[6-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]piperazine-1-carboxylate; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-(pyrimidin-2-yl)piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[6-[4-(2-methoxyphenyl)piperazin-1-yl]hexyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[6-[4-(2-nitrophenyl)piperazin-1-yl]hexyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-pyrazin-2-yl)piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[6-[4-[2-(methylsulfanyl)phenyl]piperazin-1-yl]hexyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[6-[4-(2-methoxyethyl)piperazin-1-yl]hexyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(3,5-Dichloropyridin-4-yl)piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-(4-Acetylpiperazin-1-yl)hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-[(Furan-2-yl)carbonyl]piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-[(tetrahydrofuran-2-yl)carbonyl]piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(Cyclopentylcarbonyl)piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[6-[4-[(5-methylisoxazol-3-yl)carbonyl]piperazin-1-yl]hexyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-(phenylacetyl)piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[6-[4-(4-methoxybenzoyl)piperazin-1-yl]hexyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[6-[4-(2-methoxybenzoyl)piperazin-1-yl]hexyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[6-[4-(methoxyacetyl)piperazin-1-yl]hexyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(2-Chlorobenzoyl)piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(2-Fluorobenzoyl)piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-(4-Benzoylpiperazin-1-yl)hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(Cyclobutylcarbonyl)piperazin-1-yl]hexyl]-2,5-dihydromethyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(3,4-Dimethoxybenzoyl)piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-[(phenylsulfanyl)acetyl]piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-(phenoxyacetyl)piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-(3-phenyl-1-oxopropyl)piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-[(1,3-Benzodioxol-5-yl)carbonyl]piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[6-[4-[(4-methoxyphenyl)acetyl]piperazin-1-yl]hexyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[6-[4-(2-methylbenzoyl)piperazin-1-yl]hexyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(4-Chlorobenzoyl)piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-[(thien-2-yl)acetyl]piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-[(4 Chlorophenoxy)acetyl]piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(3-Cyclopentyl-1-oxopropyl)piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(3-Chlorobenzoyl)piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-[4-trifluoromethyl)benzoyl]piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(4-cyanobenzoyl)piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(3,3-Dimethyl-1-oxobutyl)piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[6-[4-(3-methyl-1-oxobutyl)piperazin-1-yl]hexyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-[(phenylmethoxy)acetyl]piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(Cyclopentylacetyl)piperazin-1-yl]hexyl-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(2,6-Difluorobenzoyl)piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(2,6-Dichlorobenzoyl)piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(3-Fluorobenzoyl)piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[6-[4-(3-methoxybenzoyl)piperazin-1-yl]hexyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-[3-(trifuoromethyl)benzoyl]piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[6-[4-(3-methylbenzoyl)piperazin-1-yl]hexyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(4-Fluorobenzoyl)piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[6-[4-(4-methylbenzoyl)piperazin-1-yl]hexyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[6-[4-[(naphthalen-1-yl)carbonyl]piperazin-1-yl]hexyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[6-[4-[(naphthalen-2-yl)carbonyl]piperazin-1-yl]hexyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(3-Cyanobenzoyl)piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(Cyclohexylcarbonyl)piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[6-[4-(3-methoxy-1-oxopropyl)piperazin-1-yl]hexyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[6-[4-[(2-methoxyethoxy)acetyl]piperazin-1-yl]hexyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[6-[4-[[2-(2-methoxyethoxy)ethoxy]acetyl]piperazin-1-yl]hexyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4-[6-[4-(Cyclopropylsulfonyl)piperazin-1-yl]hexyl]-2,5-dihydro-3-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[6-[4-(2-methoxyethyl)sulfonyl]piperazin-1-yl]hexyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[6-[4-[[2-(2-methoxyethoxy)ethyl]sulfonyl]piperazin-1-yl]hexyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[6-[4-[[2-[2-(2-methoxyethoxy)ethoxy]ethyl]sulfonyl]-piperazin-1-yl]hexyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)-benzonitrile; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N,N-dimethylpiperazine-1-sulfonamide; 4-[3-[6-[4-[[4-(1,1-Dimethylethyl)phenoxy]acetyl]-piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-(phenylsulfonyl)piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[6-[4-(methylsulfonyl)piperazin-1-yl]hexyl]-2,5-dihydro-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[6-[4-[(4-methylphenyl)-sulfonylpiperazin-1-yl]hexyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; N-[4-[[4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]piperazin-1-yl]sulfonyl]phenyl]acetamide; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-[(phenylmethyl)sulfonyl]piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-[(4-Cyanophenyl)sulfonyl]piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl[6-[4-[(naphthalen-2-yl)sulfonyl]piperazin-1-yl]hexyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-[[5-(Dimethylamino)naphthalen-1-yl]sulfonyl]piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-[(thien-2-yl)sulfonyl]piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-[(Quinolin-8-yl)sulfonyl]piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-[(2-Fluorophenyl)sulfonyl]piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-[(2-Chlorophenyl)sulfonyl]piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-[(2-Cyanophenyl)sulfonyl]piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-[(3-Cyanophenyl)sulfonyl]piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[6-[4-[[5-[2-methyl-5-(trifluoromethyl)-2H-pyrazol-3-yl]thien-2-yl]sulfonyl]piperazin-1-yl]hexyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[6-[4-[[1,2,3,4-tetrahydro-2-(trifluoroacetyl)isoquinolin-7-yl]sulfonyl]piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-[(3,5-Dimethylisoxazol-4-yl)sulfonyl]piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-[(5-Chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[6-[4-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-piperazin-1-yl]hexyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[6-(1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(1,1-dimethylethyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-phenylpiperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(naphthalen-1-yl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(naphthalen-2-yl)piperazine-1-carboxamide; N-(4-Cyanophenyl)-4-[6-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(1-methylethyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[3-(trifluoromethyl)phenyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(2-fluorophenyl)piperazine-1-carboxamide; N-(2-Chlorophenyl)-4-[6-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(2-methoxyphenyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[2-(trifluoromethyl)phenyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(2-methylphenyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(3-fluorophenyl)piperazine-1-carboxamide; N-(3-Chlorophenyl)-4-[6-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-1-pyrrol-3-yl]hexyl]-N-(3-methoxyphenyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(3-methylphenyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(4-fluorophenyl)piperazine-1-carboxamide; N-(4-Chlorophenyl)-4-[6-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(4-methoxyphenyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[4-(trifluoromethyl)phenyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(4-methylphenyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(prop-2-enyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-cyclohexylpiperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(phenylmethyl)piperazine-1-carboxamide; N-(3-Cyanophenyl)-4-[6-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(3,5-dimethoxyphenyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[3-(methylsulfanyl)phenyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(4-phenoxyphenyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[4-(methylsulfanyl)phenyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[4-(1-methylethyl)phenyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(2-phenylethyl)piperazine-1-carboxamide; N-([1,1′-Biphenyl]-2-yl)-4-[6-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[4-(phenylmethoxy)phenyl]piperazine-1-carboxamide; N-(2-Cyanophenyl)-4-[6-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[2-(thien-2-yl)ethyl]piperazine-1-carboxamide; (1R-trans)-4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(2-phenylcyclopropyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(2,6-difluorophenyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(2,6-dichlorophenyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(2,4-dimethoxyphenyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(2,5-dimethoxyphenyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(2,6-dimethylphenyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(trichloroacetyl)piperazine-1-carboxamide; (S)-4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(1-phenylethyl)piperazine-1-carboxamide; (R)-4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[1-(naphthalen-1-yl)ethyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(2,4,6-trichlorophenyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[2-(1-methylethyl)phenyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(3,5-dichlorophenyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(2,4,6-trimethylphenyl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[4-[(trifluoromethyl)sulfanyl]phenyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[(2,4-dichlorophenyl)methyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl)-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[2-(methylsulfanyl)phenyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(2,6-dichloropyridin-4-yl)piperazine-1-carboxamide; (R)-4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(1-phenylethyl)piperazine-1-carboxamide; (S)-4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[1-(naphthalen-1-yl)ethyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[1-methyl-1-[3-(1-methylethenyl)phenyl]ethyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[2-(trifluoromethoxy)phenyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-tricyclo[3.3.1.1^(3,7)]dec-1-yl)piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl)hexyl]-N-[4-(dimethylamino)phenyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[3-[(trifluoromethyl)sulfanyl]phenyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[(2-methylphenyl)methyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[(3-methylphenyl)methyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[(4-methylphenyl)methyl]piperazine-1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[(4-methoxyphenyl)methyl]piperazine 1-carboxamide; 4-[6-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(1,1,3,3-tetramethylbutyl)piperazine-1-carboxamide; 4-[3-[7-(4-Acetylpiperazin-1-yl)heptyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[7-(4-(1-oxopropyl)piperazin-1-yl)heptyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[7-[4-(Cyclopropylcarbonyl)piperazin-1-yl)heptyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[7-[4-(methoxyacetyl)piperazin-1-yl]heptyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[7-[4-(3-methoxy-1-oxopropyl)piperazin-1-yl]heptyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[7-[4-[(2-methoxyethoxy)acetyl]piperazin-1-yl]heptyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[7-[4-[[2-(2-methoxyethoxy)ethoxy]acetyl]piperazin-1-yl]heptyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[7-[4-(2-methoxybenzoyl)piperazin-1-yl]heptyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[7-[4-(methylsulfonyl)piperazin-1-yl]heptyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[7-[4-(Ethylsulfonyl)piperazin-1-yl]heptyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[7-[4-(Cyclopropylsulfonyl)piperazin-1-yl]heptyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[7-[4-(2-methoxyethyl)sulfonyl]piperazin-1-yl]heptyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[7-(4-[[2-(2-methoxyethoxy)ethyl]sulfonyl]piperazin-1-yl]heptyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[7-[4-[(2-(2-(2-methoxyethoxy)ethoxy]ethyl]sulfonyl]-piperazin-1-yl]heptyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[7-[4-(phenylsulfonyl)piperazin-1-yl]heptyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[7-[4-[(phenylmethyl)sulfonyl]piperazin-1-yl]heptyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[7-[4-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-piperazin-1-yl]heptyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[7-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]heptyl]-N-(1-methylethyl)piperazine-1-carboxamide; 4-[7-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]heptyl]-N-ethylpiperazine-1-carbothioamide; Methyl 4-[7-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]heptyl]piperazine-1-carboxylate; S-Methyl 4-[7-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]heptyl]piperazine-1-carbothioate; 4-[7-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]heptyl]-N,N-dimethylpiperazine-1-sulfonamide; 4-[3-[8-(4-Acetylpiperazin-1-yl)octyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[8-(4-(1-oxopropyl)piperazin-1-yl)octyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[8-[4-(Cyclopropylcarbonyl)piperazin-1-yl]octyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[8-[4-(methoxyacetyl)piperazin-1-yl]octyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[8-[4-(3-methoxy-1-oxopropyl)piperazin-1-yl]octyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[8-[4-[(2-methoxyethoxy)acetyl]piperazin-1-yl]octyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[8-[4-[[2-(2-methoxyethoxy)ethoxy]acetyl]piperazin-1-yl]octyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[8-[4-(2-methoxybenzoyl)piperazin-1-yl]octyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[8-[4-(methylsulfonyl)piperazin-1-yl]octyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[8-[4-(Ethylsulfonyl)piperazin-1-yl]octyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[8-[4-(Cyclopropylsulfonyl)piperazin-1-yl]octyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[8-[4-(2-methoxyethyl)sulfonyl]piperazin-1-yl]octyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[8-[4-[[2-(2-methoxyethoxy)ethyl]sulfonyl]piperazin-1-yl]octyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-[8-[4-[[2-[2-(2-methoxyethoxy)ethoxy]-ethyl]sulfonyl]piperazin-1-yl]octyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[8-[4-(phenylsulfonyl)piperazin-1-yl]octyl-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-2,5-dioxo-4-[8-[4-[(phenylmethyl)sulfonyl]piperazin-1-yl]octyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2,5-Dihydro-3-methyl-4-[8-[4-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-piperazin-1-yl]octyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[8-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]octyl]-N-(1-methylethyl)piperazine-1-carboxamide; 4-[8-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]octyl]-N-ethylpiperazine-1-carbothioamide; Methyl 4-[8-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]octyl]piperazine-1-carboxylate; S-Methyl 4-[8-[1-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]octyl]piperazine-1-carbothioate; 4-[8-[1-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]octyl]-N,N-dimethylpiperazine-1-sulfonamide; N-[4-[2,5-Dihydro-3-[6-[4-(2-methoxybenzoyl)piperazin-1-yl]hexyl]-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)phenyl]acetamide; N-[4-[3-[6-[4-(Cyclobutylcarbonyl)piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)phenyl]acetamide; N-[4-[2,5-Dihydro-3-methyl-2,51dioxo[6-[4-[(thien-2-yl)-carbonyl]piperazin-1-yl]hexyl]-1H-pyrrol-1-yl]-2-(trifluoromethyl)phenyl]acetamide; N-[4-[3-[6-[4-[4-(Dimethylamino)benzoyl]piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)phenyl]acetamide; N-[4-[3-[6-(4-Acetylpiperazin-1-yl)hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)phenyl]acetamide; N-[4-[2,5-Dihydro-3-methyl[6-[4-(methylsulfonyl)piperazin-1-yl]hexyl]-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)phenyl]acetamide; N-[4-[3-[6-[4-[(2,1,3-Benzothiadiazol-4-yl)sulfonyl]piperazin-1-yl]hexyl]-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-1-yl]-2-(trifluoromethyl)phenyl]acetamide; 4-[6-[1-[4-(ACETYLAMINO)-3-(TRIFLUOROMETHYL)PHENYL]-2,5-DIHYDRO-4-METHYL-2,5-DIOXO-1H-PYRROL-3-YL]HEXYL]-N-(PYRIDIN-4-YL)PIPERAZINE-1-CARBOXAMIDE; 3-[6-[4-(Cyclobutylcarbonyl)piperazin-1-yl]hexyl]-4-methyl-1-[4-nitro-3-(trifluoromethyl)phenyl]-1H-pyrrole-2,5-dione; 3-[6-[4-[4-(Dimethylamino)benzoyl]piperazin-1-yl]hexyl]-4-methyl-1-[4-nitro-3-(trifluoromethyl)phenyl]-1H-pyrrole-2,5-dione; 3-[6-(4-Acetylpiperazin-1-yl)hexyl]-4-methyl-1-[4-nitro-3-(trifluoromethyl)-phenyl]-1H-pyrrole-2,5-dione; 3-Methyl-4-[6-[4-(methylsufonyl)piperazin-1-yl]hexyl]-1-[4-nitro-3-(trifluoromethyl)phenyl]-1H-pyrrole-2,5-dione; 3-[6-[4-[(2,1,3-Benzothiadiazol-4-yl)sulfonyl]piperazin-1-yl]hexyl]-4-methyl-1-[4-nitro-3-(trifluoromethyl)phenyl]-1H-pyrrole-2,5-dione; 1-[3,4-Bis(trifluoromethyl)phenyl]-3-[6-[4-(2-methoxybenzoyl)piperazin-1-yl]hexyl]-4-methyl-1H-pyrrole-2,5-dione; 3-[6-(4-Acetylpiperazin-1-yl)hexyl]-1-[3,4-bis(trifluoromethyl)phenyl]-4-methyl-1H-pyrrole-2,5-dione; 1-[3,4-Bis(trifluoromethyl)phenyl]-3-[6-[4-(cyclobutylcarbonyl)piperazin-1-yl]hexyl]-4-methyl-1H-pyrrole-2,5-dione; 1-[3,4-Bis(trifluoromethyl)phenyl]-3-methyl-4-[6-[4-[(thien-2-yl)carbonyl]-piperazin-1-yl]hexyl]-1H-pyrrole-2,5-dione; 1-[3,4-Bis(trifluoromethyl)phenyl]-3-[6-[4-[4-(dimethylamino)benzoyl]piperazin-1-yl]hexyl]-4-methyl-1H-pyrrole-2,5-dione; 1-[3,4-Bis(trifluoromethyl)phenyl]-3-methyl-4-[6-[4-(methylsulfonyl)piperazin-1-yl]hexyl]-1H-pyrrole-2,5-dione; 3-[6-[4-[(2,1,3-Benzothiadiazol-4-yl)sulfonyl]piperazin-1-yl]hexyl]-1-[3,4-bis(trifluoromethyl)phenyl]-4-methyl-1H-pyrrole-2,5-dione; -[3-Fluoro-4-(trifluoromethyl)phenyl]-3-[6-[4-(2-methoxybenzoyl)piperazin-1-yl]hexyl]-4-methyl-1H-pyrrole-2,5-dione; 3-[6-[4-(Cyclobutylcarbonyl)piperazin-1-yl]hexyl]-1-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1H-pyrrole-2,5-dione; 1-[3-Fluoro-4-(trifluoromethyl)phenyl]-3-methyl-4-[6-[4-(thien-2-yl)carbonyl]piperazin-1-yl]hexyl]-1H-pyrrole-2,5-dione; 3-[6-[4-[4-(Dimethylamino)benzoyl]piperazin-1-yl]hexyl-]-1-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1H-pyrrole-2,5-dione; 3-[6-[4-Acetylpiperazin-1-yl)hexyl]-1-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1H-pyrrole-2,5-dione; 1-[3-Fluoro-4-(trifluoromethyl)phenyl]-3-methyl-4-[6-[4-(methylsulfonyl)-piperazin-1-yl]hexyl]-1H-pyrrole-2,5-dione; 3-[6-[4-[(2,1,3-Benzothiadiazol-4-yl)sulfonyl]piperazin-1-yl]hexyl]-1-[3-fluoro-(trifluoromethyl)phenyl]-4-methyl-1H-pyrrole-2,5-dione; 3-[4-(4-Acetylpiperazin-1-yl)butyl]-1-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-4-methyl-1H-pyrrole-2,5-dione; 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-methyl-4-[4-[4-(1-oxopropyl)-piperazin-1-yl]butyl]-1H-pyrrole-2,5-dione; 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-[4-[4-[(2-methoxyethoxy)acetyl]piperazin-1-yl]butyl]-4-methyl-1H-pyrrole-2,5-dione; 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-[4-[4-[[2-(2-methoxyethoxy)ethoxy]acetyl]piperazin-1-yl]butyl]-4-methyl-1H-pyrrole-2,5-dione; 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-methyl-4-[4-[4-(methylsulfonyl)piperazin-1-yl]butyl]-1H-pyrrole-2,5-dione; 4-[4-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]-N-ethylpiperazine-1-carbothioamide; 4-[4-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]-N-propylpiperazine-1-carbothioamide; 4-[4-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]butyl]-N-(prop-2-enyl)piperazine-1-carbothioamide; 3-[5-(4-Acetylpiperazin-1-yl)pentyl]-1-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-4-methyl-1H-pyrrole-2,5-dione; 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-methyl-4-[5-[4-(1-oxopropyl)-piperazin-1-yl]pentyl]-1H-pyrrole-2,5-dione; 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-[5-[4-[(2-methoxyethoxy)acetyl]piperazin-1-yl]pentyl]-4-methyl-1H-pyrrole-2,5-dione; 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-[5-[4-[[2-(2-methoxyethoxy)ethoxy]acetyl]piperazin-1-yl]pentyl]-4-methyl-1H-pyrrole-2,5-dione; 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-methyl-4-[5-[4-(methylsulfonyl)piperazin-1-yl]pentyl]-1H-pyrrole-2,5-dione; 3-[5-[4-(Cyclopropylsulfonyl)piperazin-1-yl]pentyl]-1-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-4-methyl-1H-pyrrole-2,5-dione; 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-[5-[4-[[2-[2-(2-methoxyethoxy)ethoxy]ethyl]sulfonyl]piperazin-1-yl]pentyl]-4-methyl-1H-pyrrole-2,5-dione; 4-[5-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-ethylpiperazine-1-carbothioamide; 4-[5-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-propylpiperazine-1-carbothioamide; 4-[5-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]pentyl]-N-(prop-2-enyl)piperazine-1-carbothioamide; 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-[6-[4-(2-methoxybenzoyl)piperazin-1-yl]hexyl]-4-methyl-1H-pyrrole-2,5-dione; 3-[6-[4-(Cyclobutylcarbonyl)piperazin-1-yl]hexyl]-1-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-4-methyl-1H-pyrrole-2,5-dione; 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-methyl-4-[6-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]hexyl]-1H-pyrrole-2,5-dione; 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-[6-[4-[4-(dimethylamino)benzoyl]piperazin-1-yl]hexyl]-4-methyl-1H-pyrrole-2,5-dione; 3-[6-(4-Acetylpiperazin-1-yl)hexyl]-1-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-4-methyl-1H-pyrrole-2,5-dione; 4-[4-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N,N-dimethylpiperazine-1-sulfonamide; 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-methyl-4-[6-[4-(methylsulfonyl)piperazin-1-yl]hexyl]-1H-pyrrole-2,5-dione; 3-[6-[4-[(2,1,3-Benzothiadiazolyl)sulfonyl]piperazin-1-yl]hexyl]-1-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-4-methyl-1H-pyrrole-2,5-dione; 1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-3-[6-[4-(ethylsulfonyl)piperazin-1-yl]hexyl]-4-methyl-1H-pyrrole-2,5-dione; 4-[6-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-ethylpiperazine-1-carbothioamide; 4-[6-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-propylpiperazine-1-carbothioamide; 4-[6-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(prop-2-enyl)piperazine-1-carbothioamide; 4-[6-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(phenylmethyl)piperazine-1-carbothioamide; 4-[6-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-[(4-methylphenyl)methyl]piperazine-1-carbothioamide; N-[(4-Chlorophenyl)methyl]-4-[6-[1-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]piperazine-1-carbothioamide; 4-[6-[1-(1,3-Dihydro-1,1-oxoisobenzofuran-5-yl)-2,5-dihydro-4-methyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-phenylpiperazine-1-carbothioamide; 4-[6-[1-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-2,5-dihydromethyl-2,5-dioxo-1H-pyrrol-3-yl]hexyl]-N-(2,6-dimethylphenyl)piperazine-1-carbothioamide; 3-[6-[4-(2-Methoxybenzoyl)piperazin-1-yl]hexyl]-4-methyl-1-(4-methyl-1-oxo-1H-2,3-benzoxazin-6-yl)-1H-pyrrole-2,5-dione; 3-[6-[4-(Cyclobutylcarbonyl)piperazin-1-yl]hexyl]-4-methyl-1-(4-methyl-1-oxo-1H-2,3-benzoxazin-6-yl)-1H-pyrrole-2,5-dione; 3-Methyl-1-(4-methyl-1-oxo-1H-2,3-benzoxazin-6-yl)-4-[6-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]hexyl]-1H-pyrrole-2,5-dione; 3-[6-[4-[4-(Dimethylamino)benzoyl]piperazin-1-yl]hexyl]-4-methyl-1-(4-methyl-1-oxo-1H-2,3-benzoxazin-6-yl)-1H-pyrrole-2,5-dione; 3-(6-(4-Acetylpiperazin-1-yl)hexyl]-4-methyl-1-(4-methyl-1-oxo-1H-2,3-benzoxazin-6-yl)-1H-pyrrole-2,5-dione; 3-Methyl-1-(4-methyl-1-oxo-1H-2,3-benzoxazin-6-yl)-4-[6-[4-(methylsulfonyl)piperazin-1-yl]hexyl]-1H-pyrrole-2,5-dione; 1-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-3-[6-[4-(2-methoxybenzoyl)piperazin-1-yl]hexyl]-4-methyl-1H-pyrrole-2,5-dione; 3-[6-[4-(Cyclobutylcarbonyl)piperazin-1-yl]hexyl]-1-(2,3-dihydro-1-oxo-1H-inden-5-yl)-4-methyl-1H-pyrrole-2,5-dione; 1-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-3-methyl-4-[6-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]hexyl]-1H-pyrrole-2,5-dione; 1-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-3-[6-[4-[4-(dimethylamino)benzoyl]-piperazin-1-yl]hexyl]-4-methyl-1H-pyrrole-2,5-dione; 3-[6-(4-Acetylpiperazin-1-yl)hexyl]-1-(2,3-dihydro-1-oxo-1H-inden-5-yl)-4-methyl-1H-pyrrole-2,5-dione; 1-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-3-methyl-4-[6-[4-(methylsulfonyl)-piperazin-1-yl]hexyl]-1H-pyrrole-2,5-dione; 3-[6-[4-[(2,1,3-Benzothiadiazol-4-yl)sulfonyl]piperazin-1-yl]hexyl]-1-(2,3-dihydro-1-oxo-1H-inden-5-yl)-4-methyl-1H-pyrrole-2,5-dione; 4-[3-[2-(4-Acetylpiperazin-1-yl)ethyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[2-[4-(1-oxopropyl)piperazin-1-yl]ethyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[2-[4-(2-methyl-1-oxopropyl)piperazin-1-yl]ethyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[2-[4-(1-oxobutyl)piperazin-1-yl]ethyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[2-[4-(Cyclopropylcarbonyl)piperazin-1-yl]ethyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[2-[4-(Cyclobutylcarbonyl)piperazin-1-yl]ethyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[2-[4-[(thien-2-yl)acetyl]piperazin-1-yl]ethyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[2-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]ethyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[2-[4-[(pyridin-4-yl)carbonyl]piperazin-1-yl]ethyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[2-[4-(methylsulfonyl)piperazin-1-yl]ethyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[2-[4-(Ethylsulfonyl)piperazin-1-yl]ethyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[2-[4-(propylsulfonyl)piperazin-1-yl]ethyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[2-[4-(phenylsulfonyl)piperazin-1-yl]ethyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[2-[4-[(4-Cyanophenyl)sulfonyl]piperazin-1-yl]ethyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[2-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]ethyl]-N-ethylpiperazine-1-carbothioamide; 4-[2-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]ethyl]-N-propylpiperazine-1-carbothioamide; 4-[2-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]ethyl]-N-(prop-2-enyl)piperazine-1-carbothioamide; S-Methyl 4-[2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]ethyl]piperazine-1-carbothioate; S-ETHYL 4-[2-[3-[4-CYANO-3-(TRIFLUOROMETHYL)PHENYL]-5,5-DIMETHYL-4-OXO-2-THIOXOIMIDAZOLIDIN-1-YL]ETHYL]PIPERAZINE-1-CARBOTHIOATE; 4-[3-[3-[4-(2-Methoxybenzoyl)piperazin-1-yl]propyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[3-(4-Acetylpiperazin-1-yl)propyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[3-[4-(1-oxopropyl)piperazin-1-yl]-propyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[3-[4-(2-methyl-1-oxopropyl)piperazin-1-yl]propyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[3-[4-(1-oxobutyl)piperazin-1-yl]propyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[3-[4(Cyclopropylcarbonyl)piperazin-1-yl]propyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[3-[4-(Cyclobutylcarbonyl)piperazin-1-yl]propyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[3-[4-[(thien-2-yl)acetyl]piperazin-1-yl]propyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[3-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]propyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[3-[4-[(pyridin-4-yl)carbonyl]piperazin-1-yl]propyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[3-[4-(3-Methoxy-1-oxopropyl)piperazin-1-yl]propyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[3-[4-[(2-Methoxyethoxy)acetyl]piperazin-1-yl]propyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[3-[4-[[2-(2-Methoxyethoxy)ethoxy]acetyl]piperazin-1-yl]propyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[3-[4-(methylsulfonyl)piperazin-1-yl]propyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[3-[4-(Ethylsulfonyl)piperazin-1-yl]propyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[3-[4-(propylsulfonyl)piperazin-1-yl]propyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[3-[4-(phenylsulfonyl)piperazin-1-yl]propyl]-2-thioxoimidazolidin-1-yl)]-2-(trifluoromethyl)benzonitrile; 4-[3-[3-[4-[(4-Cyanophenyl)sulfonyl]piperazin-1-yl]propyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]propyl]-N-ethylpiperazine-1-carbothioamide; 4-[3-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]propyl]-N-propylpiperazine-1-carbothioamide; 4-[3-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]propyl]-N-(prop-2-enyl)piperazine-1-carbothioamide; S-Methyl 4-[3-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]propyl]piperazine-1-carbothioate; S-Ethyl 4-[3-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]propyl]piperazine-1-carbothioate; 4-[3-[4-[4-(2-Methoxybenzoyl)piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-(4-Acetylpiperazin-1-yl)butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[4-[4-(1-oxopropyl)piperazin-1-yl]butyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[4-[4-(2-methyl-1-oxopropyl)piperazin-1-yl]butyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[4-[4-(1-oxobutyl)piperazin-1-yl]butyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(Cyclopropylcarbonyl)piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(Cyclobutylcarbonyl)piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[4-[4-[(thien-2-yl)acetyl]piperazin-1-yl]butyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(3-Methoxy-1-oxopropyl)piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-[(2-Methoxyethoxy)acetyl]piperazin-1-yl]butyl]-4,4-dimethyl-5-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-[[2-(2-Methoxyethoxy)ethoxy]acetyl]piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-[(1,3-Dimethyl-1H-pyrazol-5-yl)carbonyl]piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-[(Furan-3-yl)carbonyl]piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-[(2,5-Dimethylfuran-3-yl)carbonyl]piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-[(Isoxazol-5-yl)carbonyl]piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[4-[4-[(S-methylisoxazol-3-yl)carbonyl]piperazin-1-yl]butyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[4-[4-[(thien-3-yl)carbonyl]piperazin-1-yl]butyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[4-[4-[(4-methyl-1,2,3-thiadiazol-4-yl)carbonyl]piperazin-1-yl]butyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-[(Furan-2-yl)carbonyl]piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[4-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]butyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[4-[4-[(pyridin-4-yl)carbonyl]piperazin-1-yl]butyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[4-[4-(methylsulfonyl)piperazin-1-yl]butyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(ethylsulfonyl)piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[4-[4-(propylsulfonyl)piperazin-1-yl]butyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[4-[4-(phenylsulfonyl)piperazin-1-yl]butyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-[(4-Cyanophenyl)sulfonyl]piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[4-[4-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperazin-1-yl]butyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-[(3,5-Dimethylisoxazol-4-yl)sulfonyl]piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]butyl]-N-ethylpiperazine-1-carbothioamide; 4-[4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]butyl]-N-propylpiperazine-1-carbothioamide; 4-[4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]butyl]-N-(prop-2-enyl)piperazine-1-carbothioamide; S-Methyl 4-[4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]butyl]piperazine-1-carbothioate; S-Ethyl 4-[4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]butyl]piperazine-1-carbothioate; 4-[3-[5-(4-Acetylpiperazin-1-yl)pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[5-[4-[1-oxopropyl)piperazin-1-yl]pentyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[5-[4-(2-methyl-1-oxopropyl)piperazin-1-yl]pentyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[5-[4-(1-oxobutyl)piperazin-1-yl]pentyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(Cyclopropylcarbonyl)piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(Cyclobutylcarbonyl)piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[5-[4-[(thien-2-yl)acetyl]piperazin-1-yl]pentyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(3-Methoxy-1-oxopropyl)piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[(2-Methoxyethoxy)acetyl]piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[[2-(2-Methoxyethoxy)ethoxy]acetyl]piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluorometbyl)benzonitrile; 4-[3-[5-[4-[(1,3-Dimethyl-1H-pyrazol-5-yl)carbonyl]piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[(Furan-3-yl)carbonyl]piperazin-1-yl]pentyl]-4,4-dimethyl-5-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[(2,5-Dimethylfuran-3-yl)carbonyl]piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[(Isoxazol-5-yl)carbonyl]piperazin-1-yl]pentyl]-4,4-dimethyl-5-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[5-[4-[(5-methylisoxazol-3-yl)carbonyl]piperazin-1-yl]pentyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[5-[4-[(thien-3-yl)carbonyl]piperazin-1-yl]pentyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[5-[4-[(4-methyl-1,2,3-thiadiazol-4-yl)carbonyl]piperazin-1-yl]pentyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[5-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]pentyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[5-[4-[(pyridin-4-yl)carbonyl]piperazin-1-yl]pentyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[5-[4-(methylsulfonyl)piperazin-1-yl]pentyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(Ethylsulfonyl)piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[5-[4-(propylsulfonyl)piperazin-1-yl]pentyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[5-[4-(phenylsulfonyl)piperazin-1-yl]pentyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[(4-Cyanophenyl)sulfonyl]piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[(2-Methoxyethyl)sulfonyl]piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[[2-(2-Methoxyethoxy)ethyl]sulfonyl]piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[[2-[2-(2-Methoxyethoxy)ethoxy]ethyl]sulfonyl]piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[5-[4-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperazin-1-yl]pentyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[(3,5-Dimethylisoxazol-4-yl)sulfonyl]piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[5-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]-N-ethylpiperazine-1-carbothioamide; 4-[5-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]-N-propylpiperazine-1-carbothioamide; 4-[5-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]-N-(prop-2-enyl)piperazine-1-carbothioamide; S-Methyl 4-[5-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]piperazine-1-carbothioate; S-ETHYL 4-[5-[3-[4-CYANO-3-(TRIFLUOROMETHYL)PHENYL]-5,5-DIMETHYL-4-OXO-2-THIOXOIMIDAZOLIDIN-1-YL]PENTYL]PIPERAZINE-1-CARBOTHIOATE; 4-[4,4-Dimethyl-3-[6-(4-methylpiperazin-1-yl)hexyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[6-[4-(1-methylethyl)piperazin-1-yl]hexyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(2-Methoxybenzoyl)piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-(4-Acetylpiperazin-1-yl)hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[6-[4-(1-oxopropyl)piperazin-1-yl]hexyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[6-[4-(2-methyl-1-oxopropyl)piperazin-1-yl]hexyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[6-[4-(1-oxobutyl)piperazin-1-yl]hexyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(Cyclopropylcarbonyl)piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(Cyclobutylcarbonyl)piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(3-Methoxy-1-oxopropyl)piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-[(2-Methoxyethoxy)acetyl]piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-[[2-(2-Methoxyethoxy)ethoxy]acetyl]piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[6-[4-[(thien-2-yl)acetyl]piperazin-1-yl]hexyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-[(Furan-2-yl)carbonyl]piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[6-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]hexyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[6-[4-[(pyridin-4-yl)carbonyl]piperazin-1-yl]hexyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[6-[4-(methylsulfonyl)piperazin-1-yl]hexyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(Ethylsulfonyl)piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[6-[4-(propylsulfonyl)piperazin-1-yl]hexyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[6-[4-(phenylsulfonyl)piperazin-1-yl]hexyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-[(4-Cyanophenyl)sulfonyl]piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[6-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]-N-ethylpiperazine-1-carbothioamide; 4-[6-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]-N-propylpiperazine-1-carbothioamide; 4-[6-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]-N-(prop-2-enyl)piperazine-1-carbothioamide; S-Methyl 4-[6-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]piperazine-1-carbothioate; S-ETHYL 4-[6-[3-[4-CYANO-3-(TRIFLUOROMETHYL)PHENYL]-5,5-DIMETHYL4-OXO-2-THIOXOIMIDAZOLIDIN-1-YL]HEXYL]PIPERAZINE-1-CARBOTHIOATE; 4-[4,4-Dimethyl-3-[7-(4-methylpiperazin-1-yl)heptyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[7-(4-Acetylpiperazin-1-yl)heptyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[7-[4-(methylsulfonyl)piperazin-1-yl]heptyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[8-[4-(2-methyl-1-oxopropyl)piperazin-1-yl]octyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[8-[4-(Cyclopropylcarbonyl)piperazin-1-yl]octyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[8-[4-(Cyclobutylcarbonyl)piperazin-1-yl]octyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[8-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]octyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[8-[4-[(pyridin-4-yl)carbonyl]piperazin-1-yl]octyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[8-[4-(methylsulfonyl)piperazin-1-yl]octyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-3-[8-[4-(propylsulfonyl)piperazin-1-yl]octyl]-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[8-[4-[(1-methylethyl)sulfonyl]piperazin-1-yl]octyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[8-[4-[(2-Methoxyethyl)sulfonyl]piperazin-1-yl]octyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[8-[4-[(4-Cyanophenyl)sulfonyl]piperazin-1-yl]octyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[8-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]octyl]-N-ethylpiperazine-1-carbothioamide; 4-[8-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]octyl]-N-(prop-2-enyl)piperazine-1-carbothioamide; S-METHYL 4-[8-[3-[4-CYANO-3-(TRIFLUOROMETHYL)PHENYL]-5,5-DIMETHYL-4-OXO-2-THIOXOIMIDAZOLIDIN-1-YL]OCTYL]PIPERAZINE-1-CARBOTHIOATE; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[3-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]propyl]-2-thioxoimidazolidin-4-one; 3-[1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[3-[4-[4-(dimethylamino)benzoyl]piperazin-1-yl]propyl]-5,5-dimethyl-2-thioxoimidazolidin-4-one; N-[(4-Chlorophenyl)methyl]-4-[3-[3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]propyl]piperazine-1-carbothioamide; S-Ethyl 4-[3-[3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]propyl]piperazine-1-carbothioate; 4-[3-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]propyl]-N,N-diethylpiperazine-1-carboxylic acid amide; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[4-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]butyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[4-[4-(2-methoxybenzoyl)piperazin-1-yl]butyl]-5,5-dimethyl-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[4-[4-[4-(dimethylamino)benzoyl]piperazin-1-yl]butyl]-5,5-dimethyl-2-thioxoimidazolidin-4-one; 1-[4-[4-[2,1,3-Benzothiadiazol-4-yl)sulfonyl]piperazin-1-yl]butyl]-3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-2-thioxoimidazolidin-4-one; N-(2,6-Dichloropyridin-4-yl)-4-[4-[3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]butyl]piperazine-1-carboxylic acid amide; S-Methyl 4-[4-[3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]butyl]piperazine-1-carbothioate; S-Ethyl 4-[4-[3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]butyl]piperazine-1-carbothioate; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[5-[4-(2-methyl-1-oxopropyl)piperazin-1-yl]pentyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[5-[4-[(thien-2-yl)acetyl]piperazin-1-yl]pentyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[5-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]pentyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[5-[4-ethylsulfonyl)piperazin-1-yl]pentyl]-5,5-dimethyl-2-thioxoimidazolidin-4-one; 4-[[4-[5-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]piperazin-1-yl]sulfonyl]benzonitrile; S-Ethyl 4-[5-[3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]piperazine-1-carbothioate; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[6-[4-(2-methoxybenzoyl)piperazin-1-yl]hexyl]-5,5-dimethyl-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[6-[4-[4-(dimethylamino)benzoyl]piperazin-1-yl]hexyl]-5,5-dimethyl-2-thioxoimidazolidin-4-one; 3-[[4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]piperazin-1-yl]carbonyl]benzonitrile; 1-[6-(4-Acetylpiperazin-1-yl)hexyl]-3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[6-[4-(1-oxopropyl)piperazin-1-yl]hexyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[6-[4-(2-methyl-1-oxopropyl)piperazin-1-yl]hexyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[6-[4-(1-oxobutyl)piperazin-1-yl]hexyl]-2-thioxoimidazolidin-4-one; 1-[6-[4-(Cyclopropylcarbonyl)piperazin-1-yl]hexyl]-3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-2-thioxoimidazolidin-4-one; 1-[6-[4-(Cyclobutylcarbonyl)piperazin-1-yl]hexyl]-3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[6-[4-[(pyridin-4-yl)carbonyl]piperazin-1-yl]hexyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[6-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]hexyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[6-[4-[(thien-2-yl)acetyl]piperazin-1-yl]hexyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[6-[4-(methylsulfonyl)piperazin-1-yl]hexyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[6-[4-(ethylsulfonyl)piperazin-1-yl]hexyl]-5,5-dimethyl-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[6-[4-(propylsulfonyl)piperazin-1-yl]hexyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[6-[4-(phenylsulfonyl)piperazin-1-yl]hexyl]-2-thioxoimidazolidin-4-one; 4-[[4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]piperazin-1-yl]sulfonyl]benzonitrile; 1-[6-[4-[(2,1,3-Benzothiadiazol-4-yl)sulfonyl]piperazin-1-yl]hexyl]-3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-2-thioxoimidazolidin-4-one; 4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]-N-[3-(methylsulfanyl)phenyl]piperazine-1-carboxylic acid amide; 4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]-N-(3-fluorophenyl)piperazine-1-carboxylic acid amide; 4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]-N-(4-fluorophenyl)piperazine-1-carboxylic acid amide; 4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]-N-ethylpiperazine-1-carbothioamide; 4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]-N-propylpiperazine-1-carbothioamide; 4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]-N-(prop-2-enyl)piperazine-1-carbothioamide; 4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]-N-phenylpiperazine-1-carbothioamide; 4-[6-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]-N-(phenylmethyl)piperazine-1-carbothioamide; S-Methyl 4-[6-[3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]piperazine-1-carbothioate; S-Ethyl 4-[6-[3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]piperazine-1-carbothioate; 4-[6-[3-(1,3-DIHYDRO-1-OXOISOBENZOFURAN-5-YL)-5,5-DIMETHYL-4-OXO-2-THIOXOIMIDAZOLIDIN-1-YL)HEXYL]-N,N-DIETHYLPIPERAZINE-1-CARBOXYLIC ACID AMIDE; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[7-[4-(2-methoxybenzoyl)piperazin-1-yl]heptyl]-5,5-dimethyl-2-thioxoimidazolidin-4-one; 1-[7-(4-Acetylpiperazin-1-yl)heptyl]-3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[7-[4-(1-oxopropyl)piperazin-1-yl]heptyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[7-[4-(2-methyl-1-oxopropyl)piperazin-1-yl]heptyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[7-[4-(1-oxobutyl)piperazin-1-yl]heptyl]-2-thioxoimidazolidin-4-one; 1-[7-[4-(Cyclopropylcarbonyl)piperazin-1-yl]heptyl]-3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-2-thioxoimidazolidin-4-one; 1-[7-[4-(Cyclobutylcarbonyl)piperazin-1-yl]heptyl]-3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[7-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]heptyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[7-[4-[(thien-2-yl)acetyl]piperazin-1-yl]heptyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[7-[4-(methylsulfonyl)piperazin-1-yl]heptyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[7-[4-(ethylsulfonyl)piperazin-1-yl]heptyl]-5,5-dimethyl-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[7-[4-(propylsulfonyl)piperazin-1-yl]heptyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[7-[4-(phenylsulfonyl)piperazin-1-yl]heptyl]-2-thioxoimidazolidin-4-one; 4-[7-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]heptyl]-N-ethylpiperazine-1-carbothioamide; 4-[7-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]heptyl]-N-propylpiperazine-1-carbothioamide; 4-[7-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]heptyl]-N-(prop-2-enyl)piperazine-1-carbothioamide; S-Methyl 4-[7-[3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]heptyl]piperazine-1-carbothioate; S-Ethyl 4-[7-[3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]heptyl]piperazine-1-carbothioate; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[8-[4-(2-methoxybenzoyl)piperazin-1-yl]octyl]-5,5-dimethyl-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[8-[4-[4-(dimethylamino)benzoyl]piperazin-1-yl]octyl]-5,5-dimethyl-2-thioxoimidazolidin-4-one; 1-[8-(4-Acetylpiperazin-1-yl)octyl]-3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[8-[4-(1-oxopropyl)piperazin-1-yl]octyl]-2-thioxoimidazolidin-4-one; 1-[8-[4-(Cyclopropylcarbonyl)piperazin-1-yl]octyl]-3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-2-thioxoimidazolidin-4-one; 1-[8-[4-(Cyclobutylcarbonyl)piperazin-1-yl]octyl]-3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[8-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]octyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[8-[4-[(thien-2-yl)acetyl]piperazin-1-yl]octyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[8-[4-[(pyridin-4-yl)carbonyl]piperazin-1-yl]octyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[8-[4-(methylsulfonyl)piperazin-1-yl]octyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-1-[8-[4-(ethylsulfonyl)piperazin-1-yl]octyl]-5,5-dimethyl-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[8-[4-(propylsulfonyl)piperazin-1-yl]octyl]-2-thioxoimidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-2-thioxo-1-[8-[4-[(2,2,2-trifluoroethyl)sulfonyl]piperazin-1-yl]octyl]imidazolidin-4-one; 3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-1-[8-[4-(phenylsulfonyl)piperazin-1-yl]octyl]-2-thioxoimidazolidin-4-one; 4-[8-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]octyl]-N-[3-(methylsulfanyl)phenyl]piperazine-1-carboxylic acid amide; 4-[8-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]octyl]-N-(3-fluorophenyl)piperazine-1-carboxylic acid amide; 4-[8-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]octyl]-N-ethylpiperazine-1-carbothioamide; 4-[8-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]octyl]-N-propylpiperazine-1-carbothioamide; 4-[8-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]octyl]-N-(prop-2-enyl)piperazine-1-carbothioamide; 4-[8-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]octyl]-N-(phenylmethyl)piperazine-1-carbothioamide; 4-[8-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]octyl]-N-(phenyl-piperazine-1-carbothioamide; S-Methyl 4-[8-[3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]octyl]piperazine-1-carbothioate; S-Ethyl 4-[8-[3-(1,3-dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]octyl]piperazine-1-carbothioate; 4-[8-[3-(1,3-Dihydro-1-oxoisobenzofuran-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]octyl]-N,N-diethylpiperazine-1-carboxylic acid amide; 6-[4,4-Dimethyl-5-oxo-3-[5-[4-(methylsulfonyl)piperazin-1-yl]pentyl]-2-thioxoimidazolidin-1-yl]-4-methyl-1H-2,3-benzoxazin-1-one; 6-[4,4-Dimethyl-5-oxo-3-[6-[4-(methylsulfonyl)piperazin-1-yl]hexyl]-2-thioxoimidazolidin-1-yl]-4-methyl-1H-2,3-benzoxazin-1-one; 1-[6-(4-Acetylpiperazin-1-yl)hexyl]-3-(2,3-dihydro-1-oxo-1H-inden-5-yl)-5,5-dimethyl-2-thioxoimidazolidin-4-one; 3-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-5,5-dimethyl-1-[6-[4-(2-methyl-1-oxopropyl)piperazin-1-yl]hexyl]-2-thioxoimidazolidin-4-one; 3-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-5,5-dimethyl-1-[6-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]hexyl]-2-thioxoimidazolidin-4-one; 3-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-5,5-dimethyl-1-[6-[4-[(pyridin-4-yl)carbonyl]piperazin-1-yl]hexyl]-2-thioxoimidazolidin-4-one; 3-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-5,5-dimethyl-1-[6-[4-(methylsulfonyl)piperazin-1-yl]hexyl]-2-thioxoimidazolidin-4-one; 3-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-5,5-dimethyl-1-[6-[4-(propylsulfonyl)piperazin-1-yl]hexyl]-2-thioxoimidazolidin-4-one; 4-[6-[3-(2,3-Dihydro-1-oxo-1H-inden-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]-N-ethylpiperazine-1-carbothioamide; and S-Methyl 4-[6-[3-(2,3-dihydro-1-oxo-1H-inden-5-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]piperazine-1-carbothioate.
 9. A compound according to claim 1, selected from the group consisting of: 4-[3-[3-[4-[(2-Methoxyethyl)sulfonyl]piperazin-1-yl]propyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]butyl]piperazine-1-carbonitrile; rel-4-[3-[4-[(2R,5S)-4-Acetyl-2,5-dimethylpiperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-(4-Acetylhexahydro-1H-1,4-diazepin-1-yl)butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[4-(2R,5S)-2,5-Dimethyl-4-(2-methyl-1-oxopropyl)piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(2-Hydroxy-2-methyl-1-oxopropyl)piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(2,2-Dimethyl-1-oxopropyl)piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[4-[(2R,5S)-4-(2,2-Dimethyl-1-oxopropyl)-2,5-dimethylpiperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(2,2-Dimethyl-1-oxopropyl)hexahydro-1H-1,4-diazepin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[4-[(2R,5S)-4-(Cyclopropylcarbonyl)-2,5-dimethylpiperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-(Methoxyacetyl)piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[Hexahydro-4-(3-methoxy-1-oxopropyl)-1H-1,4-diazepin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-2-thioxo-3-[4-[4-(trifluoroacetyl)piperazine-1-butyl]imidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[Hexahydro-4-(trifluoroacetyl)-1H-1,4-diazepin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-[(Furan-2-yl)carbonyl]hexahydro-1H-1,4-diazepin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[Hexahydro-4-[(thien-2-yl)carbonyl]-1H-1,4-diazepin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[4,4-Dimethyl-3-[4-[(2R,5S)-2,5-dimethyl-4-(methylsulfonyl)piperazin-1-yl]butyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[Hexahydro-4-(methylsulfonyl)-1H-1,4-diazepin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[4-[4-[(2-Methoxyethyl)sulfonyl]piperazin-1-yl]butyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile; S-Methyl 4-[4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]butyl]hexahydro-1H-1,4-diazepine-1-carbothioate; N,N-Dimethyl 4-[4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]butyl]piperazine-1-sulfonamide; 4-[3-[5-[4-(2-Methoxybenzoyl)piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[5-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]piperazine-1-carbonitrile; rel-4-[3-[5-[(2R,6S)-4-Acetyl-2,6dimethylpiperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-(4-Acetylhexahydro-1H-1,4-diazepin-1-yl)pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[Hexahydro-4-(2-methyl-1-oxopropyl)-1H-1,4-diazepin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(2-Hydroxy-2-methyl-1-oxopropyl)piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(2,2-Dimethyl-1-oxopropyl)piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(2,2-Dimethyl-1-oxopropyl)hexahydro-1H-1,4-diazepin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-(Methoxyacetyl)piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-2-thioxo-3-[5-[4-(trifluoroacetyl)piperazin-1-yl]pentyl]imidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[(Furan-3-yl)carbonyl]hexahydro-1H-1,4-diazepin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[Hexahydro-4-[(thien-3-yl)carbonyl]-1H-1,4-diazepin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[4-[(Furan-2-yl)carbonyl]hexahydro-1H-1,4-diazepin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[Hexahydro-4-[(thien-2-yl)carbonyl]-1H-1,4-diazepin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[5-[(2R,6S)-2,6-Dimethyl-4-(methylsulfonyl)piperazin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[5-[Hexahydro-4-(methylsulfonyl)-1H-1,4-diazepin-1-yl]pentyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; S-Methyl 4-[5-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]hexahydro-1H-1,4-diazepine-1-carbothioate; N,N-Dimethyl 4-[5-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pentyl]piperazine-1-sulfonamide; 4-[6-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]piperazine-1-carbonitrile; rel-4-[3-[6-[(2R,5S)-4-Acetyl-2,5-dimethylpiperazin-1-yl]hexyl]-4,4-dimethyl-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[6-[(2R,6S)-4-Acetyl-2,6-dimethylpiperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[6-[(2R,5S)-2,5-Dimethyl-4-(2-methyl-1-oxopropyl)piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[Hexahydro-4-(2-methyl-1-oxopropyl)-1H-1,4-diazepin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(2-Hydroxy-2-methyl-1-oxopropyl)piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(2,2-Dimethyl-1-oxopropyl)piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[6-[(2R,5S)-4-(2,2-Dimethyl-1-oxopropyl)-2,5-dimethylpiperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[6-[(2R,6S)-4-(2,2-Dimethyl-1-oxopropyl)-2,6-dimethylpiperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[6-[(2R,5S)-4-(Cyclopropylcarbonyl)-2,5-dimethylpiperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-(Methoxyacetyl)piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[6-[(2R,5S)4-(3-Methoxy-1-oxopropyl)-2,5-dimethylpiperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[Hexahydro-4-(3-methoxy-1-oxopropyl)-1H-1,4-diazepin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-2-thioxo-3-[6-[4-(trifluoroacetyl)piperazin-1-yl]hexyl]imidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[6-[(2R,5S)-2,5-Dimethyl-4trifluoroacetyl)piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[6-[(2R,5S)-4-[(Furan-3-yl)carbonyl]-2,5-dimethylpiperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[6-[(2R,5S)-4-[(Isoxazol-5-yl)carbonyl]-2,5-dimethylpiperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[6-[(2R,5S)-4-[(Furan-2-yl)carbonyl]-2,5-dimethylpiperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-[(Furan-2-yl)carbonyl]hexahydro-1H-1,4-diazepin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[6-[(2R,5S)-2,5-Dimethyl-4-[(thien-2-yl)carbonyl]piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[Hexahydro-4-[(thien-2-yl)carbonyl]-1H-1,4-diazepin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel4-[3-[6-[(2R,5S)-2,5-Dimethyl-4-(methylsulfonyl)piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[6-[(2R,6S)-2,6-Dimethyl-4-(methylsulfonyl)piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[Hexahydro-4-methylsulfonyl)-1H-1,4-diazepin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[6-[(2R,5S)-4-(Ethylsulfonyl)-2,5-dimethylpiperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-3-[6-[4-[(1-methylethyl)sulfonyl]piperazin-1-yl]hexyl]-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[6-[4-[(2-Methoxyethyl)sulfonyl]piperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; S-Methyl 4-[6-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]hexyl]hexahydro-1H-1,4-diazepine-1-carbothioate; 4-[7-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]heptyl]piperazine-1-carbonitrile; rel-4-[3-[7-[(2R,6S)-4-Acetyl-2,6-dimethylpiperazin-1-yl]heptyl]-4,4-dimethyl-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[7-[4-(2-Hydroxy-2-methyl-1-oxopropyl)piperazin-1-yl]heptyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[7-[4-(2,2-Dimethyl-1-oxopropyl)piperazin-1-yl]heptyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[7-[(2R,6S)-4-(2,2-Dimethyl-1-oxopropyl)-2,6-dimethylpiperazin-1-yl]heptyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[7-[4-(Methoxyacetyl)piperazin-1-yl]heptyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-2-thioxo-3-[7-[4-(trifluoroacetyl)piperazin-1-yl]heptyl]imidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[7-[(2R,6S)-2,6-Dimethyl-4-(trifluoroacetyl)piperazin-1-yl]heptyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[7-[(2R,6S)-2,6-Dimethyl-4-(methylsulfonyl)piperazin-1-yl]heptyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[7-(4-[(2-Methoxyethyl)sulfonyl]piperazin-1-yl]heptyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[8-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]octyl]piperazine-1-carbonitrile; rel-4-[3-[8-[(2R,6S)-4-Acetyl-2,6-dimethylpiperazin-1-yl]octyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[8-[4-(2-Hydroxy-2-methyl-1-oxopropyl)piperazin-1-yl]octyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; rel-4-[3-[8-[(2R,6S)-4-(2,2-Dimethyl-1-oxopropyl)-2,6-dimethylpiperazin-1-yl]hexyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[8-[4-(Methoxyacetyl)piperazin-1-yl]octyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-2-thioxo-3-[8-[4-(trifluoroacetyl)piperazin-1-yl]octyl]imidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[3-[8-[4-(Methoxyacetyl)piperazin-1-yl]octyl]-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-[4,4-Dimethyl-5-oxo-2-thioxo-3-[8-[4-(trifluoroacetyl)piperazin-1-yl]octyl]imidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile and N,N-Dimethyl 4-[8-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]octyl]piperazine-1-sulfonamide.
 10. Process for the production of a compound of formula I according to claim 1, which comprises: either reacting a compound of formula VIII

in which V, W, n, i, j, R and R′ have the meaning indicated with one of the reagents Z—N═O, Z—N═S, Z—COCl, Z—SO₂Cl, ZO—COCl, ZS—COCl, ZZ′N—COCl, in which Z and Z′ have the meaning indicated, in the presence of a base, or reacting a compound of the formula VII V—W—(CH₂)_(n)—I  VII with a product of the formula VI

in which i, j, Y, Z, R and R′ have the meaning indicated, in the presence of a base and optionally then converting the resulting product into a pharmacologically compatible salt.
 11. An intermediate of the formula VIII:

in which V stands for a substituted aromatic radical of formula II,

in which A stands for an acetyl group, an acetylamino group, a cyano group, a nitro group, a trifluoromethyl group or a halogen B stands for a hydrogen atom, a halogen or a trifluoromethyl group, or A and B together stand for a cyclic group of formula II or IV that is bonded to the aromatic ring, whereby E stands for a methylene group or an oxygen atom,

W stands for a group of formula V,

in which T stands for carbon, and a double bond is present between Q and T, and Q means a group ═C(CH₃)— and U means oxygen, n is one of the integral values 1, 2, 3, 4, 5, 6, 7, or 8, i and j, independently of one another, are 1 or 2, whereby i+j is 2 or 3, and R and R′, independently of one another, are a hydrogen atom or a methyl group.
 12. An intermediate of the formula VIII:

in which V stands for a substituted aromatic radical of formula II,

in which A and B together stand for a cyclic group of formula III or IV that is bonded to the aromatic ring, whereby E stands for a methylene group or an oxygen atom,

W stands for a group of formula V,

in which T stands for nitrogen, and a single bond is present between Q and T, and Q means a group —C(CH₃)₂— and U means sulfur, n is one of the integral values 2, 3, 4, 5, 6, 7, or 8, i and j, independently of one another, are 1 or 2, whereby i+j is 2 or 3, R and R′, independently of one another, are a hydrogen atom or a methyl group.
 13. An intermediate of formula VII: V—W—(CH₂)_(n)—I  VII in which V stands for a substituted aromatic radical of formula II,

in which A stands for an acetyl group, an acetylamino group, a cyano group, a nitro group, a trifluoromethyl group or a halogen, B stands for a hydrogen atom, a halogen or a trifluoromethyl group, or A and B together stand for a cyclic group of formula III or IV that is bonded to the aromatic ring, whereby E stands for a methylene group or an oxygen atom,

W stands for a group of formula V,

in which T stands for carbon, and a double bond is present between Q and T, and Q means a group ═C(CH₃)— and U means oxygen, n is one of the integral values 1, 2, 3, 4, 5, 6, 7, or
 8. 14. An intermediate of formula VII: V—W—(CH₂)_(n)—I  VII in which V stands for a substituted aromatic radical of formula II,

in which A and B together stand for a cyclic group of formula III or IV that is bonded to the aromatic ring, whereby E stands for a methylene group or an oxygen atom,

W stands for a group of formula V.

in which T stands for nitrogen, and a single bond is present between Q and T, and Q means a group —C(CH)₂— and U means sulfur, and n is one of the integral values 2, 3, 4, 5, 6, 7, or
 8. 15. A pharmaceutical composition which comprises at least one compound of formula I according to claim 1, together with at least one pharmaceutically compatible adjuvant or vehicle.
 16. A compound of claim 1, wherein halogen, in each occurrence, is fluorine or chlorine.
 17. A compound of claim 1, wherein: aryl in each occurrence is phenyl, naphthalen-1-yl, naphthalen-2-yl, [1,1′-biphenyl]-2-yl, [1,1′-biphenyl]-3-yl or [1,1′-biphenyl]-4-yl, heteroaryl, in each occurrence, is pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, benzofuranyl, benzothienyl, 1,3-benzodioxolyl, 2,1,3-benzothiadiazolyl, indolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, pyrrolyl, pyrazolyl or imidazolyl, and heterocyclyl, in each occurrence, is piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydroflranyl, tetrahydrothienyl, imidazolidinyl or pyrrolidinyl group.
 18. A method for preparing a pharmaceutical composition which comprises combining at least one compound of formula I according to claim 1, with at least one pharmaceutically compatible adjuvant or vehicle.
 19. A method for treating prostate cancer which comprises administering a compound of claim 1 to a patient in need thereof.
 20. A method for treating benign prostate hyperplasia, andogenetic alopecia, hirsutism or androgen-dependent acne which comprises administering a compound of claim 1 to a patient in need thereof. 